

N. Pizza M. Rappuoli R. Dougan G.  
 MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.  
*J Immunol.* 1999 Dec 15;163(12):6502-10.  
 PMID: 10586042 [PubMed - indexed for MEDLINE]

111: Durrant LG, Buckley DJ, Robins RA, Spendlove I. Related Articles, Links  
 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.  
*Int J Cancer.* 2000 Jan 1;85(1):87-92.  
 PMID: 10585589 [PubMed - indexed for MEDLINE]

112: Plate JM, Shott S, Harris JE. Related Articles, Links  
 Immunoregulation in pancreatic cancer patients.  
*Cancer Immunol Immunother.* 1999 Aug;48(5):270-9.  
 PMID: 10478644 [PubMed - indexed for MEDLINE]

113: Barratt-Boyes SM, Vlad A, Finn OJ. Related Articles, Links  
 Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.  
*Clin Cancer Res.* 1999 Jul;5(7):1918-24.  
 PMID: 10430099 [PubMed - indexed for MEDLINE]

114: Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R. Related Articles, Links  
 A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group.  
*Hepatology.* 1999 Aug;30(2):531-6.  
 PMID: 10421664 [PubMed - indexed for MEDLINE]

115: Meyer D, Torres JV. Related Articles, Links  
 Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs.  
*Viral Immunol.* 1999;12(2):117-29.  
 PMID: 10413358 [PubMed - indexed for MEDLINE]

116: Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. Related Articles, Links  
 CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.  
*Nat Med.* 1999 Jul;5(7):774-9.  
 PMID: 10395322 [PubMed - indexed for MEDLINE]

117: Schirmbeck R, Melber K, Reimann J. Related Articles, Links  
 Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen.  
*Int Immunol.* 1999 Jul;11(7):1093-102.  
 PMID: 10383942 [PubMed - indexed for MEDLINE]

118: Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Related Articles, Links  
 Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.  
*Cell Immunol.* 1999 Jun 15;194(2):143-9.  
 PMID: 10383817 [PubMed - indexed for MEDLINE]

119: [Hsu SC, Chargelegue D, Obeid OE, Steward MW.](#) [Related Articles](#) [Links](#)

 Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus.  
J Gen Virol. 1999 Jun;80 ( Pt 6):1401-5.  
PMID: 10374957 [PubMed - indexed for MEDLINE]

120: [Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vourakis J, Cole DJ.](#) [Related Articles](#) [Links](#)

 Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.  
Clin Cancer Res. 1999 May;5(5):1173-82.  
PMID: 10353754 [PubMed - indexed for MEDLINE]

121: [Elliott SL, Pye S, Le T, Mateo L, Cox J, Macdonald L, Scalzo AA, Forbes CA, Suhrbier A.](#) [Related Articles](#) [Links](#)

 Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.  
Vaccine. 1999 Apr 9;17(15-16):2009-19.  
PMID: 10217601 [PubMed - indexed for MEDLINE]

122: [Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, Romero P, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A.](#) [Related Articles](#) [Links](#)

 Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A\*0201/Kb transgenic mice.  
J Immunol. 1999 Mar 15;162(6):3566-73.  
PMID: 10092815 [PubMed - indexed for MEDLINE]

123: [Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A.](#) [Related Articles](#) [Links](#)

 Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans.  
J Immunol. 1999 Mar 1;162(5):3088-95.  
PMID: 10072562 [PubMed - indexed for MEDLINE]

124: [Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Storkus WJ.](#) [Related Articles](#) [Links](#)

 HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines.  
J Immunol. 1999 Mar 1;162(5):3070-8.  
PMID: 10072560 [PubMed - indexed for MEDLINE]

125: [Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB, Shoemaker H.](#) [Related Articles](#) [Links](#)

 Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.  
Oncogene. 1998 Dec 17;17(24):3125-35. Erratum in: Oncogene 1999 Apr 8;18(14):2411. Shoemaker H [corrected to Schoemaker H].  
PMID: 9872328 [PubMed - indexed for MEDLINE]

126: [Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, Chisari FV, Guidotti LG, Chesnut RW, Livingston B, Sette A.](#) [Related Articles](#) [Links](#)

 The optimization of helper T lymphocyte (HTL) function in vaccine development.  
Immunol Res. 1998;18(2):79-92. Review.  
PMID: 9844827 [PubMed - indexed for MEDLINE]

Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A.

 **127:** Morrison LD, Javadian A, Chalian AA, Agadjanyan MG, Weiner [Related Articles](#), [Links](#) [DB](#).  
 Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. *Vaccine*. 1998 Nov;16(19):1828-35.  
 PMID: 9795388 [PubMed - indexed for MEDLINE]

 **128:** da Silva J, Hughes AL. [Related Articles](#), [Links](#)  
 Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). *Mol Biol Evol*. 1998 Oct;15(10):1259-68.  
 PMID: 9787432 [PubMed - indexed for MEDLINE]

 **129:** Fernando GJ, Stewart TJ, Tindle RW, Frazer JH. [Related Articles](#), [Links](#)  
 Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. *J Immunol*. 1998 Sep 1;161(5):2421-7.  
 PMID: 9725239 [PubMed - indexed for MEDLINE]

 **130:** Bessler WG, Heinevetter L, Wiesmuller KH, Jung G, Baier W, Huber M, Lorenz AR, Esche UV, Mittenbuhler K, Hoffmann P. [Related Articles](#), [Links](#)  
 Bacterial cell wall components as immunomodulators--I. Lipopeptides as adjuvants for parenteral and oral immunization. *Int J Immunopharmacol*. 1997 Sep-Oct;19(9-10):547-50.  
 PMID: 9637352 [PubMed - indexed for MEDLINE]

 **131:** Oseroff C, Sette A, Wentworth P, Celis E, Maewal A, Dahlberg C, Fikes J, Kubo RT, Chesnut RW, Grey HM, Alexander J. [Related Articles](#), [Links](#)  
 Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. *Vaccine*. 1998 May;16(8):823-33.  
 PMID: 9627940 [PubMed - indexed for MEDLINE]

 **132:** Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR. [Related Articles](#), [Links](#)  
 Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization. *J Immunol*. 1998 Jun 1;160(11):5522-9.  
 PMID: 9605156 [PubMed - indexed for MEDLINE]

 **133:** Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DJ, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ. [Related Articles](#), [Links](#)  
 Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. *J Immunol*. 1998 Feb 1;160(3):1139-47.  
 PMID: 9570527 [PubMed - indexed for MEDLINE]

 **134:** Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. [Related Articles](#), [Links](#)  
 Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. *J Exp Med*. 1998 Mar 2;187(5):693-702.  
 PMID: 9480979 [PubMed - indexed for MEDLINE]

 **135:** Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A. [Related Articles](#), [Links](#)

 **Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.**  
J Immunol. 1998 Feb 15;160(4):1717-23.  
PMID: 9469429 [PubMed - indexed for MEDLINE]

 **136: Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD.** [Related Articles](#), [Links](#)  
  
**Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons.**  
J Infect Dis. 1997 Oct;176(4):859-66.  
PMID: 9333142 [PubMed - indexed for MEDLINE]

 **137: Franke ED, Corradin G, Hoffman SL.** [Related Articles](#), [Links](#)  
  
**Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.**  
J Immunol. 1997 Oct 1;159(7):3424-33.  
PMID: 9317141 [PubMed - indexed for MEDLINE]

 **138: Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA.** [Related Articles](#), [Links](#)  
  
**Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.**  
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10856-61.  
PMID: 9380724 [PubMed - indexed for MEDLINE]

 **139: Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, Chesnut RW, Sette A.** [Related Articles](#), [Links](#)  
  
**The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.**  
J Immunol. 1997 Aug 1;159(3):1383-92.  
PMID: 9233635 [PubMed - indexed for MEDLINE]

 **140: Zhu X, Venkataprasad N, Thangaraj HS, Hill M, Singh M, Ivanyi J, Vordermeier HM.** [Related Articles](#), [Links](#)  
  
**Functions and specificity of T cells following nucleic acid vaccination of mice against *Mycobacterium tuberculosis* infection.**  
J Immunol. 1997 Jun 15;158(12):5921-6.  
PMID: 9190945 [PubMed - indexed for MEDLINE]

 **141: Nakamura Y, Kameoka M, Tobiume M, Kaya M, Ohki K, Yamada T, Ikuta K.** [Related Articles](#), [Links](#)  
  
**A chain section containing epitopes for cytotoxic T, B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein.**  
Vaccine. 1997 Apr;15(5):489-96.  
PMID: 9160516 [PubMed - indexed for MEDLINE]

 **142: An LL, Whitten JL.** [Related Articles](#), [Links](#)  
  
**A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.**  
J Virol. 1997 Mar;71(3):2292-302.  
PMID: 9032365 [PubMed - indexed for MEDLINE]

 **143: Harris SJ, Roth JF, Savage N, Woodrow SA, Hemingway IK, Hoyne GF, Lamb JR, Layton GT.** [Related Articles](#), [Links](#)  
  
**Prediction of murine MHC class I epitopes in a major house dust mite allergen and induction of T1-type CD8+ T cell responses.**  
Int Immunol. 1997 Feb;9(2):273-80.  
PMID: 9040009 [PubMed - indexed for MEDLINE]

**144:** [Partidos CD, Delmas A, Steward MW](#) [Related Articles](#) [Links](#)  
 **Structural requirements for synthetic immunogens to induce measles virus specific CTL responses.**  
*Mol Immunol.* 1996 Nov;33(16):1223-9.  
 PMID: 9129158 [PubMed - indexed for MEDLINE]

**145:** [Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA](#) [Related Articles](#) [Links](#)  
 **Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting.**  
*Eur J Immunol.* 1996 Jul;26(7):1489-96.  
 PMID: 8766551 [PubMed - indexed for MEDLINE]

**146:** [Van Gool SW, Zhang Y, Kasran A, de Boer M, Ceuppens JL](#) [Related Articles](#) [Links](#)  
 **T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.**  
*Scand J Immunol.* 1996 Jul;44(1):21-9.  
 PMID: 8693288 [PubMed - indexed for MEDLINE]

**147:** [Bottius E, BenMohamed L, Brahim K, Gras H, Lepers JP, Raharimalala L, Aikawa M, Meis J, Slierendregt B, Tartar A, Thomas A, Druilhe P](#) [Related Articles](#) [Links](#)  
 **A novel *Plasmodium falciparum* sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes.**  
*J Immunol.* 1996 Apr 15;156(8):2874-84.  
 PMID: 8609407 [PubMed - indexed for MEDLINE]

**148:** [Partidos CD, Vohra P, Steward MW](#) [Related Articles](#) [Links](#)  
 **Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.**  
*Immunology.* 1996 Feb;87(2):179-85.  
 PMID: 8698377 [PubMed - indexed for MEDLINE]

**149:** [Shirai M, Chen M, Arichi T, Masaki T, Nishioka M, Newman M, Nakazawa T, Feinstone SM, Berzofsky JA](#) [Related Articles](#) [Links](#)  
 **Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.**  
*J Infect Dis.* 1996 Jan;173(1):24-31.  
 PMID: 8537666 [PubMed - indexed for MEDLINE]

**150:** [Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK](#) [Related Articles](#) [Links](#)  
 **Construction and immunogenicity of *Salmonella typhimurium* vaccine vectors that express HIV-1 gp120.**  
*Vaccine.* 1995 Dec;13(17):1697-705.  
 PMID: 8719522 [PubMed - indexed for MEDLINE]

**151:** [Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG](#) [Related Articles](#) [Links](#)  
 **Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.**  
*Eur J Immunol.* 1995 Dec;25(12):3467-73.  
 PMID: 8566039 [PubMed - indexed for MEDLINE]

**152:** [Blazevic V, Ranki A, Krohn KJ](#) [Related Articles](#) [Links](#)  
 **Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.**

AIDS Res Hum Retroviruses. 1995 Nov;11(11):1335-42.  
PMID: 8573390 [PubMed - indexed for MEDLINE]

 **153:** [Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, Gomard E.](#) [Related Articles](#), [Links](#)

 Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides.  
Vaccine. 1995 Oct;13(14):1339-45.  
PMID: 8585291 [PubMed - indexed for MEDLINE]

 **154:** [Bishop DK, DeBruyne LA, Chan S, Xu S, Eichwald EJ.](#) [Related Articles](#), [Links](#)

 Dissociation of mouse cardiac transplant rejection and donor alloantigen-specific T cell responsiveness.  
Transpl Immunol. 1995 Sep;3(3):222-8.  
PMID: 8581410 [PubMed - indexed for MEDLINE]

 **155:** [Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Stewart T, Fernando GJ.](#) [Related Articles](#), [Links](#)

 A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.  
Clin Exp Immunol. 1995 Aug;101(2):265-71.  
PMID: 7544248 [PubMed - indexed for MEDLINE]

 **156:** [Roelen DL, van Bree FP, van Beelen E, van Rood JJ, Claas FH.](#) [Related Articles](#), [Links](#)

 No evidence of an influence of the noninherited maternal HLA antigens on the alloreactive T cell repertoire in healthy individuals.  
Transplantation. 1995 Jun 27;59(12):1728-33.  
PMID: 7541578 [PubMed - indexed for MEDLINE]

 **157:** [Berzofsky JA.](#) [Related Articles](#), [Links](#)

 Designing peptide vaccines to broaden recognition and enhance potency.  
Ann N Y Acad Sci. 1995 May 31;754:161-8. No abstract available.  
PMID: 7625650 [PubMed - indexed for MEDLINE]

 **158:** [Lehtinen M, Hibma MH, Stellato G, Kuoppala T, Paavonen J.](#) [Related Articles](#), [Links](#)

 Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16.  
Biochem Biophys Res Commun. 1995 Apr 17;209(2):541-6.  
PMID: 7733923 [PubMed - indexed for MEDLINE]

 **159:** [Kita H, Moriyama T, Kaneko T, Hiroishi K, Harase I, Miura H, Nakamura I, Inamori H, Kodama T, Ohnishi S, et al.](#) [Related Articles](#), [Links](#)

 A helper T-cell antigen enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro.  
J Med Virol. 1995 Apr;45(4):386-91.  
PMID: 7545209 [PubMed - indexed for MEDLINE]

 **160:** [Bishop DK, Li W, Chan SY, Ensley RD, Shelby J, Eichwald EJ.](#) [Related Articles](#), [Links](#)

 Helper T lymphocyte unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses.  
Transplantation. 1994 Sep 15;58(5):576-84.  
PMID: 7522364 [PubMed - indexed for MEDLINE]

 **161:** [Yang Y, Ertl HC, Wilson JM.](#) [Related Articles](#), [Links](#)

 MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy

hepatocytes in mice infected with E1-deleted recombinant adenoviruses.  
*Immunity*. 1994 Aug;1(5):433-42.  
 PMID: 7533647 [PubMed - indexed for MEDLINE]

 **162:** Kim J, Narnchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, Aanstoot HJ, Turck CW, Erlich H, Lennon V, et al. [Related Articles](#), [Links](#)  
**Higher autoantibody levels and recognition of a linear NH<sub>2</sub>-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.**  
*J Exp Med*. 1994 Aug 1;180(2):595-606.  
 PMID: 7519242 [PubMed - indexed for MEDLINE]

 **163:** Borges E, Wiesmuller KH, Jung G, Walden P. [Related Articles](#), [Links](#)  
**Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid.**  
*J Immunol Methods*. 1994 Aug 1;173(2):253-63.  
 PMID: 7519223 [PubMed - indexed for MEDLINE]

 **164:** Valmori D, Romero JF, Men Y, Maryanski JL, Romero P, Corradin G [Related Articles](#), [Links](#)  
**Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone.**  
*Eur J Immunol*. 1994 Jun;24(6):1458-62.  
 PMID: 7515816 [PubMed - indexed for MEDLINE]

 **165:** Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA [Related Articles](#), [Links](#)  
**Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.**  
*J Immunol*. 1994 Jan 15;152(2):549-56.  
 PMID: 8283036 [PubMed - indexed for MEDLINE]

 **166:** Touraine JL, Roncarelo MG, Plotnick H, Bachetta R, Spits H [Related Articles](#), [Links](#)  
**T lymphocytes from human chimeras do recognize antigen in the context of allogeneic determinants of the major histocompatibility complex.**  
*Immunol Lett*. 1993 Dec;39(1):9-12.  
 PMID: 7511565 [PubMed - indexed for MEDLINE]

 **167:** Stubler G, Walden P. [Related Articles](#), [Links](#)  
**Collaboration of helper and cytotoxic T lymphocytes.**  
*Eur J Immunol*. 1993 Sep;23(9):2279-86.  
 PMID: 7690327 [PubMed - indexed for MEDLINE]

 **168:** Kundig TM, Castelmur I, Bachmann MF, Abraham D, Binder D, Hengartner H, Zinkernagel RM [Related Articles](#), [Links](#)  
**Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus.**  
*J Virol*. 1993 Jun;67(6):3680-3.  
 PMID: 7684471 [PubMed - indexed for MEDLINE]

 **169:** Martinon F, Gras-Masse H, Boutillon C, Chirat F, Deprez B, Guillet JG, Gomard E, Tartar A, Levy JP [Related Articles](#), [Links](#)  
**Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.**  
*J Immunol*. 1992 Nov 15;149(10):3416-22.  
 PMID: 1385524 [PubMed - indexed for MEDLINE]

170: Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D. [Related Articles](#), [Links](#)  
 T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.  
*J Immunol Methods*. 1992 Oct 19;155(1):95-9.  
 PMID: 1383348 [PubMed - indexed for MEDLINE]

171: Guerder S, Matzinger P. [Related Articles](#), [Links](#)  
 A fail-safe mechanism for maintaining self-tolerance.  
*J Exp Med*. 1992 Aug 1;176(2):553-64.  
 PMID: 1386876 [PubMed - indexed for MEDLINE]

172: Nixon DF, Broliden K, Ogg G, Broliden PA. [Related Articles](#), [Links](#)  
 Cellular and humoral antigenic epitopes in HIV and SIV.  
*Immunology*. 1992 Aug;76(4):515-34. Review. No abstract available.  
 PMID: 1383131 [PubMed - indexed for MEDLINE]

173: Fayolle C, Deriaud E, Leclerc C. [Related Articles](#), [Links](#)  
 In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help.  
*J Immunol*. 1991 Dec 15;147(12):4069-73.  
 PMID: 1684372 [PubMed - indexed for MEDLINE]

174: De Groot AS, Clerici M, Hosnalin A, Hughes SH, Barnd D, Hendrix CW, Houghten R, Shearer GM, Berzofsky JA. [Related Articles](#), [Links](#)  
 Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope.  
*J Infect Dis*. 1991 Dec;164(6):1058-65.  
 PMID: 1720151 [PubMed - indexed for MEDLINE]

175: Gao XM, Zheng B, Liew FY, Brett S, Tite J. [Related Articles](#), [Links](#)  
 Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides.  
*J Immunol*. 1991 Nov 15;147(10):3268-73.  
 PMID: 1682377 [PubMed - indexed for MEDLINE]

176: Perkins DL, Betriz G, Wang YS, Smith JA, Gefter ML. [Related Articles](#), [Links](#)  
 Comparison of class I- and II-restricted T cell recognition of the identical peptide.  
*Eur J Immunol*. 1991 Nov;21(11):2781-9.  
 PMID: 1718759 [PubMed - indexed for MEDLINE]

177: Hirsch R, Archibald J, Gress RE. [Related Articles](#), [Links](#)  
 Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.  
*J Immunol*. 1991 Oct 1;147(7):2088-93.  
 PMID: 1833451 [PubMed - indexed for MEDLINE]

178: Wu JY, Riggan CH, Seals JR, Murphy CJ, Newman MJ. [Related Articles](#), [Links](#)  
 In vitro measurement of antigen-specific cell-mediated immune responses using recombinant HIV-1 proteins adsorbed to latex microspheres.  
*J Immunol Methods*. 1991 Sep 20;143(1):1-9.  
 PMID: 1717603 [PubMed - indexed for MEDLINE]

179: Berzofsky JA. [Related Articles](#), [Links](#)  
 Development of artificial vaccines against HIV using defined epitopes.  
*FASEB J*. 1991 Jul;5(10):2412-8. Review.

PMID: 1712327 [PubMed - indexed for MEDLINE]

180: [Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, Letvin NL.](#) [Related Articles](#), [Links](#)

 Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.

Science. 1991 Apr 19;252(5004):440-3.

PMID: 1708168 [PubMed - indexed for MEDLINE]

181: [Berzofsky JA.](#) [Related Articles](#), [Links](#)

 Mechanisms of T cell recognition with application to vaccine design.

Mol Immunol. 1991 Mar;28(3):217-23.

PMID: 1708102 [PubMed - indexed for MEDLINE]

182: [Berzofsky JA.](#) [Related Articles](#), [Links](#)

 Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.

Biotechnol Ther. 1991;2(1-2):123-35. Review.

PMID: 1726961 [PubMed - indexed for MEDLINE]

183: [Yewdell JW, Bennink JR.](#) [Related Articles](#), [Links](#)

 The binary logic of antigen processing and presentation to T cells.

Cell. 1990 Jul 27;62(2):203-6. Review. No abstract available.

PMID: 1695549 [PubMed - indexed for MEDLINE]

184: [Gao XM, Liew FY, Tite JP.](#) [Related Articles](#), [Links](#)

 A dominant Th epitope in influenza nucleoprotein. Analysis of the fine specificity and functional repertoire of T cells recognizing a single determinant.

J Immunol. 1990 Apr 1;144(7):2730-7.

PMID: 1690775 [PubMed - indexed for MEDLINE]

185: [Schoeller J, Rubin B.](#) [Related Articles](#), [Links](#)

 Mouse cytolytic T cells reactive with rat islet tumour RIN 5AH-B cells.

APMIS. 1990 Mar;98(3):281-6.

PMID: 2138467 [PubMed - indexed for MEDLINE]

186: [Nakao H, Eguchi K, Kawakami A, Migita K, Otsubo T, Ueki Y, Shimomura C, Tezuka H, Matsunaga M, Maeda K, et al.](#) [Related Articles](#), [Links](#)

 Phenotypic characterization of lymphocytes infiltrating synovial tissue from patients with rheumatoid arthritis: analysis of lymphocytes isolated from minced synovial tissue by dual immunofluorescent staining.

J Rheumatol. 1990 Feb;17(2):142-8.

PMID: 1690803 [PubMed - indexed for MEDLINE]

187: [Cease KB.](#) [Related Articles](#), [Links](#)

 Peptide component vaccine engineering: targeting the AIDS virus.

Int Rev Immunol. 1990;7(1):85-107. Review.

PMID: 1722499 [PubMed - indexed for MEDLINE]

188: [Brondz BD, Osipova TV, Aptikaeva GE, Kronin VV.](#) [Related Articles](#), [Links](#)

 Difference between antigen-binding receptor repertoires in effector cytotoxic T lymphocytes and their secondary precursors (memory cells) specific to H-2K<sup>b</sup>.

Res Immunol. 1990 Jan;141(1):43-57.

PMID: 1693215 [PubMed - indexed for MEDLINE]

189: [Gao XM, Liew FY, Tite JP.](#) [Related Articles](#), [Links](#)

 Identification and characterization of T helper epitopes in the nucleoprotein of influenza A virus.  
J Immunol. 1989 Nov 1;143(9):3007-14.  
PMID: 2478631 [PubMed - indexed for MEDLINE]

 **190:** Weyand CM, Goronzy J, Swarztrauber K, Fathman CG. [Related Articles](#), [Links](#)  
Immunosuppression by anti-CD4 treatment in vivo. Cellular and humoral responses to alloantigens.  
Transplantation. 1989 Jun;47(6):1039-42.  
PMID: 2472024 [PubMed - indexed for MEDLINE]

 **191:** Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT. [Related Articles](#), [Links](#)  
Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.  
J Exp Med. 1989 Jun 1;169(6):1961-76.  
PMID: 2471770 [PubMed - indexed for MEDLINE]

 **192:** van Binnendijk RS, Poelen MC, de Vries P, Voorma HO, Osterhaus AD, Uytdehaag FG. [Related Articles](#), [Links](#)  
Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones.  
J Immunol. 1989 Apr 15;142(8):2847-54.  
PMID: 2467943 [PubMed - indexed for MEDLINE]

 **193:** Hosteller LW, Romerdahl CA, Kripke ML. [Related Articles](#), [Links](#)  
Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.  
Cancer Res. 1989 Mar 1;49(5):1207-13.  
PMID: 2465081 [PubMed - indexed for MEDLINE]

 **194:** Gautam SC, Battisto JR. [Related Articles](#), [Links](#)  
Feeding trinitrochlorobenzene inhibits development of hapten-specific cytotoxic T lymphocytes by interfering with helper T-cell function.  
Reg Immunol. 1989 Jan-Feb;2(1):33-41.  
PMID: 2534947 [PubMed - indexed for MEDLINE]

 **195:** Hayward A, Giller R, Levin M. [Related Articles](#), [Links](#)  
Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes.  
Viral Immunol. 1989 Fall;2(3):175-84.  
PMID: 2483504 [PubMed - indexed for MEDLINE]

 **196:** Gluckman JC. [Related Articles](#), [Links](#)  
[Immune response to human immunodeficiency virus and prospects for vaccination]  
Ann Med Interne (Paris). 1989;140(5):408-11. Review. French. No abstract available.  
PMID: 2480729 [PubMed - indexed for MEDLINE]

 **197:** Foxwell B, Taylor D, Ryffel B. [Related Articles](#), [Links](#)  
Comparison of the structure of the murine interleukin 2 (IL 2) receptor on cytotoxic and helper T cell lines by chemical cross-linking of 125I-labeled IL 2.  
Eur J Immunol. 1988 Oct;18(10):1515-9. Erratum in: Eur J Immunol 1989 Jan;19(1):221.  
PMID: 2973414 [PubMed - indexed for MEDLINE]

 **198:** Payne J, Huber BT, Cannon NA, Schneider R, Schilham MW, Acha-Orbea H, MacDonald HR, Hengartner H. [Related Articles](#), [Links](#)

 Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor.  
Proc Natl Acad Sci U S A. 1988 Oct;85(20):7695-8.  
PMID: 2459713 [PubMed - indexed for MEDLINE]

 **199:** [Havran WL, Fitch FW](#) Related Articles, Links  
  
 Effects of anti-Lyt-2 and anti-L3T4 monoclonal antibodies on the function of cytotoxic T lymphocyte/helper T lymphocyte hybrid T cell clones.  
J Immunol. 1988 Sep 15;141(6):1808-12.  
PMID: 2459190 [PubMed - indexed for MEDLINE]

 **200:** [Kanagawa O](#) Related Articles, Links  
  
 Antibody-mediated activation of T cell clones as a method for screening hybridomas producing antibodies to the T cell receptor.  
J Immunol Methods. 1988 Jun 13;110(2):169-78.  
PMID: 2454267 [PubMed - indexed for MEDLINE]

 **201:** [Brondz BD, Osipova TV](#) Related Articles, Links  
  
 [The main difference between the repertoire of receptors of effector T-killers and their secondary precursors (memory cells)]  
Bull Eksp Biol Med. 1988 Jun;105(6):694-7. Russian.  
PMID: 2455562 [PubMed - indexed for MEDLINE]

 **202:** [Yasukawa M, Inatsuki A, Kobayashi Y](#) Related Articles, Links  
  
 Helper activity in antigen-specific antibody production mediated by CD4+ human cytotoxic T cell clones directed against herpes simplex virus.  
J Immunol. 1988 May 15;140(10):3419-25.  
PMID: 2452188 [PubMed - indexed for MEDLINE]

 **203:** [Bueso-Ramos CE, Donahoe RM, Nicholson JK, Madden JJ, Falek A](#) Related Articles, Links  
  
 Cytofluorometric analyses of human T cell CD2/CD4 inter-molecular interactions.  
J Immunol. 1988 Mar 1;140(5):1414-20.  
PMID: 2964474 [PubMed - indexed for MEDLINE]

 **204:** [Zoller M, Andriguetto G](#) Related Articles, Links  
  
 Induction of tolerance towards TNP entails down-regulation of an autoimmune attack.  
Immunology. 1988 Feb;63(2):205-12.  
PMID: 2965095 [PubMed - indexed for MEDLINE]

 **205:** [Pilarski LM, Krowka JF, Deans JP](#) Related Articles, Links  
  
 Soluble antigen-specific helper molecules active in the induction of cytotoxic T lymphocytes.  
Ann N Y Acad Sci. 1988;532:136-48. Review. No abstract available.  
PMID: 2972240 [PubMed - indexed for MEDLINE]

 **206:** [Fujiwara H, Hamaoka T](#) Related Articles, Links  
  
 Cellular mechanisms of tumor rejection in vivo and enhanced induction of anti tumor protective immunity applicable to tumor-specific immunotherapy.  
Prog Exp Tumor Res. 1988;32:69-103. Review. No abstract available.  
PMID: 2967523 [PubMed - indexed for MEDLINE]

 **207:** [Cassell D, Forman J](#) Related Articles, Links  
  
 Linked recognition of helper and cytotoxic antigenic determinants for the

generation of cytotoxic T lymphocytes.  
*Ann N Y Acad Sci.* 1988;532:51-60.  
 PMID: 2460011 [PubMed - indexed for MEDLINE]

**208:** [Sun D, Meyermann R, Wekerle H.](#) Related Articles, Links

Cytotoxic T cells in autoimmune disease of the central nervous system.  
*Ann N Y Acad Sci.* 1988;532:221-9. No abstract available.  
 PMID: 2460009 [PubMed - indexed for MEDLINE]

**209:** [Rothbard JB, Taylor WR.](#) Related Articles, Links

A sequence pattern common to T cell epitopes.  
*EMBO J.* 1988 Jan;7(1):93-100.  
 PMID: 2452085 [PubMed - indexed for MEDLINE]

**210:** [Lamb JR, McMichael AJ, Rothbard JB.](#) Related Articles, Links

T-cell recognition of influenza viral antigens.  
*Hum Immunol.* 1987 Jun;19(2):79-89. Review. No abstract available.  
 PMID: 2440836 [PubMed - indexed for MEDLINE]

**211:** [Walker C, Bettens F, Pichler WJ.](#) Related Articles, Links

Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation.  
*Eur J Immunol.* 1987 Jun;17(6):873-80.  
 PMID: 2439351 [PubMed - indexed for MEDLINE]

**212:** [Crispe IN, Bevan MJ.](#) Related Articles, Links

Expression and functional significance of the J11d marker on mouse thymocytes.  
*J Immunol.* 1987 Apr 1;138(7):2013-8.  
 PMID: 2435787 [PubMed - indexed for MEDLINE]

**213:** [Owens T, Miller JF.](#) Related Articles, Links

Interaction in vivo between hapten-specific suppressor T cells and an in vitro cultured helper T cell line.  
*J Immunol.* 1987 Mar 15;138(6):1687-92.  
 PMID: 2950167 [PubMed - indexed for MEDLINE]

**214:** [McDermott MR, Lukacher AE, Braciale VL, Braciale TJ, Bienenstock J.](#) Related Articles, Links

Characterization and in vivo distribution of influenza-virus-specific T-lymphocytes in the murine respiratory tract.  
*Am Rev Respir Dis.* 1987 Jan;135(1):245-9.  
 PMID: 2432811 [PubMed - indexed for MEDLINE]

**215:** [Mentzer SJ, Krensky AM, Burakoff SJ.](#) Related Articles, Links

Mapping functional epitopes of the human LFA-1 glycoprotein: monoclonal antibody inhibition of NK and CTL effectors.  
*Hum Immunol.* 1986 Nov;17(3):288-96.  
 PMID: 2432044 [PubMed - indexed for MEDLINE]

**216:** [Krowka JF, Shiozawa C, Diener E, Pilarski LM.](#) Related Articles, Links

Functional activity of soluble antigen-specific helper T cell molecules. Requirement for separable entities for the induction of cytotoxic T cell and B cell responses.  
*Transplantation.* 1986 Aug;42(2):162-7.  
 PMID: 2426845 [PubMed - indexed for MEDLINE]

**217:** [McConnell HM, Watts TH, Weis RM, Brian AA.](#) Related Articles, Links

 Supported planar membranes in studies of cell-cell recognition in the immune system.  
Biochim Biophys Acta. 1986 Jun 12;864(1):95-106. Review. No abstract available.  
PMID: 2941079 [PubMed - indexed for MEDLINE]

 **218:** Krowka JF, Singh B, Fotedar A, Mosmann T, Giedlin MA, Pilarski LM. [Related Articles](#), [Links](#)  
A requirement for physical linkage between determinants recognized by helper molecules and cytotoxic T cell precursors in the induction of cytotoxic T cell responses.  
J Immunol. 1986 May 15;136(10):3561-6.  
PMID: 2422257 [PubMed - indexed for MEDLINE]

 **219:** Heuer J, Kolsch E. [Related Articles](#), [Links](#)  
Selective elimination through a cytolytic mechanism of bovine serum albumin-specific T helper lymphocytes by T suppressor cells with the same antigen specificity.  
Eur J Immunol. 1986 Apr;16(4):400-4.  
PMID: 2422041 [PubMed - indexed for MEDLINE]

 **220:** Henny FC, Olijns PJ, Tanke HJ, Paul LC, van Es LA. [Related Articles](#), [Links](#)  
Comparison of monoclonal antibodies used for immunological monitoring of renal transplant recipients.  
Transplantation. 1986 Apr;41(4):442-7.  
PMID: 2421466 [PubMed - indexed for MEDLINE]

 **221:** Greenstein JL, Foran JA, Gorga JC, Burakoff SJ. [Related Articles](#), [Links](#)  
The role of T cell accessory molecules in the generation of class II-specific xenogeneic cytolytic T cells.  
J Immunol. 1986 Apr 1;136(7):2358-63.  
PMID: 2419431 [PubMed - indexed for MEDLINE]

 **222:** Reinherz EL. [Related Articles](#), [Links](#)  
Surface receptors involved in human T lymphocyte activation.  
Mt Sinai J Med. 1986 Mar;53(3):210-5. No abstract available.  
PMID: 2422552 [PubMed - indexed for MEDLINE]

 **223:** Jovanovic R, Worner T, Lieber CS, Paronetto F. [Related Articles](#), [Links](#)  
Lymphocyte subpopulations in patients with alcoholic liver disease.  
Dig Dis Sci. 1986 Feb;31(2):125-30.  
PMID: 2417790 [PubMed - indexed for MEDLINE]

 **224:** Hayglass KT, Naides SJ, Scott CF Jr, Benacerraf B, Sy MS. [Related Articles](#), [Links](#)  
T cell development in B cell-deficient mice. IV. The role of B cells as antigen-presenting cells in vivo.  
J Immunol. 1986 Feb 1;136(3):823-9.  
PMID: 2416835 [PubMed - indexed for MEDLINE]

 **225:** Moran TM, Reale MA, Monestier M, Mayer R, Schulman JL, Bona CA. [Related Articles](#), [Links](#)  
Idiotype of anti-influenza virus immune responses.  
Concepts Immunopathol. 1986;3:233-52. Review. No abstract available.  
PMID: 2439206 [PubMed - indexed for MEDLINE]

 **226:** Nakamura M, Ross DT, Briner TJ, Gefter ML. [Related Articles](#), [Links](#)  
Cytolytic activity of antigen-specific T cells with helper phenotype.  
J Immunol. 1986 Jan;136(1):44-7.  
PMID: 2415627 [PubMed - indexed for MEDLINE]

**227:** Lefrancois L, Puddington L, Machamer CE, Bevan MJ. [Related Articles](#) [Links](#)

 Acquisition of cytotoxic T lymphocyte-specific carbohydrate differentiation antigens. *J Exp Med.* 1985 Oct 1;162(4):1275-93. PMID: 2413157 [PubMed - indexed for MEDLINE]

**228:** Britten V, Hudson L. [Related Articles](#) [Links](#)

 Isolation and characterisation of human T-cell lines from a patient with Chagas' disease. *Lancet.* 1985 Sep 21;2(8456):637-9. PMID: 2412080 [PubMed - indexed for MEDLINE]

**229:** Mannel DN, Droege W, Falk W. [Related Articles](#) [Links](#)

 A combination of soluble helper factors bypasses the requirement for stimulator cells and induces nonspecific cytotoxic T cell responses. *Immunobiology.* 1985 Sep;170(3):146-57. PMID: 2414210 [PubMed - indexed for MEDLINE]

**230:** Simon MM, Nerz G, Prester M, Moll H. [Related Articles](#) [Links](#)

 Immunoregulation by mouse T cell clones. III. Cloned H-Y-specific cytotoxic T cells secrete a soluble mediator(s) that inhibits cytotoxic responses by acting on both Lyt-2- and L3T4- lymphocytes. *Eur J Immunol.* 1985 Aug;15(8):773-83. PMID: 2411568 [PubMed - indexed for MEDLINE]

**231:** Hackett CJ, Hurwitz JL, Dietzschold B, Gerhard W. [Related Articles](#) [Links](#)

 A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus. *J Immunol.* 1985 Aug;135(2):1391-4. PMID: 2409149 [PubMed - indexed for MEDLINE]

**232:** Lukacher AE, Morrison LA, Braciale VL, Malissen B, Braciale TJ. [Related Articles](#) [Links](#)

 Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. *J Exp Med.* 1985 Jul 1;162(1):171-87. PMID: 2409206 [PubMed - indexed for MEDLINE]

**233:** Mizushima Y, Fujiwara H, Takai Y, Shearer GM, Hamaoka T. [Related Articles](#) [Links](#)

 Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses. *J Natl Cancer Inst.* 1985 Jun;74(6):1269-73. PMID: 3158772 [PubMed - indexed for MEDLINE]

**234:** Andriguetto G, Zoller M. [Related Articles](#) [Links](#)

 Time course analysis of regulation of cytotoxic T cells. *Cell Immunol.* 1985 Jun;93(1):178-88. PMID: 3158408 [PubMed - indexed for MEDLINE]

**235:** Scott CF Jr, Tsurufuji M, Naides SJ, Sy MS. [Related Articles](#) [Links](#)

 Regulation of hapten-specific T-cell response. II. Functional analysis of helper T cells and cytotoxic T cells in animals suppressed by azobenzeneearsonate (ABA)-specific suppressor T cells. *Cell Immunol.* 1985 Jun;93(1):144-56. PMID: 3158405 [PubMed - indexed for MEDLINE]

236: [Rupp F, Acha-Orbea H, Hengartner H, Zinkernagel R, Joho R](#) [Related Articles](#) [Links](#)

Identical V beta T-cell receptor genes used in alloreactive cytotoxic and antigen plus I-A specific helper T cells.  
*Nature*. 1985 May 30-Jun 5;315(6018):425-7.  
 PMID: 2582268 [PubMed - indexed for MEDLINE]

237: [Juretic A, Malenica B, Juretic E, Klein J, Nagy ZA](#) [Related Articles](#) [Links](#)

Helper effects required during in vivo priming for a cytolytic response to the H-Y antigen in nonresponder mice.  
*J Immunol*. 1985 Mar;134(3):1408-14.  
 PMID: 2578505 [PubMed - indexed for MEDLINE]

238: [Woollett GR, Barclay AN, Puklavec M, Williams AF](#) [Related Articles](#) [Links](#)

Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes.  
*Eur J Immunol*. 1985 Feb;15(2):168-73.  
 PMID: 2578966 [PubMed - indexed for MEDLINE]

239: [Comoglio PM, Prat M, Brett S](#) [Related Articles](#) [Links](#)

Enhancement of immunity against RSV-induced sarcomas by generation of haptene-reactive helper T lymphocytes.  
*Immunology*. 1985 Feb;54(2):289-95.  
 PMID: 2578431 [PubMed - indexed for MEDLINE]

240: [Hamaoka T, Takai Y, Kosugi A, Mizushima Y, Shima J, Kusama T, Fujiwara H](#) [Related Articles](#) [Links](#)

The augmentation of tumor-specific immunity using haptene muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptene MDP derivative cross-reactive with *Bacillus Calmette Guerin* and its application to enhanced induction of tumor immunity.  
*Cancer Immunol Immunother*. 1985;20(3):183-8.  
 PMID: 2933141 [PubMed - indexed for MEDLINE]

241: [Toder V, Blank M, Nebel L](#) [Related Articles](#) [Links](#)

Cytotoxic T lymphocytes, interleukin-2 and trophoblast involvement.  
*Contrib Gynecol Obstet*. 1985;14:23-35. Review. No abstract available.  
 PMID: 2415297 [PubMed - indexed for MEDLINE]

242: [Culbert EJ, Kontiainen S, Feldmann M](#) [Related Articles](#) [Links](#)

The relationship between secreted and cell surface antigen-binding molecules synthesized by T cells. I. Function-related isotypic determinants on T cells defined by antisera to antigen-specific helper and suppressor factors.  
*Immunology*. 1984 Nov;53(3):481-90.  
 PMID: 6208146 [PubMed - indexed for MEDLINE]

243: [Yasukawa M, Zarling JM](#) [Related Articles](#) [Links](#)

Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.  
*J Immunol*. 1984 Nov;133(5):2736-42.  
 PMID: 6207243 [PubMed - indexed for MEDLINE]

244: [Ohta N, Reinsmoen NL, Bach FH](#) [Related Articles](#) [Links](#)

Cellular basis of anti-SB response.  
*Hum Immunol*. 1984 Nov;11(3):127-41.

PMID: 6083998 [PubMed - indexed for MEDLINE]

□ 245: [Moretta A, Pantaleo G, Maggi E, Mingari MC.](#)[Related Articles](#), [Links](#)

 Recent advances in the phenotypic and functional analysis of human T lymphocytes.

Semin Hematol. 1984 Oct;21(4):257-69. Review. No abstract available.  
PMID: 6208614 [PubMed - indexed for MEDLINE]

□ 246: [Tite JP, Janeway CA Jr.](#)[Related Articles](#), [Links](#)

 Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis.

Eur J Immunol. 1984 Oct;14(10):878-86.  
PMID: 6208035 [PubMed - indexed for MEDLINE]

□ 247: [Krowka JF, Shiozawa C, Diener E, Paetkau V, Pilarski LM.](#)[Related Articles](#), [Links](#)

 Induction of cytotoxic lymphocyte responses by antigen-specific helper factors.

J Immunol. 1984 Oct;133(4):2018-24.  
PMID: 6206146 [PubMed - indexed for MEDLINE]

□ 248: [Wolos JA, Smith JB.](#)[Related Articles](#), [Links](#)

 Helper cells in the autologous mixed lymphocyte reaction (AMLR). IV. H-2 restriction and specificity of cytotoxic cells induced by AMLR helper factor.

Cell Immunol. 1984 Sep;87(2):714-9.  
PMID: 6235927 [PubMed - indexed for MEDLINE]

□ 249: [Fitch FW, Lancki DW, Dialynas DP.](#)[Related Articles](#), [Links](#)

 Contributions of T cell clones to an understanding of the T cell receptor for antigen.

Transplantation. 1984 Sep;38(3):201-8. Review.  
PMID: 6206629 [PubMed - indexed for MEDLINE]

□ 250: [Sopori ML, Cohen DA, Cherian S, Roszman TL, Kaplan AM.](#)[Related Articles](#), [Links](#)

 T-lymphocyte heterogeneity in the rat: separation of distinct rat T-lymphocyte populations which respond in syngeneic and allogeneic mixed lymphocyte reactions.

Cell Immunol. 1984 Aug;87(1):295-303.  
PMID: 6204777 [PubMed - indexed for MEDLINE]

□ 251: [Ting CC, Hargrove ME.](#)[Related Articles](#), [Links](#)

 Regulation of the activation of cytotoxic T lymphocytes by prostaglandins and antigens.

J Immunol. 1984 Aug;133(2):660-6.  
PMID: 6203973 [PubMed - indexed for MEDLINE]

□ 252: [Kwong PC, Kilburn DG, Teh HS.](#)[Related Articles](#), [Links](#)

 Induction of CTL responses to alloantigens by a Db-specific T helper clone.

J Immunol. 1984 Aug;133(2):653-9.  
PMID: 6203972 [PubMed - indexed for MEDLINE]

□ 253: [Czitrom AA, Gascoigne NR, Edwards S, Waterfield DJ.](#)[Related Articles](#), [Links](#)

 Induction of minor alloantigen-specific T cell subsets in vivo: recognition of processed antigen by helper but not by cytotoxic T cell precursors.

J Immunol. 1984 Jul;133(1):33-9.

PMID: 6202785 [PubMed - indexed for MEDLINE]

 254: [Vargo PM, Battisto JR.](#)[Related Articles](#), [Links](#)

Tolerance to Mls-disparate cells induces suppressor T cells that act at the helper level to prevent *in vivo* generation of cytolytic lymphocytes to hapten-altered self.

J Immunol. 1984 Jun;132(6):2796-801.

PMID: 6233362 [PubMed - indexed for MEDLINE]

 255: [Karasuyama H, Kim M, Okumura K, Tada T.](#)[Related Articles](#), [Links](#)

Heterogeneity of Ig $\kappa$ -linked allotypic determinants expressed on functional T cell subsets as detected by monoclonal antibodies.

Eur J Immunol. 1984 May;14(5):413-20.

PMID: 6202527 [PubMed - indexed for MEDLINE]

 256: [Clayberger C, Dekruyff RH, Cantor H.](#)[Related Articles](#), [Links](#)

Immunoregulatory activities of autoreactive T cells: an I-A-specific T cell clone mediates both help and suppression of antibody responses.

J Immunol. 1984 May;132(5):2237-43.

PMID: 6201537 [PubMed - indexed for MEDLINE]

b

 257: [Callard RE, Winger CM, Tiernan SL.](#)[Related Articles](#), [Links](#)

Antigen-specific suppression of human antibody responses by allogeneic T cells. I. Frequency and antigen specificity of allogeneic suppressor T cells and their role in major histocompatibility complex-controlled genetic restriction.

J Exp Med. 1984 Apr 1;159(4):1225-37.

PMID: 6200565 [PubMed - indexed for MEDLINE]

 258: [Wee SL, Bach FH.](#)[Related Articles](#), [Links](#)

Functionally distinct human T cell clones that produce lymphokines with IL-2-like activity.

Hum Immunol. 1984 Mar;9(3):175-88.

PMID: 6199338 [PubMed - indexed for MEDLINE]

 259: [Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.](#)[Related Articles](#), [Links](#)

Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.

J Immunol. 1984 Mar;132(3):1571-7.

PMID: 6198397 [PubMed - indexed for MEDLINE]

 260: [Fujiwara H, Shimizu Y, Takai Y, Wakamiya N, Ueda S, Kato S, Hamaoka T.](#)[Related Articles](#), [Links](#)

The augmentation of tumor-specific immunity by virus help. I.

Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.

Eur J Immunol. 1984 Feb;14(2):171-5.

PMID: 6199215 [PubMed - indexed for MEDLINE]

 261: [Gascoigne NR, Lai PK.](#)[Related Articles](#), [Links](#)

T helper cell lines that augment *in vivo* cytotoxic T-cell responses to minor alloantigens.

Cell Immunol. 1984 Feb;83(2):302-12.

PMID: 6198100 [PubMed - indexed for MEDLINE]

 262: [Scott CF Jr, Tsurufuji M, Lu CY, Finberg R, Sy MS.](#)[Related Articles](#), [Links](#)

Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-

 **lpr/lpr and MRL/Mp-+/+ mice.**  
J Immunol. 1984 Feb;132(2):633-9.  
PMID: 6197469 [PubMed - indexed for MEDLINE]

**263: Qvigstad E, Thorsby E, Reinsmoen NL, Bach FH.** [Related Articles](#), [Links](#)

 Close association between the Dw14 (LD40) subtype of HLA-DR4 and a restriction element for antigen-specific T-cell clones.  
Immunogenetics. 1984;20(5):583-8. No abstract available.  
PMID: 6209217 [PubMed - indexed for MEDLINE]

**264: Bach FH.** [Related Articles](#), [Links](#)

 Elicitation of T-lymphocyte responses by major histocompatibility complex encoded determinants.  
Prog Clin Biol Res. 1984;149:221-33. No abstract available.  
PMID: 6204339 [PubMed - indexed for MEDLINE]

**265: Pilarski LM, Wegmann TG.** [Related Articles](#), [Links](#)

 Antigen-specific helper T cells recognize determinants encoded in the H-2D region of the H-2 gene complex.  
Immunogenetics. 1984;19(4):301-10.  
PMID: 6201440 [PubMed - indexed for MEDLINE]

**266: Thorsby E.** [Related Articles](#), [Links](#)

 The role of HLA in T cell activation.  
Hum Immunol. 1984 Jan;9(1):1-7. No abstract available.  
PMID: 6198308 [PubMed - indexed for MEDLINE]

**267: Takai Y, Mizuochi T, Fujiwara H, Hamaoka T.** [Related Articles](#), [Links](#)

 Effects of hapten epitope structure and hapten-self conjugation pattern on T cell specificity and Ir gene control in hapten-self cytotoxic and helper T cell responses.  
J Immunol. 1984 Jan;132(1):57-62.  
PMID: 6197460 [PubMed - indexed for MEDLINE]

**268: Miller SD, Butler LD, Cleveland RP, Moorhead JW, Claman HN, Chiller JC.** [Related Articles](#), [Links](#)

 T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.  
Cell Immunol. 1983 Dec;82(2):378-93.  
PMID: 6197193 [PubMed - indexed for MEDLINE]

**269: Niederkom JY, Streilein JW.** [Related Articles](#), [Links](#)

 Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.  
J Immunol. 1983 Dec;131(6):2670-4.  
PMID: 6196396 [PubMed - indexed for MEDLINE]

**270: Widmer MB, Bach FH.** [Related Articles](#), [Links](#)

 Antigen specificity and helper characteristics of antigen-driven helper-cell-independent cytolytic T lymphocytes.  
Transplantation. 1983 Nov;36(5):565-7.  
PMID: 6195786 [PubMed - indexed for MEDLINE]

**271: Oger J, Roos R, Antel JP.** [Related Articles](#), [Links](#)

 **Immunology of multiple sclerosis.**  
Neurol Clin. 1983 Aug;1(3):655-79.  
PMID: 6209537 [PubMed - indexed for MEDLINE]

**272: Chatenoud L, Chkoff N, Kreis H, Bach JF.** [Related Articles](#), [Links](#)

 **Interest in and limitations of monoclonal anti-T-cell antibodies for the follow-up of renal transplant patients.**  
Transplantation. 1983 Jul;36(1):45-50.  
PMID: 6191417 [PubMed - indexed for MEDLINE]

**273: Miller SD, Butler LD.** [Related Articles](#), [Links](#)

 **T cell responses induced by the parenteral injection of antigen-modified syngeneic cells. I. Induction, characterization, and regulation of antigen-specific T helper cells involved in delayed-type hypersensitivity responses.**  
J Immunol. 1983 Jul;131(1):77-85.  
PMID: 6190929 [PubMed - indexed for MEDLINE]

**274: Robbins DS, Fudenberg HH.** [Related Articles](#), [Links](#)

 **Editorial retrospective. Human lymphocyte subpopulations in metastatic neoplasia--six years later.**  
N Engl J Med. 1983 Jun 30;308(26):1595-7. No abstract available.  
PMID: 6190084 [PubMed - indexed for MEDLINE]

**275: Wilkinson NM, Ishikawa H, Kubota E, Dutton RW, Saito K.** [Related Articles](#), [Links](#)

 **Fetal calf serum-injected F1 mice spontaneously generate specific anti-parental cytotoxic T lymphocytes in vitro culture.**  
Cell Immunol. 1983 Jun;78(2):236-48.  
PMID: 6190576 [PubMed - indexed for MEDLINE]

**276: Friedman SM, Thompson GS.** [Related Articles](#), [Links](#)

 **Functionally restricted, allospecific, human helper T cell lines that amplify either B cell or cytolytic T cell responses.**  
J Exp Med. 1983 May 1;157(5):1675-80.  
PMID: 6189944 [PubMed - indexed for MEDLINE]

**277: Chan MM, Tada N, Kimura S, Hoffmann MK, Miller RA, Stutman O, Hammerling U.** [Related Articles](#), [Links](#)

 **Characterization of T lymphocyte subsets with monoclonal antibodies: discovery of a distinct marker, Ly-m22, of T suppressor cells.**  
J Immunol. 1983 May;130(5):2075-8.  
PMID: 6187835 [PubMed - indexed for MEDLINE]

**278: Gautam SC, Hilfiker ML, Battisto JR.** [Related Articles](#), [Links](#)

 **In vivo development of cytolytic T lymphocytes (CTL) to hapten-altered self: Mls-disparate cells facilitate the response by neutralizing IL 2 inhibitor.**  
J Immunol. 1983 Feb;130(2):533-7.  
PMID: 6217243 [PubMed - indexed for MEDLINE]

**279: Roopenian DC, Widmer MB, Orosz CG, Bach FH.** [Related Articles](#), [Links](#)

 **Helper cell-independent cytolytic T lymphocytes specific for a minor histocompatibility antigen.**  
J Immunol. 1983 Feb;130(2):542-5.  
PMID: 6184397 [PubMed - indexed for MEDLINE]

**280: Goodman JW, Sercarz EE.** [Related Articles](#), [Links](#)

 The complexity of structures involved in T-cell activation.  
Annu Rev Immunol. 1983;1:465-98. Review. No abstract available.  
PMID: 6085787 [PubMed - indexed for MEDLINE]

 **281:** Klein J, Marusic M, Nagy ZA. Related Articles, Links

 The seven rules of MHC restriction.  
Transplant Proc. 1982 Sep;14(3):581-3. No abstract available.  
PMID: 6184862 [PubMed - indexed for MEDLINE]

 **282:** Einberg R, Ertl HC, Shapiro ME. Related Articles, Links

 Virus-specific cytolytic cells. Their in vivo function.  
Surv Immunol Res. 1982;1(3):248-54. Review. No abstract available.  
PMID: 6195715 [PubMed - indexed for MEDLINE]

 **283:** Falkoff RM, Scavulli JF, Dutton RW. Related Articles, Links

 Independent analysis of T helper and T killer cell function in young and old NZB mice.  
J Immunol. 1978 Sep;121(3):897-902.  
PMID: 80432 [PubMed - indexed for MEDLINE]

[Display](#) [Summary](#)  Show:  [Sort](#)  [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 16 2004 07:00:47



National  
Library  
of Medicine



Entrez PubMed Nucleotide Protein Genoms Structure OMIM PMC Journals Books

Search PubMed for Cytotoxic T cell epitope AND T helper cell epitope Go! Clear

Limits

Preview/Index

History

Clipboard

Details

Display Summary

Show: 500

Sort

Send to

Text

One page

Items 1 - 276 of 276

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Kondo Y, Asabe S, Kobayashi K, Shiina M, Niitsuma H, Ueno Y, Kobayashi T, Shimosegawa T.](#) Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. *J Med Virol.* 2004 Nov;74(3):425-33. PMID: 15368520 [PubMed - indexed for MEDLINE]

2: [Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K.](#) Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. *Cancer Res.* 2004 Aug 15;64(16):5830-8. PMID: 15313927 [PubMed - indexed for MEDLINE]

3: [Ramakrishna L, Anand KK, Mohankumar KM, Ranga U.](#) Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. *J Virol.* 2004 Sep;78(17):9174-89. PMID: 15308713 [PubMed - indexed for MEDLINE]

4: [Romano M, Denis O, D'Souza S, Wang XM, Ottenhoff TH, Brule JM, Huygen K.](#) Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of *Mycobacterium tuberculosis*. *J Immunol.* 2004 Jun 1;172(11):6913-21. PMID: 15153510 [PubMed - indexed for MEDLINE]

5: [Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP.](#) Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. *Vaccine.* 2004 May 7;22(15-16):1985-91. PMID: 15121311 [PubMed - indexed for MEDLINE]

6: [Wang R, Epstein J, Charoenvit Y, Baracros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL.](#) Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. *J Immunol.* 2004 May 1;172(9):5561-9. PMID: 15100299 [PubMed - indexed for MEDLINE]

7: [Behrens GM, Li M, Davey GM, Allison J, Flavell RA, Carbone FR, Heath WR.](#) Helper requirements for generation of effector CTL to islet beta cell antigens.

J Immunol. 2004 May 1;172(9):5420-6.

PMID: 15100283 [PubMed - indexed for MEDLINE]

 **8:** [Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M.](#) Related Articles, Links  
[Beretta M.](#)

 **9:** [The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.](#) Related Articles, Links  
J Immunol. 2004 May 1;172(9):5249-61.  
PMID: 15100263 [PubMed - indexed for MEDLINE]

 **10:** [Balla-Jhagjhoorsingh SS, Koopman G, Mooij P, Koornstra W, McCormack S, Weber J, Pantaleo G, Heeney JL.](#) Related Articles, Links  
Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA-CD62L-CCR7- memory T-helper cells.  
AIDS. 2004 Apr 9;18(6):837-48.  
PMID: 15060431 [PubMed - indexed for MEDLINE]

 **11:** [Lu J, Higashimoto Y, Appella E, Celis E.](#) Related Articles, Links  
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.  
J Immunol. 2004 Apr 1;172(7):4575-82.  
PMID: 15034075 [PubMed - indexed for MEDLINE]

 **12:** [Nagata T, Aoshi T, Uchijima M, Suzuki M, Koide Y.](#) Related Articles, Links  
Cytotoxic T-lymphocyte-, and helper T-lymphocyte-oriented DNA vaccination.  
DNA Cell Biol. 2004 Feb;23(2):93-106. Review.  
PMID: 15000749 [PubMed - indexed for MEDLINE]

 **13:** [Ramakrishna V, Treml JE, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ.](#) Related Articles, Links  
Mannose receptor targeting of tumor antigen pme17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.  
J Immunol. 2004 Mar 1;172(5):2845-52.  
PMID: 14978085 [PubMed - indexed for MEDLINE]

 **14:** [Deml L, Wild J, Wagner R.](#) Related Articles, Links  
Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity.  
Methods Mol Med. 2004;94:133-57.  
PMID: 14959827 [PubMed - indexed for MEDLINE]

 **15:** [Schumacher R, Adamina M, Zurbriggen R, Bolli M, Padovan E, Zajac P, Heberer M, Spagnoli GC.](#) Related Articles, Links  
Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation.  
Vaccine. 2004 Jan 26;22(5-6):714-23.  
PMID: 14741164 [PubMed - indexed for MEDLINE]

 **16:** [Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.](#) Related Articles, Links  
Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.  
J Immunol. 2003 Dec 15;171(12):6968-75.  
PMID: 14662905 [PubMed - indexed for MEDLINE]

 **17:** [Kosor E, Gagro A, Drazenovic V, Kuzman I, Jeren T, Rakusic S, Rabatic S, Markotic A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brklicic V, Gjenero-Margan I, Kaic B, Mlinaric-Galinovic G, Kastelan A, Dekaris D.](#) Related Articles, Links

 [MHC tetramers: tracking specific immunity]  
Acta Med Croatica. 2003;57(4):255-9. Review. Croatian.  
PMID: 14639858 [PubMed - indexed for MEDLINE]

 17: [Shen L, Schroers R, Hammer J, Huang XF, Chen SY.](#) [Related Articles](#), [Links](#)  
Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.  
Cancer Immunol Immunother. 2004 May;53(5):391-403. Epub 2003 Nov 18.  
PMID: 14624313 [PubMed - indexed for MEDLINE]

 18: [Kobayashi H, Omiva R, Sodey B, Yanai M, Oikawa K, Sato K, Kimura S, Senju S, Nishimura Y, Tateno M, Celis E.](#) [Related Articles](#), [Links](#)  
Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.  
Clin Cancer Res. 2003 Nov 1;9(14):5386-93.  
PMID: 14614024 [PubMed - indexed for MEDLINE]

 19: [Rosato A, Zoso A, Milan G, Macino B, Dalla Santa S, Tosello V, Di Carlo E, Musiani P, Whalen RG, Zanovello P.](#) [Related Articles](#), [Links](#)  
Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.  
J Immunol. 2003 Nov 15;171(10):5172-9.  
PMID: 14607917 [PubMed - indexed for MEDLINE]

 20: [Benito JM, Lopez M, Lozano S, Martinez P, Kuroda M, Gonzalez- Lahoz J, Soriano V.](#) [Related Articles](#), [Links](#)  
Phenotype and functional characteristics of HIV-specific cytotoxic CD8+ T cells in chronically infected patients: dual effects of highly active antiretroviral therapy.  
J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):255-66.  
PMID: 14600569 [PubMed - indexed for MEDLINE]

 21: [Daftarian P, Ali S, Sharan R, Lacey SF, La Rosa C, Longmate J, Buck C, Siliciano RF, Diamond DJ.](#) [Related Articles](#), [Links](#)  
Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge.  
J Immunol. 2003 Oct 15;171(8):4028-39.  
PMID: 14530323 [PubMed - indexed for MEDLINE]

 22: [Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D.](#) [Related Articles](#), [Links](#)  
Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.  
Am J Transplant. 2003 Nov;3(11):1369-77.  
PMID: 14525597 [PubMed - indexed for MEDLINE]

 23: [Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P.](#) [Related Articles](#), [Links](#)  
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.  
J Immunol. 2003 Sep 1;171(5):2366-73.  
PMID: 12928383 [PubMed - indexed for MEDLINE]

 24: [Roh S, Kim K.](#) [Related Articles](#), [Links](#)  
Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells.  
Microbiol Immunol. 2003;47(6):453-60.  
PMID: 12906106 [PubMed - indexed for MEDLINE]

**25:** Vichier-Guerre S, Lo-Man R, BenMohamed L, Deriaud E, Kovats S, Leclerc C, Bay S. [Related Articles](#), [Links](#)

Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. *J Pept Res.* 2003 Sep;62(3):117-24. PMID: 12895273 [PubMed - indexed for MEDLINE]

**26:** Ishibashi H, Nakamura M, Shimoda S, Gershwin ME. [Related Articles](#), [Links](#)

T cell immunity and primary biliary cirrhosis. *Autoimmun Rev.* 2003 Jan;2(1):19-24. Review. PMID: 12848971 [PubMed - indexed for MEDLINE]

**27:** de Rijke B, Fredrix H, Zoetbrood A, Scherpen F, Witteveen H, de Witte T, van de Wiel-Van Kemenade E, Dolstra H. [Related Articles](#), [Links](#)

Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy. *Blood.* 2003 Oct 15;102(8):2885-91. Epub 2003 Jul 03. PMID: 12842998 [PubMed - indexed for MEDLINE]

**28:** Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB. [Related Articles](#), [Links](#)

P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. *Cancer Res.* 2003 Jul 1;63(13):3675-81. PMID: 12839958 [PubMed - indexed for MEDLINE]

**29:** Wang JH, Layden TJ, Eckels DD. [Related Articles](#), [Links](#)

Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus: transition from a Th1 to a Th2 response. *Hum Immunol.* 2003 Jul;64(7):662-73. PMID: 12826368 [PubMed - indexed for MEDLINE]

**30:** Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. [Related Articles](#), [Links](#)

Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. *Cancer Res.* 2003 Jun 1;63(11):2844-54. PMID: 12782590 [PubMed - indexed for MEDLINE]

**31:** Lopez-Diaz de Cerio A, Lasarte JJ, Casares N, Sarobe P, Ruiz M, Prieto J, Borrás-Cuesta F. [Related Articles](#), [Links](#)

Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. *Int Immunol.* 2003 Jun;15(6):691-9. PMID: 12750353 [PubMed - indexed or MEDLINE]

**32:** Mustafa AS, Shaban FA, Al-Attiyah R, Abal AT, El-Shamy AM, Andersen P, Oftung F. [Related Articles](#), [Links](#)

Human Th1 cell lines recognize the *Mycobacterium tuberculosis* ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules. *Scand J Immunol.* 2003 Feb;57(2):125-34. PMID: 12588658 [PubMed - indexed for MEDLINE]

**33:** Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC, Liaw YF. [Related Articles](#), [Links](#)

Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic

implications.  
J Biomed Sci. 2003 Jan-Feb;10(1):120-35.  
PMID: 12566993 [PubMed - indexed for MEDLINE]

34: Monzavi-Karbassi B, Shamloo S, Kieber-Emmons M, Jousheghany Related Articles, Links  
F, Luo P, Lin K Y, Cunto-Amesty G, Weiner DB, Kieber-Emmons  
T.

Priming characteristics of peptide mimotopes of carbohydrate antigens.  
Vaccine. 2003 Jan 30;21(7-8):753-60. Review.  
PMID: 12531355 [PubMed - indexed for MEDLINE]

35: Sakae G, Hiroi T, Nakagawa Y, Someya K, Iwatani K, Sawa Y, Related Articles, Links  
Takahashi H, Honda M, Kunisawa J, Kiyono H.

HIV mucosal vaccine: nasal immunization with gp160-encapsulated  
hemagglutinating virus of Japan-liposome induces antigen-specific CTLs  
and neutralizing antibody responses.  
J Immunol. 2003 Jan 1;170(1):495-502.  
PMID: 12496436 [PubMed - indexed for MEDLINE]

36: Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S, Related Articles, Links  
Towards patient-specific tumor antigen selection for vaccination.  
Immunol Rev. 2002 Oct;188:164-76. Review.  
PMID: 12445290 [PubMed - indexed for MEDLINE]

37: Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer JH, Related Articles, Links  
Fernando GJ.

Antigen-specific CD4+ T-cell help is required to activate a memory CD8+  
T cell to a fully functional tumor killer cell.  
Cancer Res. 2002 Nov 15;62(22):6438-41.  
PMID: 12438231 [PubMed - indexed for MEDLINE]

38: Jyothi MD, Flavell RA, Geiger TL, Related Articles, Links  
Targeting autoantigen-specific T cells and suppression of autoimmune  
encephalomyelitis with receptor-modified T lymphocytes.  
Nat Biotechnol. 2002 Dec;20(12):1215-20.  
PMID: 12426577 [PubMed - indexed for MEDLINE]

39: Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms Related Articles, Links  
ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van  
Der Burg SH, Offringa R, Melief CJ.

Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.  
Cancer Res. 2002 Nov 1;62(21):6187-93.  
PMID: 12414646 [PubMed - indexed for MEDLINE]

40: Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Related Articles, Links  
Herranz M, Sangro B, Prieto J, Borrás-Cuesta E, Celis E.

Identification of an antigenic epitope for helper T lymphocytes from  
carcinoembryonic antigen.  
Clin Cancer Res. 2002 Oct;8(10):3219-25.  
PMID: 12374692 [PubMed - indexed for MEDLINE]

41: Loomba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Related Articles, Links  
Oliveira M, Detorio M, Essex M, Wainberg MA.

Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes  
within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and  
Botswana following selection of antiretroviral drug resistance.  
Antiviral Res. 2002 Nov;56(2):129-42.  
PMID: 12367719 [PubMed - indexed for MEDLINE]

42: Lauemoller SL, Kesmir C, Corbet SL, Fomsgaard A, Holm A, Related Articles, Links  
Claesson MH, Brunak S, Buus S.

 Identifying cytotoxic T cell epitopes from genomic and proteomic information: "The human MHC project.". Rev Immunogenet. 2000;2(4):477-91. Review. PMID: 12361091 [PubMed - indexed for MEDLINE]

 43: Dearman RJ, Filby A, Humphreys IR, Kimber L. [Related Articles](#), [Links](#)

 Interleukins 5 and 13 characterize immune responses to respiratory sensitizing acid anhydrides. J Appl Toxicol. 2002 Sep-Oct;22(5):317-25. PMID: 12355561 [PubMed - indexed for MEDLINE]

 44: Zhu F, Eckels DD. [Related Articles](#), [Links](#)

 Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Hum Immunol. 2002 Sep;63(9):710-8. PMID: 12175725 [PubMed - indexed for MEDLINE]

 45: Fernando GJ, Khammanivong V, Leggatt GR, Liu WJ, Frazer IH. [Related Articles](#), [Links](#)

 The number of long-lasting functional memory depends on the nature of the initial nonspecific stimulation. Eur J Immunol. 2002 Jun;32(6):1541-9. PMID: 12115636 [PubMed - indexed for MEDLINE]

 46: Christensen JE, Christensen JP, Kristensen NN, Hansen NJ, Stryhn A, Thomsen AR. [Related Articles](#), [Links](#)

 Role of CD28 co-stimulation in generation and maintenance of virus-specific T cells. Int Immunol. 2002 Jul;14(7):701-11. PMID: 12096029 [PubMed - indexed for MEDLINE]

 47: Mukai K, Yasutomi Y, Watanabe M, Kenjo A, Aota T, Wang L, Nishikawa H, Ishihara M, Fujita T, Kurabayashi K, Shiku H. [Related Articles](#), [Links](#)

 HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations. Gene Ther. 2002 Jul;9(13):879-88. PMID: 12080382 [PubMed - indexed for MEDLINE]

 48: Buonaguro L, Racioppi L, Tornesello ML, Aira C, Visciano ML, Biryahwaho B, Sempala SD, Giraldo G, Buonaguro FM. [Related Articles](#), [Links](#)

 Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res. 2002 Jun;54(3):189-201. PMID: 12062391 [PubMed - indexed for MEDLINE]

 49: Newman MJ, Livingston B, McKinney DM, Chesnut RW, Sette A. [Related Articles](#), [Links](#)

 T-lymphocyte epitope identification and their use in vaccine development for HIV-1. Front Biosci. 2002 Jun 01;7:d1503-15. Review. PMID: 12048179 [PubMed - indexed for MEDLINE]

 50: Cho HJ, Hayashi T, Datta SK, Takabayashi K, Van Uden JH, Homer A, Corr M, Raz E. [Related Articles](#), [Links](#)

 IFN-alpha beta promote priming of antigen-specific CD4+ and CD8+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol. 2002 May 15;168(10):4907-13. PMID: 11994440 [PubMed - indexed for MEDLINE]

 51: Giuntoli RL 2nd, Lai J, Kobayashi H, Kennedy R, Celis E. [Related Articles](#), [Links](#)

 **51:** Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function.  
Clin Cancer Res. 2002 Mar;8(3):922-31.  
PMID: 11895927 [PubMed - indexed for MEDLINE]

 **52:** Le Gal FA, Prevost-Blondel A, Lengagne R, Bossus M, Farace F, Chaboissier A, Gras-Masse H, Engelhard VH, Guillet JG, Gahery-Segard H. [Related Articles](#), [Links](#)  
Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinical study.  
Int J Cancer. 2002 Mar 10;98(2):221-7.  
PMID: 11857412 [PubMed - indexed for MEDLINE]

 **53:** Armengol E, Wiesmuller KH, Wienhold D, Buttner M, Pfaff E, Jung G, Saalmuller A. [Related Articles](#), [Links](#)  
Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus.  
J Gen Virol. 2002 Mar;83(Pt 3):551-60.  
PMID: 11842250 [PubMed - indexed for MEDLINE]

 **54:** Mintern JD, Davey GM, Belz GT, Carbone FR, Heath WR. [Related Articles](#), [Links](#)  
Cutting edge: precursor frequency affects the helper dependence of cytotoxic T cells.  
J Immunol. 2002 Feb 1;168(3):977-80.  
PMID: 11801627 [PubMed - indexed for MEDLINE]

 **55:** Dorr J, Waiczies S, Wendling U, Seeger B, Zipp F. [Related Articles](#), [Links](#)  
Induction of TRAIL-mediated glioma cell death by human T cells.  
J Neuroimmunol. 2002 Jan;122(1-2):117-24.  
PMID: 11777550 [PubMed - indexed for MEDLINE]

 **56:** Guardiola J, De Berardinis P, Sartorius R, Fanutti C, Perham RN, Del Pozzo G. [Related Articles](#), [Links](#)  
Phage display of epitopes from HIV-1 elicits strong cytolytic responses in vitro and in vivo.  
Adv Exp Med Biol. 2001;495:291-8. No abstract available.  
PMID: 11774581 [PubMed - indexed for MEDLINE]

 **57:** Smith SG, Patel PM, Porte J, Selby PJ, Jackson AM. [Related Articles](#), [Links](#)  
Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.  
Clin Cancer Res. 2001 Dec;7(12):4253-61.  
PMID: 11751527 [PubMed - indexed for MEDLINE]

 **58:** Mitra-Kaushik S, Shaila MS, Karande A, Nayak R. [Related Articles](#), [Links](#)  
Idiotype and anti-idiotype specific T cell responses on transplantation with hybridomas reactive to viral hemagglutinin and human tumor antigen.  
Immunol Lett. 2002 Feb 1;80(2):81-7.  
PMID: 11750038 [PubMed - indexed for MEDLINE]

 **59:** Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA. [Related Articles](#), [Links](#)  
High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.  
J Clin Invest. 2001 Dec;108(11):1677-85.  
PMID: 11733563 [PubMed - indexed for MEDLINE]

 **60:** Belyakov IM, Hei Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsá J, Watkins DL, Ailen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA. [Related Articles](#), [Links](#)

 **Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.**  
Nat Med. 2001 Dec;7(12):1320-6.  
PMID: 11726972 [PubMed - indexed for MEDLINE]

 **61: Kobayashi H, Lu J, Celis E.** [Related Articles](#), [Links](#)

 **Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.**  
Cancer Res. 2001 Oct 15;61(20):7577-84.  
PMID: 11606397 [PubMed - indexed for MEDLINE]

 **62: Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG.** [Related Articles](#), [Links](#)

 **Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.**  
Clin Cancer Res. 2001 Oct;7(10):3012-24.  
PMID: 11595689 [PubMed - indexed for MEDLINE]

 **63: Hess AD, Thoburn C, Chen W, Miura Y, Van der Wall E.** [Related Articles](#), [Links](#)

 **The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.**  
Clin Immunol. 2001 Oct;101(1):67-76. Erratum in: Clin Immunol 2001 Dec;101(3):381.  
PMID: 11580228 [PubMed - indexed for MEDLINE]

 **64: van der Meer A, Allebes WA, Paardekooper J, Ruiter J, Joosten I.** [Related Articles](#), [Links](#)

 **HLA-C mismatches induce strong cytotoxic T-cell reactivity in the presence of an additional DRB/DQB mismatch and affect NK cell-mediated alloreactivity.**  
Transplantation. 2001 Sep 15;72(5):923-9.  
PMID: 11571460 [PubMed - indexed for MEDLINE]

 **65: Kim SK, DeMars R.** [Related Articles](#), [Links](#)

 **Epitope clusters in the major outer membrane protein of Chlamydia trachomatis.**  
Curr Opin Immunol. 2001 Aug;13(4):429-36. Review.  
PMID: 11498298 [PubMed - indexed for MEDLINE]

 **66: zum Buschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H.** [Related Articles](#), [Links](#)

 **The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.**  
J Immunol. 2001 Aug 1;167(3):1712-9.  
PMID: 11466395 [PubMed - indexed for MEDLINE]

 **67: Perlaza BL, Sauzet JP, Balde AT, Brahimi K, Tall A, Corradin G, Druilhe P.** [Related Articles](#), [Links](#)

 **Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.**  
Eur J Immunol. 2001 Jul;31(7):2200-9.  
PMID: 11449374 [PubMed - indexed for MEDLINE]

 **68: Bocher WO, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditi F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle PR, Lohr HF, Reisner Y.** [Related Articles](#), [Links](#)

 **Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera**

mouse model of chronic HBV infection.  
Eur J Immunol. 2001 Jul;31(7):2071-9.  
PMID: 11449360 [PubMed - indexed for MEDLINE]

69: Fonseca DP, Benaissa-Trouw B, van Engelen M, Kraaijeveld CA. [Related Articles](#), [Links](#)  
Snippe H, Verheul AF.

Induction of cell-mediated immunity against *Mycobacterium tuberculosis* using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.  
Infect Immun. 2001 Aug;69(8):4839-45.  
PMID: 11447158 [PubMed - indexed for MEDLINE]

70: Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. [Related Articles](#), [Links](#)

Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.  
Cancer Res. 2001 Jun 15;61(12):4773-8.  
PMID: 11406551 [PubMed - indexed for MEDLINE]

71: Ishioka GY, Fikes J, Qin M, Gianfrani C, Chesnut RW, Kahn LE, Streeter PR, Woulfe SL, Sette A. [Related Articles](#), [Links](#)

Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progeny-potentiating-4, demonstrate potent immunological function.  
Vaccine. 2001 Jun 14;19(27):3710-9.  
PMID: 11395205 [PubMed - indexed for MEDLINE]

72: Eljaafari A, Farre A, Duperrier K, Even J, Vie H, Michallet M, Souillet G, Catherine Freidel A, Gebuhrer L, Rigal D. [Related Articles](#), [Links](#)

Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells.  
Transplantation. 2001 May 27;71(10):1449-55.  
PMID: 11391234 [PubMed - indexed for MEDLINE]

73: Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, Prieto J, Borras-Cuesta F. [Related Articles](#), [Links](#)

Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity.  
Eur J Immunol. 2001 Jun;31(6):1780-9.  
PMID: 11385623 [PubMed - indexed for MEDLINE]

74: Coler RN, Campos-Neto A, Ovendale P, Day FH, Fling SP, Zhu L, Serbina N, Flynn JL, Reed SG, Alderson MR. [Related Articles](#), [Links](#)

Vaccination with the T cell antigen Mtb 8.4 protects against challenge with *Mycobacterium tuberculosis*.  
J Immunol. 2001 May 15;166(10):6227-35.  
PMID: 11342645 [PubMed - indexed for MEDLINE]

75: Franco A, Tilly DA, Gramaglia I, Croft M, Cipolla L, Meldal M, Grey HM. [Related Articles](#), [Links](#)

Epitope affinity for MHC class I determines helper requirement for CTL priming.  
Nat Immunol. 2000 Aug;1(2):145-50.  
PMID: 11248807 [PubMed - indexed for MEDLINE]

76: D'Elios MM, Bergman MP, Azzurri A, Amedei A, Benagiano M, De Pont JJ, Cianchi F, Vandenbroucke-Grauls CM, Romagnani S, Appelman BJ, Del Prete G. [Related Articles](#), [Links](#)

H(+),K(+)-ATPase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis.

Gastroenterology. 2001 Feb;120(2):377-86.  
PMID: 11159878 [PubMed - indexed for MEDLINE]

 77: [Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD.](#) [Related Articles](#), [Links](#)

 Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.  
J Exp Med. 2001 Jan 15;193(2):169-80.  
PMID: 11148221 [PubMed - indexed for MEDLINE]

 78: [Simmons CP, Hussell T, Sparer T, Walz G, Openshaw P, Dougan G.](#) [Related Articles](#), [Links](#)

 Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.  
J Immunol. 2001 Jan 15;166(2):1106-13.  
PMID: 11145691 [PubMed - indexed for MEDLINE]

 79: [Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ.](#) [Related Articles](#), [Links](#)

 APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.  
J Immunol. 2000 Dec 1;165(11):6244-51.  
PMID: 11086059 [PubMed - indexed for MEDLINE]

 80: [May J, Lell B, Luty AJ, Meyer CG, Kremsner PG.](#) [Related Articles](#), [Links](#)

 HLA-DQB1\*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections.  
J Infect Dis. 2001 Jan 1;183(1):168-72. Epub 2000 Nov 10.  
PMID: 11076705 [PubMed - indexed for MEDLINE]

 81: [Krishnan L, Sad S, Patel GB, Sprott GD.](#) [Related Articles](#), [Links](#)

 Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.  
J Immunol. 2000 Nov 1;165(9):5177-85.  
PMID: 11046050 [PubMed - indexed for MEDLINE]

 82: [Kobayashi H, Wood M, Song Y, Appella E, Celis E.](#) [Related Articles](#), [Links](#)

 Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.  
Cancer Res. 2000 Sep 15;60(18):5228-36.  
PMID: 11016652 [PubMed - indexed for MEDLINE]

 83: [BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ.](#) [Related Articles](#), [Links](#)

 Induction of CTL response by a minimal epitope vaccine in HLA A\*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.  
Hum Immunol. 2000 Aug;61(8):764-79.  
PMID: 10980387 [PubMed - indexed for MEDLINE]

 84: [Kumar A, Lifson JD, Silverstein PS, Jia F, Sheffer D, Li Z, Narayan O.](#) [Related Articles](#), [Links](#)

 Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of

homologous and heterologous simian human immunodeficiency viruses.

Virology. 2000 Aug 15;274(1):149-64.

PMID: 10936096 [PubMed - indexed for MEDLINE]

 85: [Nielsen MB, Kirkin AF, Loftus D, Nissen MH, Rivoltini L, Zeuthen J, Geisler C, Odum N.](#)

[Related Articles](#), [Links](#)

 Amino acid substitutions in the melanoma antigen recognized by T cell 1 peptide modulate cytokine responses in melanoma-specific T cells. J Immunother. 2000 Jul-Aug;23(4):405-11.

PMID: 10916749 [PubMed - indexed for MEDLINE]

 86: [Sandberg JK, Leandersson AC, Devito C, Kohleisen B, Erfle V, Achour A, Levi M, Schwartz S, Karre K, Wahren B, Hinkula J.](#)

[Related Articles](#), [Links](#)

 Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization. Virology. 2000 Jul 20;273(1):112-9.

PMID: 10891413 [PubMed - indexed for MEDLINE]

 87: [Davila E, Celis E.](#)

[Related Articles](#), [Links](#)

 Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol. 2000 Jul 1;165(1):539-47.

PMID: 10861094 [PubMed - indexed for MEDLINE]

 88: [Dadaglio G, Moukrim Z, Lo-Man R, Sheshko V, Sebo P, Leclerc C.](#)

[Related Articles](#), [Links](#)

 Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of *Bordetella pertussis*. Infect Immun. 2000 Jul;68(7):3867-72.

PMID: 10858196 [PubMed - indexed for MEDLINE]

 89: [Doan T, Herd KA, Lambert PF, Fernando GJ, Street MD, Tindle RW.](#)

[Related Articles](#), [Links](#)

 Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization.

Cancer Res. 2000 Jun 1;60(11):2810-5.

PMID: 10850419 [PubMed - indexed for MEDLINE]

 90: [Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC.](#)

[Related Articles](#), [Links](#)

 CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.

J Immunol. 2000 Jun 15;164(12):6633-9.

PMID: 10843723 [PubMed - indexed for MEDLINE]

 91: [Tripp RA, Jones L, Anderson LJ, Brown MP.](#)

[Related Articles](#), [Links](#)

 CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse.

J Immunol. 2000 Jun 1;164(11):5913-21.

PMID: 10820273 [PubMed - indexed for MEDLINE]

 92: [El Mir S, Triebel F.](#)

[Related Articles](#), [Links](#)

 A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens.

J Immunol. 2000 Jun 1;164(11):5583-9.

PMID: 10820232 [PubMed - indexed for MEDLINE]

93: [Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Kleneman P, Walker BD.](#) [Related Articles](#), [Links](#)

 [Analysis of successful immune responses in persons infected with hepatitis C virus.](#)  
*J Exp Med.* 2000 May 1;191(9):1499-512.  
 PMID: 10790425 [PubMed - indexed for MEDLINE]

94: [Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Mielie CJ.](#) [Related Articles](#), [Links](#)

 [Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.](#)  
*J Immunother.* 2000 Mar-Apr;23(2):255-66.  
 PMID: 10746552 [PubMed - indexed for MEDLINE]

95: [Ehl S, Barchet W, Oehen S, Aichele P, Hombach J, Hengartner H, Zinkernagel RM.](#) [Related Articles](#), [Links](#)

 [Donor cell persistence and activation-induced unresponsiveness of peripheral CD8+ T cells.](#)  
*Eur J Immunol.* 2000 Mar;30(3):883-91.  
 PMID: 10741405 [PubMed - indexed for MEDLINE]

96: [Morris CB, Cheng E, Thanawastien A, Cardenas-Freytag L, Clements JD.](#) [Related Articles](#), [Links](#)

 [Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide \(E7\) in combination with the mucosal adjuvant LT\(R192G\).](#)  
*Vaccine.* 2000 Mar 17;18(18):1944-51.  
 PMID: 10699345 [PubMed - indexed for MEDLINE]

97: [Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H.](#) [Related Articles](#), [Links](#)

 [CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.](#)  
*J Immunol.* 2000 Mar 1;164(5):2372-8.  
 PMID: 10679072 [PubMed - indexed for MEDLINE]

98: [Swiniarski H, Wolf SF, Sturmhoefel K, Peterson RL, Dorner AJ, O'Toole M.](#) [Related Articles](#), [Links](#)

 [IL-12-Dependent enhancement of CTL response to weak class I-restricted peptide immunogens requires coimmunization with T helper cell immunogens.](#)  
*Clin Immunol.* 2000 Mar;94(3):200-11.  
 PMID: 10692239 [PubMed - indexed for MEDLINE]

99: [Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R.](#) [Related Articles](#), [Links](#)

 [T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans.](#)  
*Infect Immun.* 2000 Mar;68(3):1719-23.  
 PMID: 10678996 [PubMed - indexed for MEDLINE]

100: [Gahery-Segard H, Pialoux G, Charmetau B, Sernet S, Poncelet H, Raux M, Tartar A, Levy JP, Gras-Masse H, Guillet JG.](#) [Related Articles](#), [Links](#)

 [Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.](#)  
*J Virol.* 2000 Feb;74(4):1694-703.  
 PMID: 10644339 [PubMed - indexed for MEDLINE]

 101: Beecham EJ, Junghans RP.

 Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.  
Clin Cancer Res. 1999 Dec;5(12):3928-41.  
PMID: 10632322 [PubMed - indexed for MEDLINE]

 102: Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S.

[Related Articles](#), [Links](#)

 Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.  
Adv Immunol. 2000;74:181-273. Review. No abstract available.  
PMID: 10605607 [PubMed - indexed for MEDLINE]

 103: Ma H, Ke Y, Li Q, Kapp JA.

[Related Articles](#), [Links](#)

 Bovine and human insulin activate CD8+-autoreactive CTL expressing both type 1 and type 2 cytokines in C57BL/6 mice.  
J Immunol. 2000 Jan 1;164(1):86-92.  
PMID: 10604997 [PubMed - indexed for MEDLINE]

 104: Simmons CP, Mastroeni P, Fowler R, Ghaem-maghami M, Lycke N, Pizza M, Rappuoli R, Dougan G.

[Related Articles](#), [Links](#)

 MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.  
J Immunol. 1999 Dec 15;163(12):6502-10.  
PMID: 10586042 [PubMed - indexed for MEDLINE]

 105: Durrant LG, Buckley DJ, Robins RA, Spendlove I.

[Related Articles](#), [Links](#)

 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.  
Int J Cancer. 2000 Jan 1;85(1):87-92.  
PMID: 10585589 [PubMed - indexed for MEDLINE]

 106: Plate JM, Shott S, Harris JE.

[Related Articles](#), [Links](#)

 Immunoregulation in pancreatic cancer patients.  
Cancer Immunol Immunother. 1999 Aug;48(5):270-9.  
PMID: 10478644 [PubMed - indexed for MEDLINE]

 107: Barratt-Boyes SM, Vlad A, Finn OJ.

[Related Articles](#), [Links](#)

 Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.  
Clin Cancer Res. 1999 Jul;5(7):1918-24.  
PMID: 10430099 [PubMed - indexed for MEDLINE]

 108: Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R.

[Related Articles](#), [Links](#)

 A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group.  
Hepatology. 1999 Aug;30(2):531-6.  
PMID: 10421664 [PubMed - indexed for MEDLINE]

 109: Meyer D, Torres JV.

[Related Articles](#), [Links](#)

 Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs.  
Viral Immunol. 1999;12(2):117-29.  
PMID: 10413358 [PubMed - indexed for MEDLINE]

 110: Diehl L, den Boer AT, Schoenberger SP, van der Voort EI,

[Related Articles](#), [Links](#)

Schumacher TN, Melief CJ, Offringa R, Toes RE.

 **CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.**  
Nat Med. 1999 Jul;5(7):774-9.  
PMID: 10395322 [PubMed - indexed for MEDLINE]

 **111:** Schirmbeck R, Melber K, Reimann J. Related Articles, Links

 **Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen.**  
Int Immunol. 1999 Jul;11(7):1093-102.  
PMID: 10383942 [PubMed - indexed for MEDLINE]

 **112:** Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Related Articles, Links

 **Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.**  
Cell Immunol. 1999 Jun 15;194(2):143-9.  
PMID: 10383817 [PubMed - indexed for MEDLINE]

 **113:** Hsu SC, Chargelegue D, Obeid OE, Steward MW. Related Articles, Links

 **Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus.**  
J Gen Virol. 1999 Jun;80 ( Pt 6):1401-5.  
PMID: 10374957 [PubMed - indexed for MEDLINE]

 **114:** Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ. Related Articles, Links

 **Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.**  
Clin Cancer Res. 1999 May;5(5):1173-82.  
PMID: 10353754 [PubMed - indexed for MEDLINE]

 **115:** Elliott SL, Pye S, Le T, Mateo L, Cox J, Macdonald L, Scalzo AA, Forbes CA, Suhrbier A. Related Articles, Links

 **Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.**  
Vaccine. 1999 Apr 9;17(15-16):2009-19.  
PMID: 10217601 [PubMed - indexed for MEDLINE]

 **116:** Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, Romero P, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A. Related Articles, Links

 **Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A\*0201/Kb transgenic mice.**  
J Immunol. 1999 Mar 15;162(6):3566-73.  
PMID: 10092815 [PubMed - indexed for MEDLINE]

 **117:** Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A. Related Articles, Links

 **Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans.**  
J Immunol. 1999 Mar 1;162(5):3088-95.  
PMID: 10072562 [PubMed - indexed for MEDLINE]

 **118:** Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Storkus WJ. Related Articles, Links

HIV-1-specific CTL responses primed in vitro by blood-derived dendritic

 cells and Th1-biasing cytokines.  
J Immunol. 1999 Mar 1;162(5):3070-8.  
PMID: 10072560 [PubMed - indexed for MEDLINE]

 119: [Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB, Shoemaker H](#). [Related Articles](#), [Links](#)

 Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.  
Oncogene. 1998 Dec 17;17(24):3125-35. Erratum in: Oncogene 1999 Apr 8;18(14):2411. Shoemaker H[corrected to Schoemaker H].  
PMID: 9872328 [PubMed - indexed for MEDLINE]

 120: [Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, Chisari FV, Guidotti LG, Chesnut RW, Livingston B, Sette A](#). [Related Articles](#), [Links](#)

 The optimization of helper T lymphocyte (HTL) function in vaccine development.  
Immunol Res. 1998;18(2):79-92. Review.  
PMID: 9844827 [PubMed - indexed for MEDLINE]

 121: [Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrison LD, Javadian A, Chalian AA, Agadjanyan MG, Weiner DB](#). [Related Articles](#), [Links](#)

 Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes.  
Vaccine. 1998 Nov;16(19):1828-35.  
PMID: 9795388 [PubMed - indexed for MEDLINE]

 122: [da Silva J, Hughes AL](#). [Related Articles](#), [Links](#)

 Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1).  
Mol Biol Evol. 1998 Oct;15(10):1259-68.  
PMID: 9787432 [PubMed - indexed for MEDLINE]

 123: [Fernando GJ, Stewart TJ, Tindle RW, Frazer JH](#). [Related Articles](#), [Links](#)

 Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.  
J Immunol. 1998 Sep 1;161(5):2421-7.  
PMID: 9725239 [PubMed - indexed for MEDLINE]

 124: [Bessler WG, Heinevetter L, Wiesmuller KH, Jung G, Baier W, Huber M, Lorenz AR, Esche UV, Mittenbuhler K, Hoffmann P](#). [Related Articles](#), [Links](#)

 Bacterial cell wall components as immunomodulators--I. Lipopeptides as adjuvants for parenteral and oral immunization.  
Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):547-50.  
PMID: 9637352 [PubMed - indexed for MEDLINE]

 125: [Oseroff C, Sette A, Wentworth P, Cetis E, Maewal A, Dahlberg C, Fikes J, Kubo RT, Chesnut RW, Grey HM, Alexander J](#). [Related Articles](#), [Links](#)

 Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses.  
Vaccine. 1998 May;16(8):823-33.  
PMID: 9627940 [PubMed - indexed for MEDLINE]

 126: [Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR](#). [Related Articles](#), [Links](#)

 Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.  
J Immunol. 1998 Jun 1;160(11):5522-9.

PMID: 9605156 [PubMed - indexed for MEDLINE]

 **127:** Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ. [Related Articles](#), [Links](#)

 Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.  
J Immunol. 1998 Feb 1;160(3):1139-47.  
PMID: 9570527 [PubMed - indexed for MEDLINE]

 **128:** Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. [Related Articles](#), [Links](#)

 Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.  
J Exp Med. 1998 Mar 2;187(5):693-702.  
PMID: 9480979 [PubMed - indexed for MEDLINE]

 **129:** Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A. [Related Articles](#), [Links](#)

 Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.  
J Immunol. 1998 Feb 15;160(4):1717-23.  
PMID: 9469429 [PubMed - indexed for MEDLINE]

 **130:** Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. [Related Articles](#), [Links](#)

 Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons.  
J Infect Dis. 1997 Oct;176(4):859-66.  
PMID: 9333142 [PubMed - indexed for MEDLINE]

 **131:** Franke ED, Corradin G, Hoffman SL. [Related Articles](#), [Links](#)

 Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.  
J Immunol. 1997 Oct 1;159(7):3424-33.  
PMID: 9317141 [PubMed - indexed for MEDLINE]

 **132:** Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA. [Related Articles](#), [Links](#)

 Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.  
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10856-61.  
PMID: 9380724 [PubMed - indexed for MEDLINE]

 **133:** Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, Chesnut RW, Sette A. [Related Articles](#), [Links](#)

 The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.  
J Immunol. 1997 Aug 1;159(3):1383-92.  
PMID: 9233635 [PubMed - indexed for MEDLINE]

 **134:** Zhu X, Venkataprasad N, Thangaraj HS, Hill M, Singh M, Ivanyi J, Vordermeier HM. [Related Articles](#), [Links](#)

 Functions and specificity of T cells following nucleic acid vaccination of mice against *Mycobacterium tuberculosis* infection.  
J Immunol. 1997 Jun 15;158(12):5921-6.  
PMID: 9190945 [PubMed - indexed for MEDLINE]

 **135:** Nakamura Y, Kameoka M, Tobiume M, Kaya M, Ohki K, Yamada T, Ikuta K. [Related Articles](#), [Links](#)

 A chain section containing epitopes for cytotoxic T, B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein.  
Vaccine. 1997 Apr;15(5):489-96.  
PMID: 9160516 [PubMed - indexed for MEDLINE]

 **136:** An LL, Whitton JL. Related Articles, Links  
 A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.  
J Virol. 1997 Mar;71(3):2292-302.  
PMID: 9032365 [PubMed - indexed for MEDLINE]

 **137:** Harris SJ, Roth JF, Savage N, Woodrow SA, Hemingway IK, Hoyne GF, Lamb JR, Layton GT Related Articles, Links  
 Prediction of murine MHC class I epitopes in a major house dust mite allergen and induction of T1-type CD8+ T cell responses.  
Int Immunol. 1997 Feb;9(2):273-80.  
PMID: 9040009 [PubMed - indexed for MEDLINE]

 **138:** Partidos CD, Delmas A, Steward MW Related Articles, Links  
 Structural requirements for synthetic immunogens to induce measles virus specific CTL responses.  
Mol Immunol. 1996 Nov;33(16):1223-9.  
PMID: 9129158 [PubMed - indexed for MEDLINE]

 **139:** Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA Related Articles, Links  
 Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting.  
Eur J Immunol. 1996 Jul;26(7):1489-96.  
PMID: 8766551 [PubMed - indexed for MEDLINE]

 **140:** Van Gool SW, Zhang Y, Kasran A, de Boer M, Ceuppens JL Related Articles, Links  
 T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.  
Scand J Immunol. 1996 Jul;44(1):21-9.  
PMID: 8693288 [PubMed - indexed for MEDLINE]

 **141:** Bottius E, BenMohamed L, Brahimi K, Gras H, Lepers JP, Raharimalala L, Aikawa M, Meis J, Slierendregt B, Tartar A, Thomas A, Druilhe P Related Articles, Links  
 A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes.  
J Immunol. 1996 Apr 15;156(8):2874-84.  
PMID: 8609407 [PubMed - indexed for MEDLINE]

 **142:** Partidos CD, Vohra P, Steward MW Related Articles, Links  
 Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.  
Immunology. 1996 Feb;87(2):179-85.  
PMID: 8698377 [PubMed - indexed for MEDLINE]

 **143:** Shirai M, Chen M, Arichi T, Masaki T, Nishioka M, Newman M, Nakazawa T, Feinstone SM, Berzofsky JA Related Articles, Links  
 Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.

J Infect Dis. 1996 Jan;173(1):24-31.  
PMID: 8537666 [PubMed - indexed for MEDLINE]

 **144:** [Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK](#) [Related Articles](#) [Links](#)

Construction and immunogenicity of *Salmonella typhimurium* vaccine vectors that express HIV-1 gp120.  
*Vaccine*. 1995 Dec;13(17):1697-705.  
PMID: 8719522 [PubMed - indexed for MEDLINE]

 **145:** [Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG](#) [Related Articles](#) [Links](#)

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.  
*Eur J Immunol*. 1995 Dec;25(12):3467-73.  
PMID: 8566039 [PubMed - indexed for MEDLINE]

 **146:** [Blazevic V, Ranki A, Krohn KJ](#) [Related Articles](#) [Links](#)

Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.  
*AIDS Res Hum Retroviruses*. 1995 Nov;11(11):1335-42.  
PMID: 8573390 [PubMed - indexed for MEDLINE]

 **147:** [Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, Gomard E](#) [Related Articles](#) [Links](#)

Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides.  
*Vaccine*. 1995 Oct;13(14):1339-45.  
PMID: 8585291 [PubMed - indexed for MEDLINE]

 **148:** [Bishop DK, DeBruyne LA, Chan S, Xu S, Eichwald EJ](#) [Related Articles](#) [Links](#)

Dissociation of mouse cardiac transplant rejection and donor alloantigen-specific T cell responsiveness.  
*Transpl Immunol*. 1995 Sep;3(3):222-8.  
PMID: 8581410 [PubMed - indexed for MEDLINE]

 **149:** [Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Stewart T, Fernando GJ](#) [Related Articles](#) [Links](#)

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.  
*Clin Exp Immunol*. 1995 Aug;101(2):265-71.  
PMID: 7544248 [PubMed - indexed for MEDLINE]

 **150:** [Roelen DL, van Bree FP, van Beelen E, van Rood JJ, Claas FH](#) [Related Articles](#) [Links](#)

No evidence of an influence of the noninherited maternal HLA antigens on the alloreactive T cell repertoire in healthy individuals.  
*Transplantation*. 1995 Jun 27;59(12):1728-33.  
PMID: 7541578 [PubMed - indexed for MEDLINE]

 **151:** [Lehtinen M, Hibma MH, Stellato G, Kuoppala T, Paavonen J](#) [Related Articles](#) [Links](#)

Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16.  
*Biochem Biophys Res Commun*. 1995 Apr 17;209(2):541-6.  
PMID: 7733923 [PubMed - indexed for MEDLINE]

 **152:** [Kita H, Moriyama T, Kaneko T, Hiroishi K, Harase I, Miura H, Nakamura I, Inamori H, Kodama T, Ohnishi S, et al](#) [Related Articles](#) [Links](#)

A helper T-cell antigen enhances generation of hepatitis C virus-specific

 cytotoxic T lymphocytes in vitro.  
J Med Virol. 1995 Apr;45(4):386-91.  
PMID: 7545209 [PubMed - indexed for MEDLINE]

 153: [Bishop DK, Li W, Chan SY, Ensley RD, Shelby J, Eichwald EJ](#) Related Articles, Links  
Helper T lymphocyte unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses.  
Transplantation. 1994 Sep 15;58(5):576-84.  
PMID: 7522364 [PubMed - indexed for MEDLINE]

 154: [Yang Y, Ertl HC, Wilson JM](#) Related Articles, Links  
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.  
Immunity. 1994 Aug;1(5):433-42.  
PMID: 7533647 [PubMed - indexed for MEDLINE]

 155: [Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, Aanstoos H, Turck CW, Erlich H, Lennon V, et al](#) Related Articles, Links  
Higher autoantibody levels and recognition of a linear NH<sub>2</sub>-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.  
J Exp Med. 1994 Aug 1;180(2):595-606.  
PMID: 7519242 [PubMed - indexed for MEDLINE]

 156: [Borges E, Wiesmuller KH, Jung G, Walden P](#) Related Articles, Links  
Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid.  
J Immunol Methods. 1994 Aug 1;173(2):253-63.  
PMID: 7519223 [PubMed - indexed for MEDLINE]

 157: [Valmori D, Romero JF, Men Y, Maryanski JL, Romero P, Corradin G](#) Related Articles, Links  
Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone.  
Eur J Immunol. 1994 Jun;24(6):1458-62.  
PMID: 7515816 [PubMed - indexed for MEDLINE]

 158: [Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA](#) Related Articles, Links  
Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.  
J Immunol. 1994 Jan 15;152(2):549-56.  
PMID: 8283036 [PubMed - indexed for MEDLINE]

 159: [Touraine JL, Roncarolo MG, Plotnicky H, Bachetta R, Spits H](#) Related Articles, Links  
T lymphocytes from human chimeras do recognize antigen in the context of allogeneic determinants of the major histocompatibility complex.  
Immunol Lett. 1993 Dec;39(1):9-12.  
PMID: 7511565 [PubMed - indexed for MEDLINE]

 160: [Stuhler G, Walden P](#) Related Articles, Links  
Collaboration of helper and cytotoxic T lymphocytes.  
Eur J Immunol. 1993 Sep;23(9):2279-86.  
PMID: 7690327 [PubMed - indexed for MEDLINE]

 161: [Kundig TM, Castelmur L, Bachmann MF, Abraham D, Binder D](#) Related Articles, Links

Hengartner H, Zinkernagel RM.  
 Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus.  
*J Virol.* 1993 Jun;67(6):3680-3.  
 PMID: 7684471 [PubMed - indexed for MEDLINE]

162: Martinon F, Gras-Masse H, Boutillon C, Chirat F, Deprez B, Guillet JG, Gomard E, Tartar A, Levy JP. [Related Articles](#), [Links](#)  
 Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.  
*J Immunol.* 1992 Nov 15;149(10):3416-22.  
 PMID: 1385524 [PubMed - indexed for MEDLINE]

163: Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D. [Related Articles](#), [Links](#)  
 T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.  
*J Immunol Methods.* 1992 Oct 19;155(1):95-9.  
 PMID: 1383348 [PubMed - indexed for MEDLINE]

164: Guerder S, Matzinger P. [Related Articles](#), [Links](#)  
 A fail-safe mechanism for maintaining self-tolerance.  
*J Exp Med.* 1992 Aug 1;176(2):553-64.  
 PMID: 1386876 [PubMed - indexed for MEDLINE]

165: Nixon DF, Brooliden K, Ogg G, Brooliden PA. [Related Articles](#), [Links](#)  
 Cellular and humoral antigenic epitopes in HIV and SIV.  
*Immunology.* 1992 Aug;76(4):515-34. Review. No abstract available.  
 PMID: 1383131 [PubMed - indexed for MEDLINE]

166: Fayolle C, Deriaud E, Leclerc C. [Related Articles](#), [Links](#)  
 In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help.  
*J Immunol.* 1991 Dec 15;147(12):4069-73.  
 PMID: 1684372 [PubMed - indexed for MEDLINE]

167: De Groot AS, Clerici M, Hosmalin A, Hughes SH, Barn D, Hendrix CW, Houghten R, Shearer GM, Berzofsky JA. [Related Articles](#), [Links](#)  
 Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope.  
*J Infect Dis.* 1991 Dec;164(6):1058-65.  
 PMID: 1720151 [PubMed - indexed for MEDLINE]

168: Gao XM, Zheng B, Liew FY, Brett S, Tite J. [Related Articles](#), [Links](#)  
 Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides.  
*J Immunol.* 1991 Nov 15;147(10):3268-73.  
 PMID: 1682377 [PubMed - indexed for MEDLINE]

169: Perkins DL, Berziz G, Wang YS, Smith JA, Gefter ML. [Related Articles](#), [Links](#)  
 Comparison of class I- and II-restricted T cell recognition of the identical peptide.  
*Eur J Immunol.* 1991 Nov;21(11):2781-9.  
 PMID: 1718759 [PubMed - indexed for MEDLINE]

170: Hirsch R, Archibald J, Gress RE. [Related Articles](#), [Links](#)  
 Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2

fragments induce a selective T helper dysfunction.

J Immunol. 1991 Oct 1;147(7):2088-93.

PMID: 1833451 [PubMed - indexed for MEDLINE]

171: [Wu JY, Riggan CH, Seals JR, Murphy CI, Newman MJ.](#) [Related Articles](#), [Links](#)

 In vitro measurement of antigen-specific cell-mediated immune responses using recombinant HIV-1 proteins adsorbed to latex microspheres. J Immunol Methods. 1991 Sep 20;143(1):1-9. PMID: 1717603 [PubMed - indexed for MEDLINE]

172: [Berzofsky JA.](#) [Related Articles](#), [Links](#)

 Development of artificial vaccines against HIV using defined epitopes. FASEB J. 1991 Jul;5(10):2412-8. Review. PMID: 1712327 [PubMed - indexed for MEDLINE]

173: [Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, Letvin NL.](#) [Related Articles](#), [Links](#)

 Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science. 1991 Apr 19;252(5004):440-3. PMID: 1708168 [PubMed - indexed for MEDLINE]

174: [Berzofsky JA.](#) [Related Articles](#), [Links](#)

 Mechanisms of T cell recognition with application to vaccine design. Mol Immunol. 1991 Mar;28(3):217-23. PMID: 1708102 [PubMed - indexed for MEDLINE]

175: [Berzofsky JA.](#) [Related Articles](#), [Links](#)

 Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. Biotechnol Ther. 1991;2(1-2):123-35. Review. PMID: 1726961 [PubMed - indexed for MEDLINE]

176: [Yewdell JW, Bennink JR.](#) [Related Articles](#), [Links](#)

 The binary logic of antigen processing and presentation to T cells. Cell. 1990 Jul 27;62(2):203-6. Review. No abstract available. PMID: 1695549 [PubMed - indexed for MEDLINE]

177: [Gao XM, Liew FY, Tite JP.](#) [Related Articles](#), [Links](#)

 A dominant Th epitope in influenza nucleoprotein. Analysis of the fine specificity and functional repertoire of T cells recognizing a single determinant. J Immunol. 1990 Apr 1;144(7):2730-7. PMID: 1690775 [PubMed - indexed for MEDLINE]

178: [Scholler J, Rubin B.](#) [Related Articles](#), [Links](#)

 Mouse cytolytic T cells reactive with rat islet tumour RIN 5AH-B cells. APMIS. 1990 Mar;98(3):281-6. PMID: 2138467 [PubMed - indexed for MEDLINE]

179: [Nakao H, Eguchi K, Kawakami A, Migita K, Otsubo T, Ueki Y, Shimomura C, Tezuka H, Matsunaga M, Maeda K, et al.](#) [Related Articles](#), [Links](#)

 Phenotypic characterization of lymphocytes infiltrating synovial tissue from patients with rheumatoid arthritis: analysis of lymphocytes isolated from minced synovial tissue by dual immunofluorescent staining. J Rheumatol. 1990 Feb;17(2):142-8. PMID: 1690803 [PubMed - indexed for MEDLINE]

180: [Cease KB.](#) [Related Articles](#), [Links](#)

 **Peptide component vaccine engineering: targeting the AIDS virus.**  
Int Rev Immunol. 1990;7(1):85-107. Review.  
PMID: 1722499 [PubMed - indexed for MEDLINE]

**181:** [Brondz BD, Osipova TV, Aptikaeva GE, Kronin VV.](#) [Related Articles](#), [Links](#)

 **Difference between antigen-binding receptor repertoires in effector cytotoxic T lymphocytes and their secondary precursors (memory cells) specific to H-2Kb.**  
Res Immunol. 1990 Jan;141(1):43-57.  
PMID: 1693215 [PubMed - indexed for MEDLINE]

**182:** [Gao XM, Liew FY, Tite JP.](#) [Related Articles](#), [Links](#)

 **Identification and characterization of T helper epitopes in the nucleoprotein of influenza A virus.**  
J Immunol. 1989 Nov 1;143(9):3007-14.  
PMID: 2478631 [PubMed - indexed for MEDLINE]

**183:** [Weyand CM, Goronzy J, Swarztrauber K, Fathman CG.](#) [Related Articles](#), [Links](#)

 **Immunosuppression by anti-CD4 treatment in vivo. Cellular and humoral responses to alloantigens.**  
Transplantation. 1989 Jun;47(6):1039-42.  
PMID: 2472024 [PubMed - indexed for MEDLINE]

**184:** [Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT.](#) [Related Articles](#), [Links](#)

 **Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.**  
J Exp Med. 1989 Jun 1;169(6):1961-76.  
PMID: 2471770 [PubMed - indexed for MEDLINE]

**185:** [van Binnendijk RS, Poelen MC, de Vries P, Voorma HO, Osterhaus AD, Uytdehaag FG.](#) [Related Articles](#), [Links](#)

 **Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones.**  
J Immunol. 1989 Apr 15;142(8):2847-54.  
PMID: 2467943 [PubMed - indexed for MEDLINE]

**186:** [Hostetler LW, Romerdahl CA, Kripke ML.](#) [Related Articles](#), [Links](#)

 **Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.**  
Cancer Res. 1989 Mar 1;49(5):1207-13.  
PMID: 2465081 [PubMed - indexed for MEDLINE]

**187:** [Gautam SC, Battisto JR.](#) [Related Articles](#), [Links](#)

 **Feeding trinitrochlorobenzene inhibits development of hapten-specific cytotoxic T lymphocytes by interfering with helper T-cell function.**  
Reg Immunol. 1989 Jan-Feb;2(1):33-41.  
PMID: 2534947 [PubMed - indexed for MEDLINE]

**188:** [Hayward A, Giller R, Levin M.](#) [Related Articles](#), [Links](#)

 **Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes.**  
Viral Immunol. 1989 Fall;2(3):175-84.  
PMID: 2483504 [PubMed - indexed for MEDLINE]

**189:** [Gluckman JC.](#) [Related Articles](#), [Links](#)

 **[Immune response to human immunodeficiency virus and prospects for vaccination]**

Ann Med Interne (Paris). 1989;140(5):408-11. Review. French. No abstract available.  
PMID: 2480729 [PubMed - indexed for MEDLINE]

 **190:** [Foxwell B, Taylor D, Ryffel B.](#) Related Articles, Links  
 Comparison of the structure of the murine interleukin 2 (IL 2) receptor on cytotoxic and helper T cell lines by chemical cross-linking of 125I-labeled IL 2.  
*Eur J Immunol.* 1988 Oct;18(10):1515-9. Erratum in: *Eur J Immunol* 1989 Jan;19(1):221.  
 PMID: 2973414 [PubMed - indexed for MEDLINE]

 **191:** [Payne J, Huber BT, Cannon NA, Schneider R, Schilham MW, Acha-Orbea H, MacDonald HR, Hengartner H.](#) Related Articles, Links  
 Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor.  
*Proc Natl Acad Sci U S A.* 1988 Oct;85(20):7695-8.  
 PMID: 2459713 [PubMed - indexed for MEDLINE]

 **192:** [Havran WL, Fitch FW.](#) Related Articles, Links  
 Effects of anti-Lyt-2 and anti-L3T4 monoclonal antibodies on the function of cytotoxic T lymphocyte/helper T lymphocyte hybrid T cell clones.  
*J Immunol.* 1988 Sep 15;141(6):1808-12.  
 PMID: 2459190 [PubMed - indexed for MEDLINE]

 **193:** [Kanagawa O.](#) Related Articles, Links  
 Antibody-mediated activation of T cell clones as a method for screening hybridomas producing antibodies to the T cell receptor.  
*J Immunol Methods.* 1988 Jun 13;110(2):169-78.  
 PMID: 2454267 [PubMed - indexed for MEDLINE]

 **194:** [Brondz BD, Osipova TV.](#) Related Articles, Links  
 [The main difference between the repertoire of receptors of effector T-killers and their secondary precursors (memory cells)]  
*Biull Eksp Biol Med.* 1988 Jun;105(6):694-7. Russian.  
 PMID: 2455562 [PubMed - indexed for MEDLINE]

 **195:** [Yasukawa M, Inatsuki A, Kobayashi Y.](#) Related Articles, Links  
 Helper activity in antigen-specific antibody production mediated by CD4+ human cytotoxic T cell clones directed against herpes simplex virus.  
*J Immunol.* 1988 May 15;140(10):3419-25.  
 PMID: 2452188 [PubMed - indexed for MEDLINE]

 **196:** [Bueso-Ramos CE, Donahoe RM, Nicholson JK, Madden JJ, Falek A.](#) Related Articles, Links  
 Cytofluorometric analyses of human T cell CD2/CD4 inter-molecular interactions.  
*J Immunol.* 1988 Mar 1;140(5):1414-20.  
 PMID: 2964474 [PubMed - indexed for MEDLINE]

 **197:** [Zoller M, Andriguetto G.](#) Related Articles, Links  
 Induction of tolerance towards TNP entails down-regulation of an autoimmune attack.  
*Immunology.* 1988 Feb;63(2):205-12.  
 PMID: 2965095 [PubMed - indexed for MEDLINE]

 **198:** [Pilarski LM, Krowka JF, Deans JP.](#) Related Articles, Links  
 Soluble antigen-specific helper molecules active in the induction of cytotoxic T lymphocytes.

Ann N Y Acad Sci. 1988;532:136-48. Review. No abstract available.  
PMID: 2972240 [PubMed - indexed for MEDLINE]

199: [Fujiwara H, Hamaoka T](#)

[Related Articles](#), [Links](#)



Cellular mechanisms of tumor rejection in vivo and enhanced induction of anti tumor protective immunity applicable to tumor-specific immunotherapy.

Prog Exp Tumor Res. 1988;32:69-103. Review. No abstract available.  
PMID: 2967523 [PubMed - indexed for MEDLINE]

200: [Cassell D, Forman J](#)

[Related Articles](#), [Links](#)



Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes.

Ann N Y Acad Sci. 1988;532:51-60.

PMID: 2460011 [PubMed - indexed for MEDLINE]

201: [Sun D, Meyermann R, Wekerle H](#)

[Related Articles](#), [Links](#)



Cytotoxic T cells in autoimmune disease of the central nervous system.

Ann N Y Acad Sci. 1988;532:221-9. No abstract available.  
PMID: 2460009 [PubMed - indexed for MEDLINE]

202: [Rothbard JB, Taylor WR](#)

[Related Articles](#), [Links](#)



A sequence pattern common to T cell epitopes.

EMBO J. 1988 Jan;7(1):93-100.

PMID: 2452085 [PubMed - indexed for MEDLINE]

203: [Lamb JR, McMichael AJ, Rothbard JB](#)

[Related Articles](#), [Links](#)



T-cell recognition of influenza viral antigens.

Hum Immunol. 1987 Jun;19(2):79-89. Review. No abstract available.  
PMID: 2440836 [PubMed - indexed for MEDLINE]

204: [Walker C, Bettens F, Pichler WJ](#)

[Related Articles](#), [Links](#)



Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation.

Eur J Immunol. 1987 Jun;17(6):873-80.  
PMID: 2439351 [PubMed - indexed for MEDLINE]

205: [Crispe IN, Bevan MJ](#)

[Related Articles](#), [Links](#)



Expression and functional significance of the J11d marker on mouse thymocytes.

J Immunol. 1987 Apr 1;138(7):2013-8.  
PMID: 2435787 [PubMed - indexed for MEDLINE]

206: [Owens T, Miller JF](#)

[Related Articles](#), [Links](#)



Interaction in vivo between hapten-specific suppressor T cells and an in vitro cultured helper T cell line.

J Immunol. 1987 Mar 15;138(6):1687-92.  
PMID: 2950167 [PubMed - indexed for MEDLINE]

207: [McDermott MR, Lukacher AE, Braciale VL, Braciale TJ, Bienenstock J](#)

[Related Articles](#), [Links](#)



Characterization and in vivo distribution of influenza-virus-specific T-lymphocytes in the murine respiratory tract.

Am Rev Respir Dis. 1987 Jan;135(1):245-9.  
PMID: 2432811 [PubMed - indexed for MEDLINE]

208: [Mentzer SJ, Krensky AM, Burakoff SJ](#)

[Related Articles](#), [Links](#)

Mapping functional epitopes of the human LFA-1 glycoprotein:

 monoclonal antibody inhibition of NK and CTL effectors.  
Hum Immunol. 1986 Nov;17(3):288-96.  
PMID: 2432044 [PubMed - indexed for MEDLINE]

 **209:** [Krowka JF, Shiozawa C, Diener E, Pilarski LM.](#) [Related Articles](#), [Links](#)  
Functional activity of soluble antigen-specific helper T cell molecules.  
Requirement for separable entities for the induction of cytotoxic T cell and B cell responses.  
Transplantation. 1986 Aug;42(2):162-7.  
PMID: 2426845 [PubMed - indexed for MEDLINE]

 **210:** [McConnell HM, Watts TH, Weis RM, Brian AA.](#) [Related Articles](#), [Links](#)  
Supported planar membranes in studies of cell-cell recognition in the immune system.  
Biochim Biophys Acta. 1986 Jun 12;864(1):95-106. Review. No abstract available.  
PMID: 2941079 [PubMed - indexed for MEDLINE]

 **211:** [Krowka JF, Singh B, Fotedar A, Mosmann T, Giedlin MA, Pilarski LM.](#) [Related Articles](#), [Links](#)  
A requirement for physical linkage between determinants recognized by helper molecules and cytotoxic T cell precursors in the induction of cytotoxic T cell responses.  
J Immunol. 1986 May 15;136(10):3561-6.  
PMID: 2422257 [PubMed - indexed for MEDLINE]

 **212:** [Heuer J, Kolsch E.](#) [Related Articles](#), [Links](#)  
Selective elimination through a cytolytic mechanism of bovine serum albumin-specific T helper lymphocytes by T suppressor cells with the same antigen specificity.  
Eur J Immunol. 1986 Apr;16(4):400-4.  
PMID: 2422041 [PubMed - indexed for MEDLINE]

 **213:** [Henny FC, Olijns P, Tanke HJ, Paul LC, van Es LA.](#) [Related Articles](#), [Links](#)  
Comparison of monoclonal antibodies used for immunological monitoring of renal transplant recipients.  
Transplantation. 1986 Apr;41(4):442-7.  
PMID: 2421466 [PubMed - indexed for MEDLINE]

 **214:** [Greenstein JL, Foran JA, Gorga JC, Burakoff SJ.](#) [Related Articles](#), [Links](#)  
The role of T cell accessory molecules in the generation of class II-specific xenogeneic cytolytic T cells.  
J Immunol. 1986 Apr 1;136(7):2358-63.  
PMID: 2419431 [PubMed - indexed for MEDLINE]

 **215:** [Reinherz EL.](#) [Related Articles](#), [Links](#)  
Surface receptors involved in human T lymphocyte activation.  
Mt Sinai J Med. 1986 Mar;53(3):210-5. No abstract available.  
PMID: 2422552 [PubMed - indexed for MEDLINE]

 **216:** [Jovanovic R, Worner T, Ljieber CS, Paronetto F.](#) [Related Articles](#), [Links](#)  
Lymphocyte subpopulations in patients with alcoholic liver disease.  
Dig Dis Sci. 1986 Feb;31(2):125-30.  
PMID: 2417790 [PubMed - indexed for MEDLINE]

 **217:** [Havglass KT, Naides SJ, Scott CF Jr, Benacerraf B, Sy MS.](#) [Related Articles](#), [Links](#)  
T cell development in B cell-deficient mice. IV. The role of B cells as antigen-presenting cells in vivo.  
J Immunol. 1986 Feb 1;136(3):823-9.

PMID: 2416835 [PubMed - indexed for MEDLINE]

218: [Moran TM, Reale MA, Monestier M, Mayer R, Schulman JL, Bona CA.](#) [Related Articles](#), [Links](#)

 **Idiotype of anti-influenza virus immune responses.**  
Concepts Immunopathol. 1986;3:233-52. Review. No abstract available.  
PMID: 2439206 [PubMed - indexed for MEDLINE]

219: [Nakamura M, Ross DT, Briner TJ, Gefter ML.](#) [Related Articles](#), [Links](#)

 **Cytolytic activity of antigen-specific T cells with helper phenotype.**  
J Immunol. 1986 Jan;136(1):44-7.  
PMID: 2415627 [PubMed - indexed for MEDLINE]

220: [Lefrancois L, Puddington L, Machamer CE, Bevan MJ.](#) [Related Articles](#), [Links](#)

 **Acquisition of cytotoxic T lymphocyte-specific carbohydrate differentiation antigens.**  
J Exp Med. 1985 Oct 1;162(4):1275-93.  
PMID: 2413157 [PubMed - indexed for MEDLINE]

221: [Britten V, Hudson L.](#) [Related Articles](#), [Links](#)

 **Isolation and characterisation of human T-cell lines from a patient with Chagas' disease.**  
Lancet. 1985 Sep 21;2(8456):637-9.  
PMID: 2412080 [PubMed - indexed for MEDLINE]

222: [Mannel DN, Droege W, Falk W.](#) [Related Articles](#), [Links](#)

 **A combination of soluble helper factors bypasses the requirement for stimulator cells and induces nonspecific cytotoxic T cell responses.**  
Immunobiology. 1985 Sep;170(3):146-57.  
PMID: 2414210 [PubMed - indexed for MEDLINE]

223: [Simon MM, Nerz G, Prester M, Moll H.](#) [Related Articles](#), [Links](#)

 **Immunoregulation by mouse T cell clones. III. Cloned H-Y-specific cytotoxic T cells secrete a soluble mediator(s) that inhibits cytotoxic responses by acting on both Lyt-2- and L3T4- lymphocytes.**  
Eur J Immunol. 1985 Aug;15(8):773-83.  
PMID: 2411568 [PubMed - indexed for MEDLINE]

224: [Hackett CJ, Hurwitz JL, Dietzschold B, Gerhard W.](#) [Related Articles](#), [Links](#)

 **A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus.**  
J Immunol. 1985 Aug;135(2):1391-4.  
PMID: 2409149 [PubMed - indexed for MEDLINE]

225: [Lukacher AE, Morrison LA, Braciale VL, Malissen B, Braciale TJ.](#) [Related Articles](#), [Links](#)

 **Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones.**  
J Exp Med. 1985 Jul 1;162(1):171-87.  
PMID: 2409206 [PubMed - indexed for MEDLINE]

226: [Mizushima Y, Fujiwara H, Takai Y, Shearer GM, Hamaoka T.](#) [Related Articles](#), [Links](#)

 **Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses.**  
J Natl Cancer Inst. 1985 Jun;74(6):1269-73.  
PMID: 3158772 [PubMed - indexed for MEDLINE]

**227: Andrigutto G, Zoller M.** [Related Articles](#), [Links](#)

Time course analysis of regulation of cytotoxic T cells. *Cell Immunol.* 1985 Jun;93(1):178-88. PMID: 3158408 [PubMed - indexed for MEDLINE]

**228: Scott CF Jr, Tsurufuji M, Naides SJ, Sy MS.** [Related Articles](#), [Links](#)

Regulation of hapten-specific T-cell response. II. Functional analysis of helper T cells and cytotoxic T cells in animals suppressed by azobenzeneearsonate (ABA)-specific suppressor T cells. *Cell Immunol.* 1985 Jun;93(1):144-56. PMID: 3158405 [PubMed - indexed for MEDLINE]

**229: Rupp F, Acha-Orbea H, Hengartner H, Zinkernagel R, Joho R.** [Related Articles](#), [Links](#)

Identical V beta T-cell receptor genes used in alloreactive cytotoxic and antigen plus I-A specific helper T cells. *Nature*. 1985 May 30-Jun 5;315(6018):425-7. PMID: 2582268 [PubMed - indexed for MEDLINE]

**230: Juretic A, Malenica B, Juretic E, Klein J, Nagy ZA.** [Related Articles](#), [Links](#)

Helper effects required during in vivo priming for a cytolytic response to the H-Y antigen in nonresponder mice. *J Immunol.* 1985 Mar;134(3):1408-14. PMID: 2578505 [PubMed - indexed for MEDLINE]

**231: Woollett GR, Barclay AN, Puklavec M, Williams AF.** [Related Articles](#), [Links](#)

Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes. *Eur J Immunol.* 1985 Feb;15(2):168-73. PMID: 2578966 [PubMed - indexed for MEDLINE]

**232: Comoglio PM, Prat M, Brett S.** [Related Articles](#), [Links](#)

Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes. *Immunology*. 1985 Feb;54(2):289-95. PMID: 2578431 [PubMed - indexed for MEDLINE]

**233: Hamaca T, Takai Y, Kosugi A, Mizushima Y, Shima J, Kusama T, Fujiwara H.** [Related Articles](#), [Links](#)

The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with *Bacillus Calmette Guerin* and its application to enhanced induction of tumor immunity. *Cancer Immunol Immunother.* 1985;20(3):183-8. PMID: 2933141 [PubMed - indexed for MEDLINE]

**234: Toder V, Blank M, Nebel L.** [Related Articles](#), [Links](#)

Cytotoxic T lymphocytes, interleukin-2 and trophoblast involvement. *Contrib Gynecol Obstet.* 1985;14:23-35. Review. No abstract available. PMID: 2415297 [PubMed - indexed for MEDLINE]

**235: Culbert EJ, Kontiainen S, Feldmann M.** [Related Articles](#), [Links](#)

The relationship between secreted and cell surface antigen-binding molecules synthesized by T cells. I. Function-related isotypic determinants on T cells defined by antisera to antigen-specific helper and suppressor factors. *Immunology*. 1984 Nov;53(3):481-90. PMID: 6208146 [PubMed - indexed for MEDLINE]

236: Yasukawa M, Zarling JM[Related Articles](#), [Links](#)

 Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.

J Immunol. 1984 Nov;133(5):2736-42.

PMID: 6207243 [PubMed - indexed for MEDLINE]

237: Ohta N, Reinsmoen NL, Bach FH[Related Articles](#), [Links](#)

 Cellular basis of anti-SB response.

Hum Immunol. 1984 Nov;11(3):127-41.

PMID: 6083998 [PubMed - indexed for MEDLINE]

238: Moretta A, Pantaleo G, Maggi E, Mingari MC[Related Articles](#), [Links](#)

 Recent advances in the phenotypic and functional analysis of human T lymphocytes.

Semin Hematol. 1984 Oct;21(4):257-69. Review. No abstract available.

PMID: 6208614 [PubMed - indexed for MEDLINE]

239: Tite JP, Janeway CA Jr[Related Articles](#), [Links](#)

 Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytosis.

Eur J Immunol. 1984 Oct;14(10):878-86.

PMID: 6208035 [PubMed - indexed for MEDLINE]

240: Krowka JE, Shiozawa C, Diener E, Paetkau V, Pilarski LM[Related Articles](#), [Links](#)

 Induction of cytotoxic lymphocyte responses by antigen-specific helper factors.

J Immunol. 1984 Oct;133(4):2018-24.

PMID: 6206146 [PubMed - indexed for MEDLINE]

241: Wolos JA, Smith JB[Related Articles](#), [Links](#)

 Helper cells in the autologous mixed lymphocyte reaction (AMLR). IV. H-2 restriction and specificity of cytotoxic cells induced by AMLR helper factor.

Cell Immunol. 1984 Sep;87(2):714-9.

PMID: 6235927 [PubMed - indexed for MEDLINE]

242: Fitch FW, Lancki DW, Dialynas DP[Related Articles](#), [Links](#)

 Contributions of T cell clones to an understanding of the T cell receptor for antigen.

Transplantation. 1984 Sep;38(3):201-8. Review.

PMID: 6206629 [PubMed - indexed for MEDLINE]

243: Sopori ML, Cohen DA, Cherian S, Roszman TL, Kaplan AM[Related Articles](#), [Links](#)

 T-lymphocyte heterogeneity in the rat: separation of distinct rat T-lymphocyte populations which respond in syngeneic and allogeneic mixed lymphocyte reactions.

Cell Immunol. 1984 Aug;87(1):295-303.

PMID: 6204777 [PubMed - indexed for MEDLINE]

244: Ting CC, Hargrove ME[Related Articles](#), [Links](#)

 Regulation of the activation of cytotoxic T lymphocytes by prostaglandins and antigens.

J Immunol. 1984 Aug;133(2):660-6.

PMID: 6203973 [PubMed - indexed for MEDLINE]

245: [Kwong PC, Kilburn DG, Teh HS.](#)

[Related Articles](#), [Links](#)

 Induction of CTL responses to alloantigens by a Db-specific T helper clone.

*J Immunol.* 1984 Aug;133(2):653-9.

PMID: 6203972 [PubMed - indexed for MEDLINE]

246: [Czitrom AA, Gascoigne NR, Edwards S, Waterfield DJ.](#)

[Related Articles](#), [Links](#)

 Induction of minor alloantigen-specific T cell subsets in vivo: recognition of processed antigen by helper but not by cytotoxic T cell precursors.

*J Immunol.* 1984 Jul;133(1):33-9.

PMID: 6202785 [PubMed - indexed for MEDLINE]

247: [Vargo PM, Battisto JR.](#)

[Related Articles](#), [Links](#)

 Tolerance to Mls-disparate cells induces suppressor T cells that act at the helper level to prevent in vivo generation of cytolytic lymphocytes to hapten-altered self.

*J Immunol.* 1984 Jun;132(6):2796-801.

PMID: 6233362 [PubMed - indexed for MEDLINE]

248: [Karasuyama H, Kim M, Okumura K, Tada T.](#)

[Related Articles](#), [Links](#)

 Heterogeneity of IgH-linked allotypic determinants expressed on functional T cell subsets as detected by monoclonal antibodies.

*Eur J Immunol.* 1984 May;14(5):413-20.

PMID: 6202527 [PubMed - indexed for MEDLINE]

249: [Clayberger C, Dekruyff RH, Cantor H.](#)

[Related Articles](#), [Links](#)

 Immunoregulatory activities of autoreactive T cells: an I-A-specific T cell clone mediates both help and suppression of antibody responses.

*J Immunol.* 1984 May;132(5):2237-43.

PMID: 6201537 [PubMed - indexed for MEDLINE]

250: [Callard RE, Winger CM, Tiernan SL.](#)

[Related Articles](#), [Links](#)

 Antigen-specific suppression of human antibody responses by allogeneic T cells. I. Frequency and antigen specificity of allogeneic suppressor T cells and their role in major histocompatibility complex-controlled genetic restriction.

*J Exp Med.* 1984 Apr 1;159(4):1225-37.

PMID: 6200565 [PubMed - indexed for MEDLINE]

251: [Wee SL, Bach FH.](#)

[Related Articles](#), [Links](#)

 Functionally distinct human T cell clones that produce lymphokines with IL-2-like activity.

*Hum Immunol.* 1984 Mar;9(3):175-88.

PMID: 6199338 [PubMed - indexed for MEDLINE]

252: [Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.](#)

[Related Articles](#), [Links](#)

 Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.

*J Immunol.* 1984 Mar;132(3):1571-7.

PMID: 6198397 [PubMed - indexed for MEDLINE]

253: [Fujiwara H, Shimizu Y, Takai Y, Wakamiya N, Ueda S, Kato S, Hamaoka T.](#)

[Related Articles](#), [Links](#)

 The augmentation of tumor-specific immunity by virus help. I.

Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.

Eur J Immunol. 1984 Feb;14(2):171-5.  
PMID: 6199215 [PubMed - indexed for MEDLINE]

 254: [Gascoigne NR, Lai PK.](#)

[Related Articles](#), [Links](#)

 T helper cell lines that augment in vivo cytotoxic T-cell responses to minor alloantigens.  
Cell Immunol. 1984 Feb;83(2):302-12.  
PMID: 6198100 [PubMed - indexed for MEDLINE]

 255: [Scott CF Jr, Tsurufuji M, Lu CY, Finberg R, Sy MS.](#)

[Related Articles](#), [Links](#)

 Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice.  
J Immunol. 1984 Feb;132(2):633-9.  
PMID: 6197469 [PubMed - indexed for MEDLINE]

 256: [Qvigstad E, Thorsby E, Reinsmoen NL, Bach FH.](#)

[Related Articles](#), [Links](#)

 Close association between the Dw14 (LD40) subtype of HLA-DR4 and a restriction element for antigen-specific T-cell clones.  
Immunogenetics. 1984;20(5):583-8. No abstract available.  
PMID: 6209217 [PubMed - indexed for MEDLINE]

 257: [Bach FH.](#)

[Related Articles](#), [Links](#)

 Elicitation of T-lymphocyte responses by major histocompatibility complex encoded determinants.  
Prog Clin Biol Res. 1984;149:221-33. No abstract available.  
PMID: 6204339 [PubMed - indexed for MEDLINE]

 258: [Pilarski LM, Wegmann TG.](#)

[Related Articles](#), [Links](#)

 Antigen-specific helper T cells recognize determinants encoded in the H-2D region of the H-2 gene complex.  
Immunogenetics. 1984;19(4):301-10.  
PMID: 6201440 [PubMed - indexed for MEDLINE]

 259: [Thorsby E.](#)

[Related Articles](#), [Links](#)

 The role of HLA in T cell activation.  
Hum Immunol. 1984 Jan;9(1):1-7. No abstract available.  
PMID: 6198308 [PubMed - indexed for MEDLINE]

 260: [Takai Y, Mizuochi T, Fujiwara H, Hamaoka T.](#)

[Related Articles](#), [Links](#)

 Effects of hapten epitope structure and hapten-self conjugation pattern on T cell specificity and Ir gene control in hapten-self cytotoxic and helper T cell responses.  
J Immunol. 1984 Jan;132(1):57-62.  
PMID: 6197460 [PubMed - indexed for MEDLINE]

 261: [Miller SD, Butler LD, Cleveland RP, Moothead JW, Claman HN, Chiller JC.](#)

[Related Articles](#), [Links](#)

 T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.  
Cell Immunol. 1983 Dec;82(2):378-93.  
PMID: 6197193 [PubMed - indexed for MEDLINE]

 262: [Niederkom JY, Streilein JW.](#)

[Related Articles](#), [Links](#)

 Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T

lymphocyte and helper T lymphocyte responses.

J Immunol. 1983 Dec;131(6):2670-4.

PMID: 6196396 [PubMed - indexed for MEDLINE]

 **263:** [Widmer MB, Bach FH.](#)

[Related Articles](#), [Links](#)

 Antigen specificity and helper characteristics of antigen-driven helper-cell-independent cytolytic T lymphocytes.

Transplantation. 1983 Nov;36(5):565-7.

PMID: 6195786 [PubMed - indexed for MEDLINE]

 **264:** [Oger J, Roos R, Antel JP.](#)

[Related Articles](#), [Links](#)

 Immunology of multiple sclerosis.

Neurol Clin. 1983 Aug;1(3):655-79.

PMID: 6209537 [PubMed - indexed for MEDLINE]

 **265:** [Chatenoud L, Chkoff N, Kreis H, Bach JF.](#)

[Related Articles](#), [Links](#)

 Interest in and limitations of monoclonal anti-T-cell antibodies for the follow-up of renal transplant patients.

Transplantation. 1983 Jul;36(1):45-50.

PMID: 6191417 [PubMed - indexed for MEDLINE]

 **266:** [Miller SD, Butler LD.](#)

[Related Articles](#), [Links](#)

 T cell responses induced by the parenteral injection of antigen-modified syngeneic cells. I. Induction, characterization, and regulation of antigen-specific T helper cells involved in delayed-type hypersensitivity responses.

J Immunol. 1983 Jul;131(1):77-85.

PMID: 6190929 [PubMed - indexed for MEDLINE]

 **267:** [Robbins DS, Fudenberg HH.](#)

[Related Articles](#), [Links](#)

 Editorial retrospective. Human lymphocyte subpopulations in metastatic neoplasia--six years later.

N Engl J Med. 1983 Jun 30;308(26):1595-7. No abstract available.

PMID: 6190084 [PubMed - indexed for MEDLINE]

 **268:** [Wilkinson NM, Ishikawa H, Kubota E, Dutton RW, Saito K.](#)

[Related Articles](#), [Links](#)

 Fetal calf serum-injected F1 mice spontaneously generate specific anti-parental cytotoxic T lymphocytes in in vitro culture.

Cell Immunol. 1983 Jun;78(2):236-48.

PMID: 6190576 [PubMed - indexed for MEDLINE]

 **269:** [Friedman SM, Thompson GS.](#)

[Related Articles](#), [Links](#)

 Functionally restricted, allospecific, human helper T cell lines that amplify either B cell or cytolytic T cell responses.

J Exp Med. 1983 May 1;157(5):1675-80.

PMID: 6189944 [PubMed - indexed for MEDLINE]

 **270:** [Chan MM, Tada N, Kimura S, Hoffmann MK, Miller RA, Stutman O, Hammerling U.](#)

[Related Articles](#), [Links](#)

 Characterization of T lymphocyte subsets with monoclonal antibodies: discovery of a distinct marker, Ly-m22, of T suppressor cells.

J Immunol. 1983 May;130(5):2075-8.

PMID: 6187835 [PubMed - indexed for MEDLINE]

 **271:** [Gautam SC, Hilfiker ML, Battisto JR.](#)

[Related Articles](#), [Links](#)

 In vivo development of cytolytic T lymphocytes (CTL) to hapten-altered self: Mls-disparate cells facilitate the response by neutralizing IL 2

inhibitor.

J Immunol. 1983 Feb;130(2):533-7.

PMID: 6217243 [PubMed - indexed for MEDLINE]

 272: [Roopenian DC, Widmer MB, Orosz CG, Bach FH.](#)

[Related Articles](#), [Links](#)

 Helper cell-independent cytolytic T lymphocytes specific for a minor histocompatibility antigen.

J Immunol. 1983 Feb;130(2):542-5.

PMID: 6184397 [PubMed - indexed for MEDLINE]

 273: [Goodman JW, Sercarz EE.](#)

[Related Articles](#), [Links](#)

 The complexity of structures involved in T-cell activation.

Annu Rev Immunol. 1983;1:465-98. Review. No abstract available.

PMID: 6085787 [PubMed - indexed for MEDLINE]

 274: [Klein J, Marusic M, Nagy ZA.](#)

[Related Articles](#), [Links](#)

 The seven rules of MHC restriction.

Transplant Proc. 1982 Sep;14(3):581-3. No abstract available.

PMID: 6184862 [PubMed - indexed for MEDLINE]

 275: [Finberg R, Ertl HC, Shapiro ME.](#)

[Related Articles](#), [Links](#)

 Virus-specific cytolytic cells. Their in vivo function.

Surv Immunol Res. 1982;1(3):248-54. Review. No abstract available.

PMID: 6195715 [PubMed - indexed for MEDLINE]

 276: [Falkoff RM, Scavulli JE, Dutton RW.](#)

[Related Articles](#), [Links](#)

 Independent analysis of T helper and T killer cell function in young and old NZB mice.

J Immunol. 1978 Sep;121(3):897-902.

PMID: 80432 [PubMed - indexed for MEDLINE]

[Display](#) [Summary](#)  Show: [500](#)  [Sort](#)  [Send to](#)  [Text](#) 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 16 2004 07:00:47



National  
Library  
of Medicine  
NLM

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <b>PubMed</b> for					<input type="button" value="Go"/>		<input type="button" value="Clear"/>		
<input type="button" value="Limits"/>		<input type="button" value="Preview/Index"/>		<input type="button" value="History"/>		<input type="button" value="Clipboard"/>		<input type="button" value="Details"/>	
<input type="button" value="Display"/> <input checked="" type="button" value="Abstract"/>					Show: <input type="button" value="20"/> <input type="button" value="Sort"/>		<input type="button" value="Send to"/> <input type="button" value="Text"/>		

[About Entrez](#)

[Text Version](#)

1: *J Immunol Methods*. 1991 Sep 20;143(1):1-9.

[Related Articles](#), [Links](#)

[Entrez PubMed](#)  
[Overview](#)  
[Help | FAQ](#)  
[Tutorial](#)  
[New/Noteworthy](#)  
[E-Utilities](#)

[PubMed Services](#)  
[Journals Database](#)  
[MeSH Database](#)  
[Single Citation Matcher](#)  
[Batch Citation Matcher](#)  
[Clinical Queries](#)  
[LinkOut](#)  
[Cubby](#)

[Related Resources](#)  
[Order Documents](#)  
[NLM Catalog](#)  
[NLM Gateway](#)  
[TOXNET](#)  
[Consumer Health](#)  
[Clinical Alerts](#)  
[ClinicalTrials.gov](#)  
[PubMed Central](#)

## **In vitro measurement of antigen-specific cell-mediated immune responses using recombinant HIV-1 proteins adsorbed to latex microspheres.**

**Wu JY, Riggin CH, Seals JR, Murphy CI, Newman MJ.**

Cambridge Biotech Corporation, Worcester, MA 01605.

Recombinant proteins representing full-length and truncated forms of the human immunodeficiency virus type 1 envelope protein gp160 were produced in *E. coli* and sf9 insect cells. These proteins were denatured and reduced as a function of purification. We adsorbed these proteins onto latex microspheres and used the protein-coated particles as a vehicle to present the antigen in vitro to splenic mononuclear cells from immune mice. Recombinant proteins presented on the latex particles induced antigen-specific proliferative responses that were dependent on the antigen concentration. The proliferative responses were similar to those produced against an identical protein used in soluble form and equivalent protein concentrations. Latex microspheres coated with recombinant proteins could also induce precursor cytotoxic T lymphocytes to mature to functional effector cells in vitro. The use of the latex microspheres to present recombinant proteins as antigens allowed for the use of denatured proteins in our assay that were not soluble in aqueous solutions, such as cell culture media. This system of delivering recombinant proteins in vitro should greatly facilitate the use of recombinant proteins in assays involving live cells.

PMID: 1717603 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine  
NLM

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMID	Journals	Books
Search <input type="text" value="PubMed"/>		<input type="checkbox"/> for <input type="text"/>		<input type="button" value="Go"/>		<input type="button" value="Clear"/>			
		<input type="button" value="Limits"/>		<input type="button" value="Preview/Index"/>		<input type="button" value="History"/>		<input type="button" value="Clipboard"/>	
		<input type="button" value="Display"/>		<input type="button" value="Abstract"/>		<input type="button" value="Show: 20"/>		<input type="button" value="Sort"/>	
								<input type="button" value="Send to"/>	
								<input type="button" value="Text"/>	

About Entrez

Text Version

1: J Immunol Methods. 1992 Oct 19;155(1):95-9.

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

## **T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.**

**Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D.**

Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.

We have previously derived MHC class I (H-2Kd) restricted cytotoxic T lymphocytes (CTL) from BALB/c mice immunized with irradiated sporozoites from Plasmodium (P.) berghei and P. yoelii. The CTL recognize synthetic peptides corresponding to a region of the circumsporozoite (CS) protein that is homologous in the two species. In the present study, we have attempted to induce CS-specific CTL by immunization with those peptides in incomplete Freund's adjuvant. Only a low level CTL response was detected in BALB/c mice immunized with synthetic peptides corresponding to the Pb or Py CTL epitopes. In contrast, CS-specific CTL responses could be readily detected in mice injected with mixtures of peptides that combined the P. berghei or P. yoelii CTL epitopes with previously defined T helper epitopes. Several different T helper epitopes were shown to enhance the response when injected as separate peptides in a mixture, or when covalently linked to a CTL epitope. These results may have general implications for the elicitation of CTL responses to defined CTL epitopes and for the design of peptide-based synthetic vaccines.

PMID: 1383348 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine  
NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show: **20**

About Entrez

Text Version

1: Immunol Lett. 1993 Dec;39(1):9-12.

[Related Articles](#), [Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

[ClinicalTrials.gov](#)

PubMed Central

## **T lymphocytes from human chimeras do recognize antigen in the context of allogeneic determinants of the major histocompatibility complex.**

**Touraine JL, Roncarolo MG, Plotnicky H, Bachetta R, Spits H.**

Transplantation and Clinical Immunology Unit, INSERM U80, Hopital Edouard Herriot, Lyon, France.

Human stem cells from the fetal liver can be transplanted to immunodeficient patients and reconstitute their immunity by giving rise to immunocompetent T lymphocytes of donor origin. Despite full HLA mismatch between donor and host, the helper T cells and the cytotoxic T cells which develop in these chimeric patients are totally functional. They recognize the antigenic peptides presented in the context of the foreign HLA molecules of the recipient, indicating that donor stem cells have been positively selected in the host environment, probably the thymic epithelial cells. By contrast, negative selection appears to be imposed upon T cells by donor hemopoietic cells, probably macrophages or dendritic cells, migrating from the transplant to the host thymus. Clonal deletion is then responsible for tolerance to donor HLA antigens, while clonal anergy explains tolerance to host HLA antigens.

PMID: 7511565 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine  
NLM

Entrez PubMed Nucleotides Protein Genome Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show: **20**

About Entrez

[Text Version](#)

1: *J Immunol.* 1994 Jan 15;152(2):549-56.

[Related Articles](#), [Links](#)

Full text article at  
[www.jimmunol.org](http://www.jimmunol.org)

## Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.

**Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA.**

Molecular Immunogenetics and Vaccine Research Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

CTL are a critical component of protective immunity against viral infections, but requirements for in vivo priming of CTL are not completely understood. Covalent linkage of a helper determinant to a CTL determinant, analogous to that required for cognate help for antibody production, does not appear to be necessary in vitro, but its necessity has not been extensively explored in vivo, especially at a molecular level. We previously defined peptides encompassing multideterminant regions of HIV-1 gp160 (cluster peptides) recognized by Th from mice and humans of multiple MHC types. To investigate the requirement for Th in the development of CTL in vivo, in the context of developing a synthetic peptide vaccine for HIV active in multiple strains of mice, we immunized with compound peptides representing an immunodominant CTL epitope, P18, of gp160, co-linearly synthesized at the C-terminus of three cluster peptides. Spleen cells from compound-peptide-immunized mice of three MHC haplotypes sharing the Dd class I MHC molecule but with different class II molecules exhibited enhanced gp160-specific CD8+ CTL activity and CD4+ Th. In contrast, immunization with P18 alone or a mixture of cluster peptide and P18 elicited only marginal CTL activity. These results imply a requirement for determinant linkage in CTL induction in vivo similar to that already well recognized for cognate help for antibody induction. The results also define promising peptide HIV vaccine candidates for induction of CTL, as well as neutralizing antibodies, in diverse MHC types.

PMID: 8283036 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine 

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books	
Search <input type="text" value="PubMed"/>				<input type="checkbox"/> for <input type="text"/>		<input type="button" value="Go"/> <input type="button" value="Clear"/>				
		<input type="button" value="Limits"/>		<input type="button" value="Preview/Index"/>		<input type="button" value="History"/>		<input type="button" value="Clipboard"/>		<input type="button" value="Details"/>
		<input type="button" value="Display"/>		<input type="button" value="Abstract"/>		<input type="button" value="Show: 20"/> <input type="button" value="Sort"/>		<input type="button" value="Send to"/>		<input type="button" value="Text"/>

About Entrez

[Text Version](#)

1: *J Immunol Methods*. 1994 Aug 1;173(2):253-63.

[Related Articles](#), [Links](#)

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

## **Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid.**

**Borges E, Wiesmuller KH, Jung G, Walden P.**

Max-Planck-Institut fur Biologie, Abteilung Immunogenetik, Tübingen, Germany.

Synthetic vaccines that specifically induce active immunity mediated by cytotoxic T lymphocytes (CTL) are of great interest considering the central role of these cells in immune responses against intracellular antigens. The influence of specific T helper (Th) cell recruitment and of the potent immunostimulating lipoamino acid tripalmitoyl-S-glycerylcysteine (P3C) on CTL mediated immunity induced by CTL epitopes was analysed and compared. Synthetic peptides that represent CTL epitopes were found to be inefficient for CTL priming. However, when combined with peptides that contain Th cell epitopes, with proteins that carry multiple Th cell epitopes or with P3C, efficient priming of CTL was obtained. The costimulating support by P3C and proteins resulted in high cytolytic activities already after 9 days whereas, in the case of single helper epitopes, incubation periods of about 4 weeks were required. The effects of P3C and helper epitopes were additive.


PMID: 7519223 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine  
NLM

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <b>PubMed</b>		for				<b>Go</b>	<b>Clear</b>		
		Limits	Preview/Index		History	Clipboard		Details	
		<b>Display</b>	Abstract			Show: 20	Sort	<b>Send to</b>	Text

About Entrez

Text Version

1: Clin Exp Immunol. 1995 Aug; 101(2):265-71.

Related Articles, Links

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

**A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.**

**Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Stewart T, Fernando GJ.**

Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.

TraT protein, known as ISCAR (= Immunostimulatory Carrier), is one of a family of integral membrane proteins (Imps) of *Escherichia coli* representing powerful carrier molecules which when injected into experimental animals generate substantial antibody and T proliferative responses to molecules conjugated to it. We extend these findings to show that ISCAR functions to stimulate Th1- and Th2-type responses, including specific cytotoxic T cells and tumour protection. We report here that by conjugating to ISCAR a 19mer peptide containing linear B epitopes, a T helper (Th) epitope, and a H-2b-restricted T cytotoxic (CTL) epitope of E7 protein of human papillomavirus type 16 (HPV16), and immunizing C57B1/6 (H-2b) mice, we elicited (i) specific IgG2a and IgG1 antibodies; (ii) IL-2 and IL-4 production by specifically recalled lymph node cells in vitro; (iii) cytotoxic T lymphocytes which specifically killed both E7 peptide-pulsed, and whole E7 gene-transfected tumour target cells; and (iv) *in vivo* protection against an E7 gene-transfected tumour cell inoculum. These findings have implications for the design of vaccines to stimulate immune responses to endogenously processed target antigens (e.g. tumour-associated antigens) without the unwanted side effects of oil-based adjuvants. In addition they support the case for a E7-targeted therapeutic vaccine for HPV-associated human cervical cancer.

PMID: 7544248 [PubMed - indexed for MEDLINE]

<b>Display</b>	Abstract			Show: 20	Sort	<b>Send to</b>	Text
----------------	----------	--	--	----------	------	----------------	------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

h

cb

hg

e

e

fcg

c

e

e

b

b

e

b

c



National  
Library  
of Medicine 

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

1: Vaccine. 1995 Oct;13(14):1339-45.

[Related Articles](#), [Links](#)


## Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides.

**Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, Gomard E.**

Laboratoire d'Immunologie des Interactions Cellulaires et Moléculaires, INSERM U152, Institut Cochin de Génétique Moléculaire, Paris, France.

Cytotoxic T lymphocytes (CTL) play a major role in protective immunity against viral diseases. However, the antigenic formulations that can be used in vaccinations able to generate virus-specific CTL responses *in vivo* have yet to be defined. We have previously shown that HIV-1-specific CTL can be elicited in mice by injecting without adjuvant a synthetic peptide of the envelope glycoprotein that has been modified by the addition of a simple lipid tail to the end of the sequence (lipopeptide). The present study set out to address the question of whether such immunogens may be appropriate for preparing a human synthetic vaccine. We first showed that CTL were effectively induced by lipopeptides when given s.c. or i.p. We evidenced that the *in vivo* induction required stimulation of a concomitant specific T helper cell response, implying the presence of at least one CD4 epitope in the synthetic sequence used. Bearing in mind the particular properties that would be required in a prospective human peptide vaccine, we conceived a strategy in which a virus-specific CTL response could be generated in mice of different haplotypes using a single lipopeptide. We therefore tested a lipopeptide construct that integrated a synthetic sequence having three colinear epitopes of the influenza virus nucleoprotein, each restricted to a different H-2 haplotype. We found that a CTL response could be elicited to all three epitopes of this chimeric multirestricted lipopeptide construct. Finally, we have attempted to estimate the duration of the responses; strong CTL activities were still present up to six months after the last injection. These findings indicate that this approach may be suitable for developing a synthetic vaccine for human use.

PMID: 8585291 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)



National  
Library  
of Medicine 

Entrez	PubMed	Nucleotide	Protein	Genomes	Structure	OMIM	PMC	Journals	Books
Search <b>PubMed</b>		for				Go	Clear		
		Limits		Preview/Index		History		Clipboard	Details
		<b>Display</b>		<b>Abstract</b>		Show: 20		Sort	Send to

About Entrez

Text Version

[ 1: J Infect Dis. 1996 Jan;173(1):24-31.

Related Articles, Links

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

**Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.**

**Shirai M, Chen M, Arichi T, Masaki T, Nishioka M, Newman M, Nakazawa T, Feinstone SM, Berzofsky JA.**

Department of Microbiology, Yamaguchi University School of Medicine, Japan.

The induction of virus-specific cytotoxic T lymphocytes (CTL) is an important part of vaccine strategy. CTL induction in vivo by two hepatitis C virus (HCV) peptides containing CTL epitopes, one from the NS5 region (P17) and one from the core (C7), was compared. P17 required covalent attachment of a helper peptide (PCLUS3 containing a cluster of epitopes from the human immunodeficiency virus envelope protein), whereas C7 did not. However, the minimal decapeptide of C7, C7A10, alone did not induce CTL. The helper cells induced by PCLUS3-17 or by C7 were shown to be CD4+ and to produce interleukin-2 (IL-2). Thus, help can be supplied by a natural helper epitope intrinsic to the CTL peptide, as in C7, or by attaching a helper epitope from another protein, as in the case of P17. The cluster peptides may be useful promiscuous helper peptides for a variety of CTL epitopes from diverse pathogens.

PMID: 8537666 [PubMed - indexed for MEDLINE]

**Display** **Abstract** Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show: **20**

About Entrez

[Text Version](#)

**1**: [Immunology](#). 1996 Feb;87(2):179-85.

[Related Articles](#), [Links](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

## Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

**Partidos CD, Vohra P, Steward MW.**

Department of Clinical Sciences, London School of Hygiene and Tropical Medicine, UK.

We have investigated the structural requirements for the induction of cytotoxic T-cell responses (CTL) in vivo after intranasal immunization with an immunodominant CTL epitope from the nucleoprotein of measles virus (MV). For the induction of CTL responses, covalent linkage of the CTL epitope to a helper T-cell epitope was required and the orientation of the epitopes influenced the immunogenicity of the CTL epitope. The presence of two copies as compared with one copy of a T-helper epitope, rendered the CTL epitope more immunogenic and resulted in the in vivo induction of MV-specific CTLs without the need for an adjuvant. The role of CTL responses to this epitope in protection after intranasal administration was evaluated in a mouse model against challenge with a neuroadapted strain of MV. Although a decreased mortality in the peptide immunized compared with that in unimmunized mice was observed, the protection achieved was not significant. These findings highlight the importance of the rational design of synthetic immunogens for the induction of CTL responses and the potential of the intranasal route for immunization.

PMID: 8698377 [PubMed - indexed for MEDLINE]

Show: **20**

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

1: Mol Immunol. 1996 Nov;33(16):1223-9.

[Related Articles](#), [Links](#)

**FULL-TEXT ARTICLE**

## Structural requirements for synthetic immunogens to induce measles virus specific CTL responses.

Partidos CD, Delmas A, Steward MW.

Department of Clinical Sciences, London School of Hygiene and Tropical Medicine, U.K.

We have studied the immunogenicity of a synthetic peptide representing a cytotoxic T cell epitope (CTL) from the nucleoprotein of measles virus (MV). For the induction of peptide and MV-specific CTL responses after subcutaneous immunization, covalent linkage of the CTL epitope to a T-helper epitope was required. The presence of two copies of the T-helper epitope at the amino terminus of the CTL epitope (TT-CTL) resulted in the induction of strong CTL responses after administration in saline. In contrast, a chimeric peptide with one copy of the T-helper epitope at the amino terminus of the CTL epitope (T-CTL) was weakly immunogenic when given in saline. Analysis of the structure of the TT-CTL chimeric peptide by CD spectroscopy revealed an alpha-helical conformation, as compared to the random coil conformation favored by the T-CTL chimeric peptide. In addition, the CD spectra of the TT-CTL peptide in the presence of small unilamellar vesicles (SUV) revealed an increased helicity, as compared to the spectra of the T-CTL chimera in the presence of SUV. This suggests that the amphipathic character of the TT-CTL chimeric construct favors its interaction with the cell membrane of antigen presenting cells, therefore, facilitating its cytosolic delivery for class I presentation. These findings highlight the importance of antigen structure for the in vivo induction of CTL responses and may have implications for the design of synthetic peptide vaccines.

PMID: 9129158 [PubMed - indexed for MEDLINE]


Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine  
NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

1: Mol Immunol. 1996 Nov;33(16):1223-9. [Related Articles, Links](#)

## Structural requirements for synthetic immunogens to induce measles virus specific CTL responses.

Partidos CD, Delmas A, Steward MW.

Department of Clinical Sciences, London School of Hygiene and Tropical Medicine, U.K.

We have studied the immunogenicity of a synthetic peptide representing a cytotoxic T cell epitope (CTL) from the nucleoprotein of measles virus (MV). For the induction of peptide and MV-specific CTL responses after subcutaneous immunization, covalent linkage of the CTL epitope to a T-helper epitope was required. The presence of two copies of the T-helper epitope at the amino terminus of the CTL epitope (TT-CTL) resulted in the induction of strong CTL responses after administration in saline. In contrast, a chimeric peptide with one copy of the T-helper epitope at the amino terminus of the CTL epitope (T-CTL) was weakly immunogenic when given in saline. Analysis of the structure of the TT-CTL chimeric peptide by CD spectroscopy revealed an alpha-helical conformation, as compared to the random coil conformation favored by the T-CTL chimeric peptide. In addition, the CD spectra of the TT-CTL peptide in the presence of small unilamellar vesicles (SUV) revealed an increased helicity, as compared to the spectra of the T-CTL chimera in the presence of SUV. This suggests that the amphipathic character of the TT-CTL chimeric construct favors its interaction with the cell membrane of antigen presenting cells, therefore, facilitating its cytosolic delivery for class I presentation. These findings highlight the importance of antigen structure for the in vivo induction of CTL responses and may have implications for the design of synthetic peptide vaccines.

PMID: 9129158 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine 

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

1: J Virol. 1997 Mar;71(3):2292-302.

[Related Articles, Links](#)

[FREE full text article at  
jvi.asm.org](#)

[Full text article  
in PubMed Central](#)

**A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses *in vivo* and confers protection against more than one pathogen.**

**An LL, Whitton JL.**

Department of Neuropharmacology, CVN-9, The Scripps Research Institute, La Jolla, California 92037, USA.

The development of safe and effective vaccines remains a major goal in the prevention, and perhaps treatment, of infectious diseases. Ideally, a single vaccine would confer protection against several pathogens and would induce both cellular and humoral arms of the immune response. We originally demonstrated that two virus-specific cytotoxic T-lymphocyte (CTL) epitopes, from the same virus but presented by different major histocompatibility complex alleles, when linked in tandem as minigenes in a recombinant vaccinia virus, could confer complete protection against subsequent viral challenge. In the study, we extended this approach, which we termed string of beads, expanding the immunogenic scope in two ways: first, by introduction of T helper (Th) and B-cell (antibody) epitopes alongside CTL epitopes and second, by including immunogenic sequences from a variety of infectious agents, five viruses and one bacterium. The vaccine (VV-sv) comprises CTL epitopes from Sendai virus, respiratory syncytial virus, and lymphocytic choriomeningitis virus (LCMV); Th epitopes from vesicular stomatitis virus and *Mycobacterium tuberculosis*; and an antibody epitope from mengovirus. The construct contains a single start codon, and the epitopes are linked directly, without intervening spacer amino acids. There was some concern that the combination of several normally immunodominant epitopes might result in a new hierarchy of dominance, in which certain epitopes predominated and others exhibited reduced immunogenicity. However we show that when analyzed in tissue culture and *in vivo*, all six epitopes are expressed. CTL and Th cells are induced *in vivo*, along with neutralizing antibody. The induced immunity is biologically relevant: after VV-sv immunization, the antimengovirus antibody confers protection against mengovirus challenge. Similarly, CTL induced by the LCMV epitope protected mice against challenge with this agent. Thus, a polyvalent, minigene-based vaccine can simultaneously induce several classes of immune response and thereby can confer protection against diverse pathogens.

PMID: 9032365 [PubMed - indexed for MEDLINE]



National  
Library  
of Medicine 

Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

[Related Articles](#), [Links](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related Resources](#)

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *J Immunol*. 1997 Aug 1;159(3):1383-92.

[Full text article at  
www.jimmunol.org](#)

## The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.

**Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, Chesnut RW, Sette A.**

Cytel Corp., San Diego, CA 92121, USA. [brian\\_livingston@cytelcorp.com](mailto:brian_livingston@cytelcorp.com)

We have previously described the development of a lipopeptide-based vaccine, Theradigm-HBV, capable of inducing CTL responses in humans. This vaccine incorporates the HLA-A2.1-restricted CTL epitope hepatitis B core Ag 18-27, linked to the universal helper T lymphocyte (HTL) epitope tetanus toxoid (TT) 830-843. Herein, we report the results of a phase I trial designed to examine the effects of Theradigm-HBV dose and regimen on the magnitude and duration of the memory CTL response. A total of four injections of up to 5 mg/dose were found to be a safe and effective means of generating substantial memory CTL responses. Precursor frequency analysis demonstrated CTL responses of similar magnitude to those previously observed in patients who successfully cleared hepatitis B virus infection and to influenza-specific memory CTL responses induced by natural exposure to influenza virus. Theradigm-HBV induced CTL responses that persisted for more than 9 months after the last injection. HTL responses were associated with significant CTL responses, and sustained HTL activity was necessary for development of persistent memory CTL activity. These results represent the first demonstration of the importance of HTL activity for development of long-lived memory CTL responses in humans. In conclusion, our results show that lipopeptides safely induce specific CTL activity in humans of such magnitude and persistence as to be of potential therapeutic significance.

PMID: 9233635 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine 

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

1: *J Immunol.* 1997 Aug 1;159(3):1383-92.

[Related Articles](#), [Links](#)

## The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.

**Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, Chesnut RW, Sette A.**

Cytel Corp., San Diego, CA 92121, USA. [brian\\_livingston@cytelcorp.com](mailto:brian_livingston@cytelcorp.com)

We have previously described the development of a lipopeptide-based vaccine, Theradigm-HBV, capable of inducing CTL responses in humans. This vaccine incorporates the HLA-A2.1-restricted CTL epitope hepatitis B core Ag 18-27, linked to the universal helper T lymphocyte (HTL) epitope tetanus toxoid (TT) 830-843. Herein, we report the results of a phase I trial designed to examine the effects of Theradigm-HBV dose and regimen on the magnitude and duration of the memory CTL response. A total of four injections of up to 5 mg/dose were found to be a safe and effective means of generating substantial memory CTL responses. Precursor frequency analysis demonstrated CTL responses of similar magnitude to those previously observed in patients who successfully cleared hepatitis B virus infection and to influenza-specific memory CTL responses induced by natural exposure to influenza virus. Theradigm-HBV induced CTL responses that persisted for more than 9 months after the last injection. HTL responses were associated with significant CTL responses, and sustained HTL activity was necessary for development of persistent memory CTL activity. These results represent the first demonstration of the importance of HTL activity for development of long-lived memory CTL responses in humans. In conclusion, our results show that lipopeptides safely induce specific CTL activity in humans of such magnitude and persistence as to be of potential therapeutic significance.

PMID: 9233635 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

[Related Articles](#), [Links](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

**1: J Immunol. 1998 Feb 15;160(4):1717-23.**

FREE full text article at  
[www.jimmunol.org](http://www.jimmunol.org)

## Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.

**Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A.**

The Cooperative Research Centre for Vaccine Technology, Queensland Institute of Medical Research, Brisbane, Australia.

Development of CD8 alphabeta CTL epitope-based vaccines requires an effective strategy capable of co-delivering large numbers of CTL epitopes. Here we describe a DNA plasmid encoding a polyepitope or "polytope" protein, which contained multiple contiguous minimal murine CTL epitopes. Mice vaccinated with this plasmid made MHC-restricted CTL responses to each of the epitopes, and protective CTL were demonstrated in recombinant vaccinia virus, influenza virus, and tumor challenge models. CTL responses generated by polytope DNA plasmid vaccination lasted for 1 yr, could be enhanced by co-delivering a gene for granulocyte-macrophage CSF, and appeared to be induced in the absence of CD4 T cell-mediated help. The ability to deliver large numbers of CTL epitopes using relatively small polytope constructs and DNA vaccination technology should find application in the design of human epitope-based CTL vaccines, in particular in vaccines against EBV, HIV, and certain cancers.

PMID: 9469429 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine 

Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search **PubMed** for

Limits

Preview/Index

History

Clipboard

Details

Show:

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: Vaccine. 1998 Nov;16(19):1828-35.

[Related Articles](#) [Links](#)

## Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes.

**Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrison LD, Javadian A, Chalian AA, Agadjanyan MG, Weiner DB.**

Department of Chemical Engineering, University of Pennsylvania, Philadelphia 19104, USA.

DNA immunization has been investigated as a potential immunization strategy against infectious diseases and cancer. To enhance a DNA vaccine's ability to induce CTL response *in vivo*, we co-administered CD80 and CD86 expression cassettes along with HIV-1 immunogens. This manipulation resulted in a dramatic increase in MHC class I-restricted and CD8+ T-cell-dependent CTL responses in both mice and chimpanzees. This strategy of engineering vaccine producing cells to be more efficient T-cell activators could be an important tool for optimizing antigen-specific T-cell-mediated immune responses in the pursuit of more rationally designed vaccines and immune therapies.

PMID: 9795388 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine 

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <b>PubMed</b>		for				Go	Clear		
		Limits		Preview/Index		History	Clipboard	Details	
		<b>Display</b>		<b>Abstract</b>		Show: 20	Sort	<b>Send to</b>	<b>Text</b>

About Entrez

Text Version

1: Vaccine. 1999 Apr 9;17(15-16):2009-19.

Related Articles, Links

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

## Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.

**Elliott SL, Pye S, Le T, Mateo L, Cox J, Macdonald L, Scalzo AA, Forbes CA, Suhrbier A.**

Co-operative Research Centre for Vaccine Technology, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Australia.

Synthetic CD8+ cytotoxic T-lymphocyte (CTL) peptide epitope based vaccines are being developed against a number of human diseases. Here we describe extensive preclinical testing of peptide epitope vaccines formulated with a protein as a source of CD4 help and Montanide ISA 720, an adjuvant currently in human clinical trials. Such water-in-oil formulations could effectively co-deliver several peptide epitopes and simultaneously induce multiple independent CTL responses. The efficiency of CTL induction by some peptides was, however, dependent on the aqueous buffer conditions, with poor performance correlating with non-covalent peptide oligomerisation. Any of a number of proteins currently used in human vaccines could supply CD4 help and no difference in CTL induction was obtained if the CD4 response was amnestic or a primary. Peptide immunisation was found to induce long term CTL memory and the recall of protective responses did not depend on an amnestic CD4 response. Slow pyroglutamic acid formation and rapid oxidation of methionine residues was observed in water-in-oil formulations, however, the latter had no effect on CTL induction. These data highlight the need to monitor for potential deleterious chemical events and interpeptide interactions, but illustrate that peptide based vaccination can effectively deliver multiple epitopes, in conjunction with any protein, and induce protective memory.

PMID: 10217601 [PubMed - indexed for MEDLINE]

**Display** **Abstract** Show: 20 Sort **Send to** **Text**

[Write to the Help Desk](#)

NCBI | NLM | NIH

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National  
Library  
of Medicine 

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <b>PubMed</b>		<input type="text"/> for <input type="button" value="Go"/>		<input type="button" value="Clear"/>					
		<input type="button" value="Limits"/>		<input type="button" value="Preview/Index"/>		<input type="button" value="History"/>		<input type="button" value="Clipboard"/>	
		<input type="button" value="Display"/>		<input type="button" value="Abstract"/>		<input type="button" value="Show: 20"/>		<input type="button" value="Sort"/>	
								<input type="button" value="Send to"/>	
								<input type="button" value="Text"/>	

About Entrez

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

1: Clin Cancer Res. 1999 May;5(5):1173-82.

Related Articles, Links

FREE full text article at  
[clincancerres.aacrjournals.org](http://clincancerres.aacrjournals.org)

**Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.**

**Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.**

Department of Surgery, Medical University of South Carolina, Charleston 29425, USA.

The mode of peptide-based cancer vaccine administration critically affects the ability to achieve a clinically relevant tumor-specific response. We have previously shown (Cole et al., Clin. Cancer Res., 3: 867-873, 1997) that a specific formulation of the polysaccharide poly-N-acetyl glucosamine (p-GlcNAc, designated as F2 gel) is an effective vehicle for sustained cytokine and peptide delivery in vitro. The purpose of this study was to evaluate the efficacy of F2 gel/peptide vaccination in the murine EG.7-OVA tumor model and to elucidate potential mechanisms involved in the observed cell-mediated response. C57BL/6 mice were given injections of 200 microl in the base of tail/footpad using either F2 gel alone or 200 microg of: SIINFEKL minimal peptide (OVA) in PBS, OVA peptide/endoplasmic reticulum insertion signal sequence fusion (ESOVA) in PBS, OVA in F2 gel, or ESOVA in F2 gel. Splenocytes were tested 10 days later for a secondary response using a Cr51 assay as well as a primary CTL response using the lactate dehydrogenase cytotoxicity assay. Splenocytes from immunized mice were harvested at specific time points and assayed for cell surface and intracellular markers. On day 10 postvaccination, animals were challenged with EG.7-OVA murine thymoma cells. Tumor size and appearance were recorded. Vaccination with F2 gel/peptide (either OVA or ESOVA) resulted in a primary T-cell response (up to 25% tumor cell-specific lysis) and no tumor growth in 69% of the mice. By 48 h, the proportion of splenic T cells had increased 4-fold compared with B cells. Presence of an increased Th1 CD4 helper population was demonstrated by IFN-gamma production. CD4 cells were activated at 24 and 48 h as shown by IL-2 receptor alpha chain expression (from 2% basal expression to 15.4% at 48 h). Activated splenic macrophages increased from 3 to 8% within 10 h, and their level of B7-2 expression doubled. Depletion of macrophages before vaccine injection abolished any tumor-specific primary CTL response. F2 gel/peptide tumor vaccine can prime the immune system in an antigen-specific manner by generating a measurable primary T-cell response with minimal peptide; this process involves macrophage presence and activation as well as induction of Th1 CD4 cells. This is the first

demonstration of a primary CTL response generated with minimal peptide vaccination using a noninfectious delivery system. These results justify additional studies to better define the mechanisms involved in F2 gel/peptide vaccination in preparation for clinical trials.

PMID: 10353754 [PubMed - indexed for MEDLINE]

---

[Display](#) [Abstract](#) [Show: 20](#) [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 16 2004 07:00:47



National  
Library  
of Medicine



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search **PubMed**

for

**Go**

**Clear**

Limits

Preview/Index

History

Clipboard

Details

**Display**

**Abstract**

Show: 20

Sort

**Send to**

**Text**

About Entrez

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related Resources](#)

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: Clin Cancer Res. 1999 May;5(5):1173-82.

[Related Articles, Links](#)

[FREE full text article at  
clincancerres.aacrjournals.org](#)

## **Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.**

**Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.**

Department of Surgery, Medical University of South Carolina, Charleston 29425, USA.

The mode of peptide-based cancer vaccine administration critically affects the ability to achieve a clinically relevant tumor-specific response. We have previously shown (Cole et al., Clin. Cancer Res., 3: 867-873, 1997) that a specific formulation of the polysaccharide poly-N-acetyl glucosamine (p-GlcNAc, designated as F2 gel) is an effective vehicle for sustained cytokine and peptide delivery in vitro. The purpose of this study was to evaluate the efficacy of F2 gel/peptide vaccination in the murine EG.7-OVA tumor model and to elucidate potential mechanisms involved in the observed cell-mediated response. C57BL/6 mice were given injections of 200 microl in the base of tail/footpad using either F2 gel alone or 200 microg of: SIINFEKL minimal peptide (OVA) in PBS, OVA peptide/endoplasmic reticulum insertion signal sequence fusion (ESOVA) in PBS, OVA in F2 gel, or ESOVA in F2 gel. Splenocytes were tested 10 days later for a secondary response using a Cr51 assay as well as a primary CTL response using the lactate dehydrogenase cytotoxicity assay. Splenocytes from immunized mice were harvested at specific time points and assayed for cell surface and intracellular markers. On day 10 postvaccination, animals were challenged with EG.7-OVA murine thymoma cells. Tumor size and appearance were recorded. Vaccination with F2 gel/peptide (either OVA or ESOVA) resulted in a primary T-cell response (up to 25% tumor cell-specific lysis) and no tumor growth in 69% of the mice. By 48 h, the proportion of splenic T cells had increased 4-fold compared with B cells. Presence of an increased Th1 CD4 helper population was demonstrated by IFN-gamma production. CD4 cells were activated at 24 and 48 h as shown by IL-2 receptor alpha chain expression (from 2% basal expression to 15.4% at 48 h). Activated splenic macrophages increased from 3 to 8% within 10 h, and their level of B7-2 expression doubled. Depletion of macrophages before vaccine injection abolished any tumor-specific primary CTL response. F2 gel/peptide tumor vaccine can prime the immune system in an antigen-specific manner by generating a measurable primary T-cell response with minimal peptide; this process involves macrophage presence and activation as well as induction of Th1 CD4 cells. This is the first

demonstration of a primary CTL response generated with minimal peptide vaccination using a noninfectious delivery system. These results justify additional studies to better define the mechanisms involved in F2 gel/peptide vaccination in preparation for clinical trials.

PMID: 10353754 [PubMed - indexed for MEDLINE]

---

[Display](#) [Abstract](#) [Show: 20](#) [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 16 2004 07:00:47



National  
Library  
of Medicine 

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Show:

[Related Articles](#), [Links](#)

[Text Version](#)

1: Clin Cancer Res. 1999 Jul;5(7):1918-24.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

FREE full text article at  
[clincancerres.aacrjournals.org](http://clincancerres.aacrjournals.org)

## Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.

**Barratt-Boyes SM, Vlad A, Finn OJ.**

Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pennsylvania 15261, USA. [smbb+pitt.edu](mailto:smbb+pitt.edu)

CTLs and antibody responses to the tumor-associated antigen MUC1 mucin can be detected in patients with adenocarcinomas of the breast, pancreas, colon, and ovary. However, neither response is generally effective at controlling disease. Methods to augment immunity to MUC1 are being designed, with the expectation that this will lead to an antitumor response. The key to eliciting potent immunity to tumor MUC1 may be in generating MUC1-specific T-helper cell responses, which, to date, have not been reported in cancer patients. We have recently demonstrated that a synthetic vaccine representing five copies of the MUC1 tandem repeat peptide can be used to prime MUC1-specific human CD4+ T cells in vitro. Here, we extend these studies to test the immunogenicity and safety of the tandem repeat peptide in the chimpanzee, which has the identical MUC1 tandem repeat sequence to the human. To promote induction of Th1-type responses, we used the novel adjuvant LeIF, a Leishmania-derived protein that is known to stimulate human peripheral blood mononuclear cells (PBMCs) and antigen-presenting cells, to produce a Th1-type cytokine profile. We found that MUC1 tandem repeat peptide administered with LeIF elicited positive, albeit transient, proliferative T-cell responses to MUC1 in the PBMCs from four of four chimpanzees. Immunization induced MUC1-specific IFN-gamma but not interleukin 4 expression in CD4+ T cells from PBMCs and draining lymph nodes. MUC1-specific CTLs were also generated that did not induce detectable autoimmune dysfunction during the 1 year of observation. We conclude that the MUC1 tandem repeat peptide can be used to elicit both T-helper and cytotoxic cell responses to MUC1 in the primate and holds promise as a safe and effective cancer vaccine.

PMID: 10430099 [PubMed - indexed for MEDLINE]

Welcome to STN International! Enter x:x

\*\*\*\*\* Welcome to STN International \*\*\*\*\*  
\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:41:07 ON 19 NOV 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'ANABSTR' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 13:41:16 ON 19 NOV 2004  
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved.

FILE 'BIOENG' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 13:41:16 ON 19 NOV 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'CAPLUS' ENTERED AT 13:41:16 ON 19 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 13:41:16 ON 19 NOV 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPUS' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'FOMAD' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'HEALSAFE' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemistry

FILE 'LIFESCI' ENTERED AT 13:41:16 ON 19 NOV 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'MEDLINE' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'NIOSHTIC' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 13:41:16 ON 19 NOV 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 13:41:16 ON 19 NOV 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 13:41:16 ON 19 NOV 2004

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAMIL' ENTERED AT 13:41:16 ON 19 NOV 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 13:41:16 ON 19 NOV 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 13:41:16 ON 19 NOV 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:41:16 ON 19 NOV 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 13:41:16 ON 19 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:41:16 ON 19 NOV 2004

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S B-cell epitope OR cytotoxic T-cell epitope OR CTL epitope  
12 FILES SEARCHED...  
14 FILES SEARCHED...  
17 FILES SEARCHED...  
25 FILES SEARCHED...  
31 FILES SEARCHED...  
32 FILES SEARCHED...  
43 FILES SEARCHED...  
48 FILES SEARCHED...  
53 FILES SEARCHED...  
63 FILES SEARCHED...  
66 FILES SEARCHED...  
71 FILES SEARCHED...

L1 48977 B-CELL EPITOPE OR CYTOTOXIC T-CELL EPITOPE OR CTL EPITOPE

=> S T helper cell epitope  
14 FILES SEARCHED...  
25 FILES SEARCHED...  
32 FILES SEARCHED...  
47 FILES SEARCHED...  
61 FILES SEARCHED...  
69 FILES SEARCHED...

L2 2313 T HELPER CELL EPITOPE

=> S L1 AND L2  
53 FILES SEARCHED...

L3 1166 L1 AND L2

=> DUP REM L3  
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,  
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,  
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING IS APPROXIMATELY 97% COMPLETE FOR L3  
PROCESSING COMPLETED FOR L3  
L4 894 DUP REM L3 (272 DUPLICATES REMOVED)

=> S L4 AND PY<=2000  
'2000' NOT A VALID FIELD CODE  
5 FILES SEARCHED...  
8 FILES SEARCHED...  
12 FILES SEARCHED...  
15 FILES SEARCHED...  
20 FILES SEARCHED...  
'2000' NOT A VALID FIELD CODE  
29 FILES SEARCHED...  
32 FILES SEARCHED...  
'2000' NOT A VALID FIELD CODE  
'2000' NOT A VALID FIELD CODE  
43 FILES SEARCHED...  
'2000' NOT A VALID FIELD CODE  
48 FILES SEARCHED...  
53 FILES SEARCHED...  
'2000' NOT A VALID FIELD CODE  
59 FILES SEARCHED...  
'2000' NOT A VALID FIELD CODE  
65 FILES SEARCHED...  
71 FILES SEARCHED...

L5 268 L4 AND PY<=2000

=> D L5 1-268

L5 ANSWER 1 OF 268 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on  
STN  
AN 1999:60696 ADISCTI  
DN 800806733  
TI HIV-specific immunity following immunization with HIV synthetic envelope  
peptides in asymptomatic HIV-infected patients.  
ADIS TITLE: HIV-1 peptide vaccine: immunogenicity.

in patients with asymptomatic disease.  
AU Pinto L A; Berzofsky J A; Fowke K R; Little R F; Merced Galindez F; et al.  
CS National Institutes of Health, Bethesda, Maryland, USA.  
SO AIDS (Oct 22, 1999), Vol. 13, pp. 2003-2012  
DT Study  
RE Vaccines | Antivirals  
FS Summary  
LA English  
WC 633

L5 ANSWER 2 OF 268 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN  
AN 1998:46354 ADISCTI  
DN 800715007  
TI Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* of Semliki Forest virus and a \*\*\*B\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* of HIV.  
AU Fernandez I M; Golding H; Benaissa Trouw B J; et al.  
SO Vaccine (Dec 1, 1998), Vol. 16, pp. 1936-1940  
DT Citation  
RE Vaccines | Antivirals  
FS Citation  
LA English

L5 ANSWER 3 OF 268 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN  
AN 1997:45986 ADISCTI  
DN 800528019  
TI Hepatitis B virus core protein mutations are concentrated in \*\*\*B\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* in progressive disease and in \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* during clinical remission.  
AU Carman W F; Boner W; Fattovich G; et al.  
SO Journal of Infectious Diseases (May 1, 1997), Vol. 175, pp. 1093-1100  
DT Citation  
RE Antivirals  
FS Citation  
LA English

L5 ANSWER 4 OF 268 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN  
AN 1992:44155 ADISCTI  
DN 807020063  
TI A \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* overlaps a major \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* in human papillomavirus type-18 E2-protein.  
AU Lehtinen M; Stellato G; Hyoty H; et al.  
CS M Lehtinen, Univ Tampere, Inst Biomed Sci, POB 607, SF-33101 Tampere, Finland.  
SO APMIS (Nov 1, 1992), Vol. 100, pp. 1022-1026  
DT Citation  
RE Antivirals  
FS Citation  
LA English

L5 ANSWER 5 OF 268 BIOENG COPYRIGHT 2004 CSA on STN  
AN 2004359099 BIOENG  
DN 4403758  
TI Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines  
AU Fernandez, IM; Harmsen, M; Benaissa-Trouw, BJ; Stuij, I; Puyk, W; Meloen, RH; Snippe, H\*; Kraaijeveld, CA  
CS Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Hospital Utrecht, HP G 04.614, Postbox 85500, 3508 GA Utrecht, The Netherlands, [mailto:H. Snippe@labazu.nl]  
SO Vaccine [Vaccine]. Vol. 16, no. 16, pp. 1531-1536. Oct 1998.  
DT ISSN: 0264-410X  
LA Journal  
SL English  
OS Immunology Abstracts; Microbiology Abstracts A: Industrial & Applied Microbiology; Medical and Pharmaceutical Biotechnology Abstracts; Virology & AIDS Abstracts

AN 2004336621 BIOENG  
DN 3980491  
TI Poly(DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines  
AU Ertl, HCJ; Varga, I; Xiang, Zhi Quan; Kaiser, K; Stephens, L; Otvos, L Jr  
CS Wistar Inst., 3601 Spruce St., Philadelphia, PA 19104, USA  
SO Vaccine, vol. 14, no. 9, pp. 879-885, 1996  
ISSN: 0264-410X  
DT Journal  
LA English  
SL English  
OS Immunology Abstracts; Medical and Pharmaceutical Biotechnology Abstracts

L5 ANSWER 7 OF 268 BIOENG COPYRIGHT 2004 CSA on STN  
AN 2004172386 BIOENG  
DN 2152811  
TI Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* .  
AU Tam, JP; Lu, Yi-An  
CS Rockefeller Univ., 1230 York Ave., New York, NY 10021, USA  
SO Proceedings of the National Academy of Sciences, USA [PROC. NATL. ACAD. SCI. USA.], vol. 86, no. 23, pp. 9084-9088, 1989  
ISSN: 0027-8424  
DT Journal  
LA English  
SL English  
OS Immunology Abstracts; Virology & AIDS Abstracts; Biotechnology Research Abstracts (through 1992)

L5 ANSWER 8 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 2001:83159 BIOSIS  
DN PREV200100083159  
TI Epitope affinity for MHC class I determines helper requirement for CTL priming.  
AU Franco, Alessandra [Reprint author]; Tilly, Darcie A.; Gramaglia, Irene; Croft, Michael; Cipolla, Laura; Meldal, Morten; Grey, Howard M.  
CS Division of Immunochemistry, La Jolla Institute for Allergy and Immunology, San Diego, CA, 92121, USA  
alessandra.franco@liai.org  
SO Nature Immunology, (August, 2000) Vol. 1, No. 2, pp. 145-150. print.  
ISSN: 1529-2908.  
DT Article  
LA English  
ED Entered STN: 14 Feb 2001  
Last Updated on STN: 12 Feb 2002

L5 ANSWER 9 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 2001:41140 BIOSIS  
DN PREV200100041140  
TI Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-alpha therapy.  
AU Radecke, Klaus; Protzer, Ulrike; Trippler, Martin; zum Bueschenfelde, Karl-Hermann Meyer; Gerken, Guido [Reprint author]  
CS Medizinische Klinik und Poliklinik, Abteil fuer Gastroenterologie/Hepatologie, Universitaetsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Germany  
SO Journal of Medical Virology, (December, 2000) Vol. 62, No. 4, pp. 479-486. print.  
CODEN: JMVIDB. ISSN: 0146-6615.  
DT Article  
LA English  
ED Entered STN: 17 Jan 2001  
Last Updated on STN: 12 Feb 2002

L5 ANSWER 10 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 2000:255006 BIOSIS  
DN PREV200000255006  
TI Interspecies major histocompatibility complex-restricted Th cell epitope on foot-and-mouth disease virus capsid protein VP4.  
AU Blanco, Esther; McCullough, Kenneth [Reprint author]; Summerfield, Artur; Fiorini, Jude; Andreu, David; Chiva, Cristina; Borras, Eva; Barnett, Paul;

CS Institute of Virology and Immunoprophylaxis, Sensemattstrasse 293, 3147, Mittelhaeusern, Switzerland  
SO Journal of Virology, (May, 2000) Vol. 74, No. 10, pp. 4902-4907. print.  
CODEN: JOVIAM. ISSN: 0022-538X.  
DT Article  
LA English  
ED Entered STN: 21 Jun 2000  
Last Updated on STN: 5 Jan 2002

L5 ANSWER 11 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 2000:237064 BIOSIS  
DN PREV200000237064  
TI Immunocontraception with zona pellucida proteins.  
AU Paterson, Margaret [Reprint author]; Jennings, Zoe A.; van Duin, Marcel; Aitken, R. John  
CS MRC Reproductive Biology Unit, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh, EH3 9ET, UK  
SO Cells Tissues Organs, (2000) Vol. 166, No. 2, pp. 228-232. print.  
ISSN: 1422-6405.  
DT Article  
LA English  
ED Entered STN: 7 Jun 2000  
Last Updated on STN: 5 Jan 2002

L5 ANSWER 12 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 2000:89029 BIOSIS  
DN PREV200000089029  
TI Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide.  
AU Zinckgraf, John W.; Winchell, Jonas M.; Silburt, Lawrence K. [Reprint author]  
CS Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT, 06269, USA  
SO Journal of Reproductive Immunology, (Dec., 1999) Vol. 45, No. 2, pp. 99-112. print.  
CODEN: JRIMDR. ISSN: 0165-0378.  
DT Article  
LA English  
ED Entered STN: 10 Mar 2000  
Last Updated on STN: 3 Jan 2002

L5 ANSWER 13 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 2000:10431 BIOSIS  
DN PREV200000010431  
TI Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice.  
AU Jiang Yanfang; Lin Chengtao; Yin Bin; He Xiangyun; Mao Yinghong; Dong Min; Xu Pei; Zhang Lianhui; Liu Baofeng; Wang Heng [Reprint author]  
CS No. 5 Dong Dan San Tiao, Rm. 562, Beijing, 100005, China  
SO Chinese Medical Journal (English Edition), (Aug., 1999) Vol. 112, No. 8, pp. 686-690. print.  
CODEN: CMJODS. ISSN: 0366-6999.  
DT Article  
LA English  
ED Entered STN: 23 Dec 1999  
Last Updated on STN: 31 Dec 2001

L5 ANSWER 14 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN  
AN 1999:371373 BIOSIS  
DN PREV199900371373  
TI A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus.  
AU Heathcote, Jenny [Reprint author]; McHutchison, John; Lee, Samuel; Tong, Myron; Benner, Kent; Minuk, Gerald; Wright, Teresa; Fikes, John; Livingston, Brian; Sette, Alex; Chestnut, Robert; CY-1899 T Cell Vaccine Study Group  
CS Western Division, Toronto Hospital, 399 Bathurst Street, 4/F West Wing, Rm. 828, Toronto, ON, M5T 2S8, Canada  
SO Hepatology, (Aug., 1999) Vol. 30, No. 2, pp. 531-536. print.  
CODEN: HPTLD9. ISSN: 0270-9139.  
DT Article

ED Entered STN: 9 Sep 1999  
Last Updated on STN: 9 Sep 1999

L5 ANSWER 15 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

AN 1998:480309 BIOSIS  
DN PREV199800480309

TI Specificity of humoral and cellular immune response against recombinant  
particles of nucleocapsid protein of human hepatitis B virus in rabbits.  
AU Isagulants, M. G. [Reprint author]; Kadoshnikov, Yu. P.; Kalinina, T. I.;  
Smirnov, V. D.; Wahren, B.

CS Ivanovsky Inst. Virol., ul. Gamalei 16, Moscow 123098, Russia  
SO Biochemistry (Moscow), (May, 1998) Vol. 63, No. 5, pp. 551-558. print.  
CODEN: BIORAK. ISSN: 0006-2979.

DT Article

LA English

ED Entered STN: 5 Nov 1998

Last Updated on STN: 5 Nov 1998

L5 ANSWER 16 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

AN 1997:274503 BIOSIS  
DN PREV199799566221

TI Generation of antibodies to human IL-12 and amphiregulin by immunization  
of Balb/c mice with diepitope multiple antigen peptides.

AU Ahlborg, Niklas [Reprint author]; Paulie, Staffan; Braesch-Andersen, Sten  
CS Dep. Immunology, Stockholm Univ., S-106 91 Stockholm, Sweden  
SO Journal of Immunological Methods, (1997) Vol. 203, No. 1, pp. 23-32.  
CODEN: JIMMBG. ISSN: 0022-1759.

DT Article

LA English

ED Entered STN: 24 Jun 1997

Last Updated on STN: 24 Jun 1997

L5 ANSWER 17 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

AN 1997:250703 BIOSIS  
DN PREV199799549906

TI Potent immunogenic short linear peptide constructs composed of \*\*\*B\*\*\*  
\*\*\*cell\*\*\* \*\*\*epitopes\*\*\* and Pan DR T helper epitopes (PADRE) for  
antibody responses in vivo.

AU Del Guercio, Marie-France [Reprint author]; Alexander, Jeff [Reprint  
author]; Kubo, Ralph T. [Reprint author]; Arrhenius, Thomas [Reprint  
author]; Maewal, Ajesh [Reprint author]; Appella, Ettore; Hoffman, Stephen  
L.; Jones, Trevor; Valmori, Danila [Reprint author]; Sakaguchi, Kazuyasu;  
Grey, Howard M.; Sette, Alessandro [Reprint author]  
CS Cytel Corporation, 3525 John Hopkins Court, San Diego, CA 92121, USA  
SO Vaccine, (1997) Vol. 15, No. 4, pp. 441-448.  
CODEN: VACCDE. ISSN: 0264-410X.

DT Article

LA English

ED Entered STN: 13 Jun 1997

Last Updated on STN: 13 Jun 1997

L5 ANSWER 18 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

AN 1997:14224 BIOSIS  
DN PREV199799313427

TI Hierarchic T-cell help to non-linked \*\*\*B\*\*\* - \*\*\*cell\*\*\*  
\*\*\*epitopes\*\*\*

AU Brons, N. H. C.; Blaich, A.; Wiesmueller, K.-H.; Schneider, F.; Jung, G.;  
Muller, C. P. [Reprint author]  
CS Lab. Natl. de Sante, PO Box 1102, L-1011 Luxembourg, Luxembourg  
SO Scandinavian Journal of Immunology, (1996) Vol. 44, No. 5, pp. 478-484.  
CODEN: SJIMAX. ISSN: 0300-9475.

DT Article

LA English

ED Entered STN: 15 Jan 1997

Last Updated on STN: 15 Jan 1997

L5 ANSWER 19 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

AN 1995:254725 BIOSIS  
DN PREV199598269025

TI Human \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\*

\*\*\*epitopes\*\*\* in the E2 protein of human papillomavirus type 16.  
AU Lehtinen, Matti [Reprint author]; Hibma, Merilyn H.; Stellato, Giovanni;  
Kuppala, Tasio; Paavonen, Jorma  
CS Dep. Chronic Viral Diseases, Natl. Public Health Inst., Helsinki, Finland  
SO Biochemical and Biophysical Research Communications, (1995) Vol. 209, No.  
2, pp. 541-546.  
CODEN: BBRCA9. ISSN: 0006-291X.  
DT Article  
LA English  
ED Entered STN: 13 Jun 1995  
Last Updated on STN: 13 Jun 1995

L5 ANSWER 20 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1995:21041 BIOSIS  
DN PREV199598035341  
TI A shared idiotope among antibodies against Semliki Forest virus.  
AU Fernandez, I. M. [Reprint author]; Ovaa, W.; Harmsen, M.; Benaissa-Trouw,  
B. J.; Bos, N. A.; Kraaijeveld, C. A.; Snippe, H.  
CS Eijkman-Winkler Inst. Med. Clinical Microbiol., Univ. Hosp., Room G  
04.6145, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands  
SO Viral Immunology, (1994) Vol. 7, No. 2, pp. 71-80.  
CODEN: VIIMET. ISSN: 0882-8245.  
DT Article  
LA English  
ED Entered STN: 11 Jan 1995  
Last Updated on STN: 11 Jan 1995

L5 ANSWER 21 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1995:21031 BIOSIS  
DN PREV199598035331  
TI Identification of Mengo virus \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitopes\*\*\*  
AU Muir, Susie; Kobasa, Darwyn; Bittle, James; Scraba, Douglas [Reprint  
author]  
CS Dep. Biochem., Univ. Alberta, Edmonton, AB T6G 2H7, Canada  
SO Journal of General Virology, (1994) Vol. 75, No. 11, pp. 2925-2936.  
CODEN: JGVIAY. ISSN: 0022-1317.  
DT Article  
LA English  
ED Entered STN: 11 Jan 1995  
Last Updated on STN: 11 Jan 1995

L5 ANSWER 22 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1994:515580 BIOSIS  
DN PREV199497528580  
TI Persistent HBV infection in HBeAg negative active liver disease is  
associated with amino acid substitutions in B and \*\*\*T\*\*\* -  
\*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* rather than in  
\*\*\*CTL\*\*\* \*\*\*epitopes\*\*\*  
AU Thursz, M. [Reprint author]; Carman, W.; Hadziyannis, S.; McIntyre, G.;  
Colman, K.; Fattovich, G.; Alberti, A.; Thomas, H. C. [Reprint author]  
CS Acad. Dep. Med., St. Mary's Hosp. Med. Sch., London, UK  
SO Journal of Hepatology, (1994) Vol. 21, No. SUPPL. 1, pp. S32.  
Meeting Info.: 29th Annual Meeting of the European Association for the  
Study of the Liver. Athens, Greece. September 7-10, 1994.  
CODEN: JOHEEC. ISSN: 0168-8278.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)  
LA English  
ED Entered STN: 3 Dec 1994  
Last Updated on STN: 3 Dec 1994

L5 ANSWER 23 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1994:204054 BIOSIS  
DN PREV199497217054  
TI Identification of a murine \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* on the major (L1) capsid protein of human papillomavirus  
type 16 and its utilization to potentiate serum and secretory antibody  
responses to a \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\*  
AU Cason, John; Kambo, Parminder; Siggers, Georgina; Jewers, Richard J.;

CS Richard Dimbleby Lab. Cancer Viroi., Rayne Inst., St. Thomas Hosp., UMDs, London SE1 7EH, UK

SO Journal of Cellular Biochemistry Supplement, (1994) Vol. 0, No. 18C, pp. 229.

Meeting Info.: Keystone Symposium on Human Tumor Viruses. Taos, New Mexico, USA. February 13-20, 1994.

ISSN: 0733-1959.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

Conference; (Meeting Poster)

LA English

ED Entered STN: 2 May 1994

Last Updated on STN: 2 May 1994

L5 ANSWER 24 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1993:500156 BIOSIS

DN PREV199396124163

TI Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki forest virus.

AU Fernandez, I. M. [Reprint author]; Snijders, A.; Benaissa-Trouw, B. J.; Harmsen, M.; Snijpe, H.; Kraaijeveld, C. A.

CS Eijkman-Winkler Lab. Med. Microbiol., Univ. Hosp. Utrecht, HP G 04.614, Postbox 85500, 3508 GA Utrecht, The Netherlands, netherlands

SO Journal of Virology, (1993) Vol. 67, No. 10, pp. 5843-5848.

CODEN: JOVIAM. ISSN: 0022-538X.

DT Article

LA English

ED Entered STN: 5 Nov 1993

Last Updated on STN: 5 Nov 1993

L5 ANSWER 25 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1993:454772 BIOSIS

DN PREV199396099672

TI Influence of the T-helper epitope on the titre and affinity of antibodies to \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* after co-immunization.

AU Shaw, D. Michael; Stanley, Carolynne M.; Partidos, Charalambos D.; Steward, Michael W.

CS Molecular Immunol. Unit, Dep. Clin. Sci., London Sci. Hygiene and Tropical Med., Keppel St., London WC1E 7HT, UK

SO Molecular Immunology, (1993) Vol. 30, No. 11, pp. 961-968.

CODEN: MOIMD5. ISSN: 0161-5890.

DT Article

LA English

ED Entered STN: 5 Oct 1993

Last Updated on STN: 5 Oct 1993

L5 ANSWER 26 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1993:320342 BIOSIS

DN PREV199396028692

TI Fewer protective \*\*\*cytotoxic\*\*\* \*\*\*T\*\*\* - \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* than \*\*\*T\*\*\* - \*\*\*helper\*\*\* - \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* on vesicular stomatitis virus.

AU Kundig, Thomas M. [Reprint author]; Castelmur, Irene; Bachmann, Martin F.; Abraham, Diana; Binder, Daniel; Hengartner, Hans; Zinkernagel, Rolf M.

CS Inst. Exp. Immunol., Univ. Zurich, Schmelzbergstr. 12, 8091 Zurich, Switzerland

SO Journal of Virology, (1993) Vol. 67, No. 6, pp. 3680-3683.

CODEN: JOVIAM. ISSN: 0022-538X.

DT Article

LA English

ED Entered STN: 12 Jul 1993

Last Updated on STN: 12 Jul 1993

L5 ANSWER 27 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1993:141379 BIOSIS

DN PREV199395074179

TI A \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* overlaps a major \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* in human papillomavirus type 18 E2 protein.

AU Lehtinen, Matti [Reprint author]; Stellato, Giovanni; Hyoty, Heikki; Nieminen, Pekka; Vesterinen, Ervo; Paavonen, Jorma

SO APMIS, (1992) VOL. 100, NO. 11, pp. 1022-1026.  
CODEN: APMSEL. ISSN: 0903-4641.

DT Article  
LA English  
ED Entered STN: 16 Mar 1993  
Last Updated on STN: 16 Mar 1993

L5 ANSWER 28 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1993:74590 BIOSIS  
DN PREV199395039090  
TI A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.  
AU Snijders, A. [Reprint author]; Benaissa-Trouw, B. J.; Visser-Vernooy, H. J.; Fernandez, I.; Snippe, H.; Kraaijeveld, C. A.  
CS Acad. Hosp. Utrecht, HP Go4.614, P.O. Box 85500, 3508 GA Utrecht, Netherlands Antilles  
SO Immunology, (1992) Vol. 77, No. 3, pp. 322-329.  
CODEN: IMMUAM. ISSN: 0019-2805.

DT Article  
LA English  
ED Entered STN: 26 Jan 1993  
Last Updated on STN: 27 Jan 1993

L5 ANSWER 29 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1993:51623 BIOSIS  
DN PREV199395027925  
TI Antibody responses to non-immunogenic synthetic peptides induced by co-immunization with immunogenic peptides.  
AU Partidos, C. D.; Obeid, O. E.; Steward, M. W. [Reprint author]  
CS Molecular Immunology Unit, Dep. Clinical Sciences, London School Hygiene Tropical Medicine, London WC1E 7HT, UK  
SO Immunology, (1992) Vol. 77, No. 2, pp. 262-266.  
CODEN: IMMUAM. ISSN: 0019-2805.

DT Article  
LA English  
ED Entered STN: 13 Jan 1993  
Last Updated on STN: 13 Jan 1993

L5 ANSWER 30 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1990:29878 BIOSIS  
DN PREV199089016844; BA89:16844  
TI DEFECTIVE \*\*\*T\*\*\* \*\*\*HELPER\*\*\* \*\*\*CELL\*\*\* \*\*\*EPITOPE\*\*\*  
RESPONSIBLE FOR THE FAILURE OF REGION 69-84 OF THE HUMAN MYELIN BASIC PROTEIN TO INDUCE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN THE LEWIS RAT.  
AU HASHIM G A [Reprint author]; GALANG A B; SRINIVASAN J V; CARVALHO E F; OFFNER H; VANDENBARK A A; CLEVELAND W L; DAY E D  
CS DIV EXP IMMUNOL, ST LUKE'S-ROOSEVELT HOSP CENT, AMSTERDAM AVE AT 114TH ST, NEW YORK, NY 10025, USA  
SO Journal of Neuroscience Research, (1989) Vol. 24, No. 2, pp. 222-230.  
CODEN: JNREDK. ISSN: 0360-4012.

DT Article  
FS BA  
LA ENGLISH  
ED Entered STN: 19 Dec 1989  
Last Updated on STN: 19 Dec 1989

L5 ANSWER 31 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
AN 1989:237316 BIOSIS  
DN PREV198936115800; BR36:115800  
TI INHIBITION OF LYMPHOPROLIFERATION BY A SYNTHETIC PEPTIDE WITH SEQUENCE IDENTITY TO HIV GP41.  
AU RUEGG C L [Reprint author]; MONELL C R; STRAND M  
CS DEP PHARMACOL MOL SCI, JOHNS HOPKINS UNIV SCH MED, BALTIMORE, MD 21205, USA  
SO Journal of Cellular Biochemistry Supplement, (1989) No. 13 PART B, pp. 259.  
Meeting Info.: MEETING ON HUMAN RETROVIRUSES HELD AT THE 18TH ANNUAL MEETING OF THE UCLA (UNIVERSITY OF CALIFORNIA-LOS ANGELES) SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, TAMARRON, COLORADO, USA, FEBRUARY 4-11, 1989. J CELL BIOCHEM SUPPL.

DT Conference; (Meeting)

FS  
BR

LA ENGLISH

ED Entered STN: 11 May 1989

Last Updated on STN: 11 May 1989

L5 ANSWER 32 OF 268 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 1989:182205 BIOSIS

DN PREV198987093471; BA87:93471

TI MULTIPLE \*\*\*T\*\*\* \*\*\*HELPER\*\*\* \*\*\*CELL\*\*\* \*\*\*EPITOPES\*\*\* OF THE CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM-BERGHEI.

AU ROMERO P J [Reprint author]; TAM J P; SCHLESINGER D; CLAVIJO P; GIBSON H; BARR P J; NUSSENZWEIG R S; NUSSENZWEIG V; ZAVALA F

CS DEP MED MOLECULAR PARASITOL, NEW YORK UNIV SCH MED, 341 EAST 25TH STREET, NEW YORK, NY 10010, USA

SO European Journal of Immunology, (1988) Vol. 18, No. 12, pp. 1951-1958. CODEN: EJIMAF. ISSN: 0014-2980.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 9 Apr 1989

Last Updated on STN: 9 Apr 1989

L5 ANSWER 33 OF 268 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN 1998-08079 BIOTECHDS

TI New peptides containing promiscuous \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins; recombinant peptide preparation for use as recombinant vaccine

AU Frazer I H; Tindle R; Azoury-Ziadeh R

PA Univ.Queensland; CSL

LO St. Lucia, Queensland, Australia; Parkville, Victoria, Australia.

PI WO 9823635 \*\*\*4 Jun 1998\*\*\*

AI WO 1997-AU820 1 Dec 1997

PRAI AU 1996-3903 29 Nov 1996

DT Patent

LA English

OS WPI: 1998-322657 [28]

L5 ANSWER 34 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN 1999:29155507 BIOTECHNO

TI Design and evaluation of a ZP3 peptide vaccine in a homologous primate model

AU Paterson M.; Wilson M.R.; Jennings Z.A.; Van Duin M.; Aitken R.J.

CS M. Paterson, Medical Research Council, Reproductive Biology Unit, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9ET, United Kingdom.

SO Molecular Human Reproduction, ( \*\*\*1999\*\*\* ), 5/4 (342-352), 29 reference(s)

CODEN: MHREFD ISSN: 1360-9947

DT Journal; Article

CY United Kingdom

LA English

SL English

L5 ANSWER 35 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN 1997:27192308 BIOTECHNO

TI Generation of antibodies to human IL-12 and amphiregulin by immunization of Balb/c mice with diepitope multiple antigen peptides

AU Ahlborg N.; Paulie S.; Braesch-Andersen S.

CS N. Ahlborg, Department of Immunology, Stockholm University, S-106 91 Stockholm, Sweden.

SO Journal of Immunological Methods, ( \*\*\*1997\*\*\* ), 204/1 (23-32), 33 reference(s)

CODEN: JIMMBG ISSN: 0022-1759

PUI S002217599700355

DT Journal; Article

CY Netherlands

LA English

SL English

L5 ANSWER 36 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:894810 CAPLUS

DN 135:59865

TI Peptide vaccine strategy for immunotherapy of HER-2/neu overexpressing

AU Dakappagari, Naveen; Woodbine, Donna-Beth; Trizzoli, Pierre; Stevens, Vernon; Kaumaya, Pravin T. P.  
CS College of Medicine, The Ohio State University, Columbus, OH, 43210, USA  
SO Peptides for the New Millennium, Proceedings of the American Peptide Symposium, 16th, Minneapolis, MN, United States, June 26-July 1, 1999 ( \*\*\*2000\*\*\* ), Meeting Date 1999, 700-701. Editor(s): Fields, Gregg B.; Tam, James P.; Barany, George. Publisher: Kluwer Academic Publishers, Dordrecht, Neth.  
CODEN: 69ATHX

DT Conference  
LA English

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2000:894803 CAPLUS

DN 135:44873  
TI In situ identification of \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitopes\*\*\* from a cellulose-bound peptide array  
AU Otvos, Laszlo, Jr.; Bokonyi, Krisztina; Pease, Anne Marie; Giles-Davis, Wynetta; Rogers, Mark E.; Hintz, Paul A.; Hoffmann, Ralf; Ertl, Hildegund C. J.  
CS The Wistar Institute, Philadelphia, PA, 19104, USA  
SO Peptides for the New Millennium, Proceedings of the American Peptide Symposium, 16th, Minneapolis, MN, United States, June 26-July 1, 1999 ( \*\*\*2000\*\*\* ), Meeting Date 1999, 685-686. Editor(s): Fields, Gregg B.; Tam, James P.; Barany, George. Publisher: Kluwer Academic Publishers, Dordrecht, Neth.  
CODEN: 69ATHX

DT Conference; General Review  
LA English

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2000:336479 CAPLUS

DN 133:103516  
TI Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice  
AU Cruz, Luis J.; Quintana, Diogenes; Iglesias, Enrique; Garcia, Yairet; Huerta, Vivian; Garay, Hilda E.; Duarte, Carlos; Reyes, Osvaldo  
CS Division de Quimica-Fisica, Centro de Ingenieria Genetica y Biotecnologia, Havana, 10600, Cuba  
SO Journal of Peptide Science ( \*\*\*2000\*\*\* ), 6(5), 217-224  
CODEN: JPSIEI; ISSN: 1075-2617  
PB John Wiley & Sons Ltd.  
DT Journal  
LA English

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 39 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:67508 CAPLUS  
DN 132:106954

TI Human transaldolase, its cDNA sequence, recombinant expression, autoantigenicity, and potential therapeutic uses  
IN Perl, Andras

PA The Research Foundation of State University of New York, USA  
SO U.S., 55 pp.

CODEN: USXXAM

DT Patent  
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6018021	A	20000125	US 1994-326119	19941019 <--
	US 5879909	A	19990309	US 1998-57762	19980409 <--

PRAI US 1994-326119 19941019

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 40 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1999:819268 CAPLUS

DN 132:77607

IN as immune stimulators for synthetic peptide immunogens  
 PA Wang, Chang Yi  
 SO United Biomedical Inc., USA  
 PCT Int. Appl., 129 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966957	A2	19991229	WO 1999-US13975	19990621 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	CA 2329772	AA	19991229	CA 1999-2329772	19990621 <--
	AU 9945808	A1	20000110	AU 1999-45808	19990621 <--
	AU 763543	B2	20030724		
	BR 9912177	A	20010410	BR 1999-12177	19990621
	EP 1089760	A1	20010411	EP 1999-928826	19990621
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518463	T2	20020625	JP 2000-555643	19990621
	US 6713301	B1	20040330	US 2000-701588	20001129
PRAI	US 1998-100412	A2	19980620		
	WO 1999-US13975	W	19990621		

L5 ANSWER 41 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:454837 CAPLUS

DN 131:241716  
 TI Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes  
 AU Boeckler, Christophe; Dautel, Dominique; Schelte, Philippe; Frisch, Benoit; Wachsmann, Dominique; Klein, Jean-Paul; Schuber, Francis  
 CS Laboratoire Chimie Bioorganique, Faculte Pharmacie, Univ. Louis Pasteur, Illkirch, F-67400, Fr.  
 SO European Journal of Immunology ( \*\*\*1999\*\*\* ), 29(7), 2297-2308  
 CODEN: EJIMAF; ISSN: 0014-2980  
 PB Wiley-VCH Verlag GmbH  
 DT Journal  
 LA English

RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 42 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:176945 CAPLUS  
 DN 130:222114

TI Human transaldolase, its cDNA sequence, recombinant expression, autoantigenicity, and potential therapeutic uses  
 IN Perl, Andras  
 PA The Research Foundation of State University of New York, USA  
 SO U.S., 55 pp., Division of U.S. Ser. No. 326,119.  
 CODEN: USXXAM

DT Patent  
 LA English

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5879909	A	19990309	US 1998-57762	19980409 <--
	US 6018021	A	20000125	US 1994-326119	19941019 <--
PRAI	US 1994-326119		19941019		

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1998:704674 CAPLUS  
 DN 130:108832

TI Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimeric peptide consisting of a \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* of Semliki Forest virus and a \*\*\*B\*\*\* - \*\*\*cell\*\*\*

AU Fernandez, I. M.; Golding, H.; Benaissa-Trouw, B. J.; De Vos, N. M.;  
 Harmsen, M.; Nottet, H. S. L. M.; Golding, B.; Puijk, W. C.; Meloen, R.  
 H.; Snijpe, H.; Kraaijeveld, C. A.  
 CS Institute for Microbiology, Infectious Diseases and Inflammation,  
 University Hospital, Utrecht, NL-3584 CX, Neth.  
 SO Vaccine ( \*\*\*1998\*\*\* ), 16(20), 1936-1940  
 CODEN: VACCDE; ISSN: 0264-410X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1998:568940 CAPLUS  
 DN 129:202088  
 TI Immunological tolerance to HIV epitopes  
 IN Scott, David; Zambidis, Elias  
 PA American National Red Cross, USA  
 SO PCT Int. Appl., 154 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9836087	A1	19980820	WO 1998-US2766	19980213 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2279492	AA	19980820	CA 1998-2279492	19980213 <--
	EP 973933	A1	20000126	EP 1998-908538	19980213 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-40581P	P	19970213		
	WO 1998-US2766	W	19980213		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:226950 CAPLUS  
 DN 126:211026

TI Fusion proteins of T-helper and \*\*\*B\*\*\* - \*\*\*cell\*\*\*  
 \*\*\*epitopes\*\*\* from the major outer membrane protein of Chlamydia  
 trachomatis and their use in vaccines  
 IN Villeneuve, Anne  
 PA Immunova, Can.; Villeneuve, Anne  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9706263	A1	19970220	WO 1996-CA538	19960808 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	CA 2228522	AA	19970220	CA 1996-2228522	19960808 <--
	AU 9666530	A1	19970305	AU 1996-66530	19960808 <--
	EP 846176	A1	19980610	EP 1996-926290	19960808 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
PRAI	GB 1995-16293	A	19950809		
	WO 1996-CA538	W	19960808		

L5 ANSWER 46 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1993:647833 CAPLUS  
 DN 119:247833

TI Mapping of B-neutralizing and \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
 \*\*\*epitopes\*\*\* on the bovine leukemia virus external glycoprotein gp51  
 AU Callebaut, Isabelle; Voneche, Veronique; Mager, Anne; Fumiere, Olivier;

CS Arsene; Portetelle, Daniel  
 SO Microbiol. Unit, Fac. Agron., Gembloux, 5030, Belg.  
 Journal of Virology ( \*\*\*1993\*\*\* ), 67(9), 5321-7  
 CODEN: JOVIAM; ISSN: 0022-538X  
 DT Journal  
 LA English

L5 ANSWER 47 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1993:470352 CAPLUS  
 DN 119:70352  
 TI HLA antigen-restricted hepatitis B virus cytotoxic T-lymphocyte ( \*\*\*CTL\*\*\* ) \*\*\*epitopes\*\*\*  
 IN Vitiello, Maria A.; Chesnut, Robert W.  
 PA Cytel Corp., USA  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9303764	A1	19930304	WO 1992-US7218	19920826 <--
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9225487	A1	19930316	AU 1992-25487	19920826 <--
	AU 687725	B2	19980305		
	EP 534615	A2	19930331	EP 1992-307764	19920826 <--
	EP 534615	A3	19940525		
	EP 534615	B1	20010103		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	ZA 9206441	A	19930607	ZA 1992-6441	19920826 <--
	JP 06510051	T2	19941110	JP 1992-504664	19920826 <--
	HU 68510	A2	19950628	HU 1994-581	19920826 <--
	EP 1018344	A2	20000712	EP 2000-102538	19920826 <--
	EP 1018344	A3	20000920		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	ES 2155060	T3	20010501	ES 1992-307764	19920826
	FI 9400918	A	19940408	FI 1994-918	19940225 <--
	NO 9400660	A	19940422	NO 1994-660	19940225 <--
	GR 3035575	T3	20010629	GR 2001-400422	20010314
	JP 2004075693	A2	20040311	JP 2003-391442	20031120
	JP 3586278	B2	20041110		
PRAI	US 1991-749568	A	19910826		
	US 1992-827682	A	19920129		
	US 1992-874491	A	19920427		
	EP 1992-307764	A3	19920826		
	JP 1993-504664	A3	19920826		
	WO 1992-US7218	A	19920826		

L5 ANSWER 48 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1992:28107 CAPLUS  
 DN 116:28107  
 TI Vaccine composition with nonimmunosuppressive T-cell epitope component  
 IN Etlinger, Howard  
 PA Hoffmann-La Roche, F., A.-G., Switz.  
 SO Eur. Pat. Appl., 17 pp.  
 CODEN: EPXXDW

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 429816	A1	19910605	EP 1990-119582	19901012 <--
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
	CA 2027317	AA	19910501	CA 1990-2027317	19901011 <--
	ZA 9008521	A	19910731	ZA 1990-8521	19901024 <--
	AU 9065571	A1	19910509	AU 1990-65571	19901026 <--
	AU 637841	B2	19930610		
	JP 03173830	A2	19910729	JP 1990-295159	19901031 <--
PRAI	GB 1989-24438		19891031		

L5 ANSWER 49 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAY91273 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:151.

L5 ANSWER 50 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91272 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:150.

L5 ANSWER 51 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91271 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:149.

L5 ANSWER 52 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91270 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:148.

L5 ANSWER 53 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91269 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 54 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91268 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:146.

L5 ANSWER 55 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91267 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:145.

L5 ANSWER 56 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91266 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:144.

L5 ANSWER 57 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91265 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:143.

L5 ANSWER 58 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91264 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:142.

L5 ANSWER 59 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91263 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:141.

L5 ANSWER 60 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91262 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:140.

L5 ANSWER 61 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91261 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:139.

L5 ANSWER 62 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91260 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:138.

L5 ANSWER 63 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91259 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:137.

129p\*\*\*

L5 ANSWER 64 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91258 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:136.

129p\*\*\*

L5 ANSWER 65 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91257 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV neutralising epitope, SEQ ID NO: 135.

129p\*\*\*

L5 ANSWER 66 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91256 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV neutralising epitope, SEQ ID NO: 134.

129p\*\*\*

L5 ANSWER 67 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91255 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV neutralising epitope, SEQ ID NO: 133.

129p\*\*\*

L5 ANSWER 68 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91254 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV neutralising epitope, SEQ ID NO: 132.

129p\*\*\*

L5 ANSWER 69 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91253 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV neutralising epitope, SEQ ID NO: 131.

129p\*\*\*

L5 ANSWER 70 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91252 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV neutralising epitope, SEQ ID NO: 130.

129p\*\*\*

L5 ANSWER 71 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91251 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:129.

129p\*\*\*

L5 ANSWER 72 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91250 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

129p\*\*\*

L5 ANSWER 73 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91249 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:127.

L5 ANSWER 74 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91248 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/HIV epitope, SEQ ID NO:126.

L5 ANSWER 75 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91247 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HIV-1 neutralising epitope, SEQ ID NO: 125.

L5 ANSWER 76 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91246 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:124.

L5 ANSWER 77 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91245 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:123.

L5 ANSWER 78 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91244 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:122.

L5 ANSWER 79 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91243 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:121.

L5 ANSWER 80 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91242 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:120.

L5 ANSWER 81 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91241 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:119.

L5 ANSWER 82 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91240 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:118.

129p\*\*\*

L5 ANSWER 83 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91239 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:117.

129p\*\*\*

L5 ANSWER 84 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91238 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:116.

129p\*\*\*

L5 ANSWER 85 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91237 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:115.

129p\*\*\*

L5 ANSWER 86 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91236 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBVsurface Ag/CETP peptide, SEQ ID NO:114.

129p\*\*\*

L5 ANSWER 87 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91235 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:113.

L5 ANSWER 88 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91234 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:112.

L5 ANSWER 89 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91233 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:111.

L5 ANSWER 90 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91232 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CETP peptide, SEQ ID NO:110.

L5 ANSWER 91 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91231 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 92 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91230 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Human cholesteryl transport protein (CETP) peptide, SEQ ID NO:108.

L5 ANSWER 93 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91229 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Human cholesteryl transport protein (CETP) peptide, SEQ ID NO:107.

L5 ANSWER 94 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91228 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Human cholesteryl transport protein (CETP) peptide, SEQ ID NO:106.

L5 ANSWER 95 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91227 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:106.

L5 ANSWER 96 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91226 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:105.

L5 ANSWER 97 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91225 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CS antigen, SEQ ID NO:105.

L5 ANSWER 98 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91224 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CS antigen, SEQ ID NO:104.

L5 ANSWER 99 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91223 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC P. falciparum circumsporozoite (CS) target antigen, SEQ ID NO:103.

L5 ANSWER 100 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91222 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Inv epitope/modified HBV surface Ag/FMDV VP1 peptide, SEQ ID NO:102.

L5 ANSWER 101 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91221 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/FMDV VP1 peptide, SEQ ID NO:101.

L5 ANSWER 102 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91220 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC FMDV VP1 synthetic immunogenic peptide, SEQ ID NO:100.

L5 ANSWER 103 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91219 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Inv epitope/modified HBV surface Ag/IgE CH3 domain, SEQ ID NO:99.

L5 ANSWER 104 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91218 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/IgE CH3 domain, SEQ ID NO:98.

L5 ANSWER 105 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91217 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/IgE CH3 domain, SEQ ID NO:97.

L5 ANSWER 106 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91216 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/IgE CH3 domain, SEQ ID NO:96.

L5 ANSWER 107 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91215 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/IgE CH3 domain, SEQ ID NO:95.

L5 ANSWER 108 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91214 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/IgE CH3 domain, SEQ ID NO:94.

L5 ANSWER 109 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91213 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/IgE CH3 domain, SEQ ID NO:93.

L5 ANSWER 110 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91212 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 111 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91211 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CD4 antigenic peptide, SEQ ID NO:91.

L5 ANSWER 112 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91210 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CD4 antigenic peptide, SEQ ID NO:90.

L5 ANSWER 113 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91209 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/CD4 antigenic peptide, SEQ ID NO:89.

L5 ANSWER 114 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91208 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Human CD4 CDR2-like domain target antigenic site, SEQ ID NO:88.

L5 ANSWER 115 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91207 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/somatostatin, SEQ ID NO:87.

L5 ANSWER 116 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91206 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/somatostatin, SEQ ID NO:86.

L5 ANSWER 117 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91205 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/somatostatin, SEQ ID NO:85.

L5 ANSWER 118 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91204 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/somatostatin, SEQ ID NO:84.

L5 ANSWER 119 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91203 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/somatostatin, SEQ ID NO:83.

L5 ANSWER 120 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91202 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/somatostatin, SEQ ID NO:82.

129p\*\*\*

L5 ANSWER 121 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91201 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/somatostatin, SEQ ID NO:81.

129p\*\*\*

L5 ANSWER 122 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91200 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Somatostatin, SEQ ID NO:80.

129p\*\*\*

L5 ANSWER 123 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91199 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Hinge spacer peptide, SEQ ID NO:79.

129p\*\*\*

L5 ANSWER 124 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91198 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Yersinia sp. invasin (Inv) epitope, SEQ ID NO:78.

129p\*\*\*

L5 ANSWER 125 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91197 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC LHRH target antigenic peptide, SEQ ID NO:77.

L5 ANSWER 126 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91196 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:76.

L5 ANSWER 127 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91195 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Inv epitope/modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:75.

L5 ANSWER 128 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91194 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:74.

L5 ANSWER 129 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91193 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 130 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91192 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:72.

L5 ANSWER 131 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91191 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:71.

L5 ANSWER 132 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91190 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:70.

L5 ANSWER 133 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91189 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:69.

L5 ANSWER 134 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91188 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:68.

L5 ANSWER 135 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91187 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:67.

L5 ANSWER 136 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91186 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:66.

L5 ANSWER 137 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91185 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HBV surface Ag/LHRH antigenic peptide, SEQ ID NO:65.

L5 ANSWER 138 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91184 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:64.

L5 ANSWER 139 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91183 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Inv epitope/modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:63.

L5 ANSWER 140 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91182 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Inv epitope/modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:62.

L5 ANSWER 141 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91181 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:61.

L5 ANSWER 142 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91180 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Inv epitope/modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:60.

L5 ANSWER 143 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91179 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:59.

L5 ANSWER 144 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91178 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:58.

L5 ANSWER 145 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91177 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:57.

L5 ANSWER 146 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91176 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:56.

L5 ANSWER 147 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91175 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:55.

L5 ANSWER 148 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91174 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 149 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91173 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:53.

L5 ANSWER 150 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91172 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:52.

L5 ANSWER 151 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91171 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:51.

L5 ANSWER 152 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91170 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:50.

L5 ANSWER 153 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91169 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:49.

L5 ANSWER 154 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91168 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:48.

L5 ANSWER 155 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91167 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:47.

L5 ANSWER 156 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91166 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:46.

L5 ANSWER 157 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91165 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:45.

L5 ANSWER 158 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91164 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:44.

L5 ANSWER 159 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91163 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:43.

L5 ANSWER 160 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91162 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:42.

L5 ANSWER 161 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91161 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:41.

L5 ANSWER 162 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91160 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:40.

L5 ANSWER 163 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91159 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:39.

L5 ANSWER 164 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91158 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:38.

L5 ANSWER 165 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91157 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:37.

L5 ANSWER 166 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91156 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC MVF Th epitope/LHRH antigenic peptide, SEQ ID NO:36.

L5 ANSWER 167 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91155 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 168 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91154 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:34.

L5 ANSWER 169 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91153 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:33.

L5 ANSWER 170 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91152 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:32.

L5 ANSWER 171 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91151 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:31.

L5 ANSWER 172 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91150 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:30.

L5 ANSWER 173 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91149 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:29.

L5 ANSWER 174 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91148 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:28.

L5 ANSWER 175 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91147 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:27.

L5 ANSWER 176 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91146 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:26.

L5 ANSWER 177 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91145 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:25.

129p\*\*\*

L5 ANSWER 178 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91144 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified HBV surface antigen promiscuous Th epitope, SEQ ID NO:24.

129p\*\*\*

L5 ANSWER 179 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91143 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC HBV surface antigen promiscuous Th epitope, SEQ ID NO:23.

129p\*\*\*

L5 ANSWER 180 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91142 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:22.

129p\*\*\*

L5 ANSWER 181 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91141 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:21.

129p\*\*\*

L5 ANSWER 182 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91140 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:20.

L5 ANSWER 183 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91139 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:19.

L5 ANSWER 184 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91138 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:18.

L5 ANSWER 185 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91137 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:17.

L5 ANSWER 186 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91136 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]

L5 ANSWER 187 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91135 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:15.

L5 ANSWER 188 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91134 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:14.

L5 ANSWER 189 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91133 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:13.

L5 ANSWER 190 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91132 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:12.

L5 ANSWER 191 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91131 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621

DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:11.

L5 ANSWER 192 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91130 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:10.

L5 ANSWER 193 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91129 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:9.

L5 ANSWER 194 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91128 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:8.

L5 ANSWER 195 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91127 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:7.

L5 ANSWER 196 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91126 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -

PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:6.

L5 ANSWER 197 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91125 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:5.

L5 ANSWER 198 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91124 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:4.

L5 ANSWER 199 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91123 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:3.

L5 ANSWER 200 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91122 peptide DGENE  
TI New artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for  
immunization against e.g. malaria, arteriosclerosis or human immune  
deficiency virus -  
IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Modified measles virus F protein promiscuous Th epitope, SEQ ID NO:2.

L5 ANSWER 201 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAY91121 peptide DGENE

\*\*\*epitope\*\*\* and derived immunogens with target antigenic site, for immunization against e.g. malaria, arteriosclerosis or human immune deficiency virus -

IN Wang C Y  
PA (UNBI-N) UNITED BIOMEDICAL INC.  
PI \*\*\*WO 9966957 A2 19991229 129p\*\*\*  
AI WO 1999-US13975 19990621  
PRAI US 1998-100412 19980620  
DT Patent  
LA English  
OS 2000-160564 [14]  
DESC Measles virus F protein promiscuous Th epitope, SEQ ID NO:1.

L5 ANSWER 202 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAW60847 peptide DGENE  
TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
\*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
e.g. generation of immune response, and particularly for treating or  
preventing papilloma virus infection  
IN Azoury-ziadeh R; Frazer I H; Tindle R  
PA (CSLC-N) CSL LTD.  
(UYQU) UNIV QUEENSLAND.  
PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
AI WO 1997-AU820 19971201  
PRAI AU 1996-3903 19961129  
DT Patent  
LA English  
OS 1998-322657 [28]  
DESC HPV18 E7 \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* 2.

L5 ANSWER 203 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAW60846 peptide DGENE  
TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
\*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
e.g. generation of immune response, and particularly for treating or  
preventing papilloma virus infection  
IN Azoury-ziadeh R; Frazer I H; Tindle R  
PA (CSLC-N) CSL LTD.  
(UYQU) UNIV QUEENSLAND.  
PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
AI WO 1997-AU820 19971201  
PRAI AU 1996-3903 19961129  
DT Patent  
LA English  
OS 1998-322657 [28]  
DESC HPV18 E7 \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* 1.

L5 ANSWER 204 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAW60845 peptide DGENE  
TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
\*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
e.g. generation of immune response, and particularly for treating or  
preventing papilloma virus infection  
IN Azoury-ziadeh R; Frazer I H; Tindle R  
PA (CSLC-N) CSL LTD.  
(UYQU) UNIV QUEENSLAND.  
PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
AI WO 1997-AU820 19971201  
PRAI AU 1996-3903 19961129  
DT Patent  
LA English  
OS 1998-322657 [28]  
DESC HPV18 E7 \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* 4.

L5 ANSWER 205 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAW60844 peptide DGENE  
TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
\*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
e.g. generation of immune response, and particularly for treating or  
preventing papilloma virus infection  
IN Azoury-ziadeh R; Frazer I H; Tindle R  
PA (CSLC-N) CSL LTD.  
(UYQU) UNIV QUEENSLAND.  
PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
AI WO 1997-AU820 19971201

DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC HPV16 E7 \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* 3.

L5 ANSWER 206 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW60843 peptide DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used fo:  
 e.g. generation of immune response, and particularly for treating or  
 preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.  
 (UYQU) UNIV QUEENSLAND.  
 PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
 AI WO 1997-AU820 19971201  
 PRAI AU 1996-3903 19961129  
 DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC HPV16 E7 \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* 2.

L5 ANSWER 207 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW60842 peptide DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used fo:  
 e.g. generation of immune response, and particularly for treating or  
 preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.  
 (UYQU) UNIV QUEENSLAND.  
 PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
 AI WO 1997-AU820 19971201  
 PRAI AU 1996-3903 19961129  
 DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC HPV16 E7 \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* 1.

L5 ANSWER 208 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW60841 peptide DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used fo:  
 e.g. generation of immune response, and particularly for treating or  
 preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.  
 (UYQU) UNIV QUEENSLAND.  
 PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
 AI WO 1997-AU820 19971201  
 PRAI AU 1996-3903 19961129  
 DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC Peptide containing a t-epitope linked to known HPV16E7 \*\*\*B\*\*\* -  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* .

L5 ANSWER 209 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW60840 peptide DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used fo:  
 e.g. generation of immune response, and particularly for treating or  
 preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.  
 (UYQU) UNIV QUEENSLAND.  
 PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
 AI WO 1997-AU820 19971201  
 PRAI AU 1996-3903 19961129  
 DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC Peptide containing a t-epitope linked to known HPV16E7 \*\*\*B\*\*\* -  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* .

AN AAW60839 peptide DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
     \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
     e.g. generation of immune response, and particularly for treating or  
     preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.  
 (UYQU) UNIV QUEENSLAND.  
 PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
 AI WO 1997-AU820 19971201  
 PRAI AU 1996-3903 19961129  
 DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC Peptide 2, encodes a \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
     \*\*\*epitope\*\*\* .

L5 ANSWER 211 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW60838 peptide DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
     \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
     e.g. generation of immune response, and particularly for treating or  
     preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.  
 (UYQU) UNIV QUEENSLAND.  
 PI \*\*\*WO 9823635 A1 19980604 70p\*\*\*  
 AI WO 1997-AU820 19971201  
 PRAI AU 1996-3903 19961129  
 DT Patent  
 LA English  
 OS 1998-322657 [28]  
 DESC Peptide 1, encodes a \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
     \*\*\*epitope\*\*\* .

L5 ANSWER 212 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW08412 peptide DGENE  
 TI Purifying synthetic lipo:peptide(s) - comprises selectively dissolving  
     impurities in aqueous solution and separating insoluble lipo:peptide,  
     e.g. by centrifugation  
 IN Arrhenius T; Kubo R T  
 PA (CYTE-N) CYTEL CORP.  
 PI \*\*\*WO 9640213 A1 19961219 31p\*\*\*  
 AI WO 1996-US9579 19960605  
 PRAI US 1995-483196 19950607  
 DT Patent  
 LA English  
 OS 1997-065139 [06]  
 DESC Tetanus toxoid peptide \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
     \*\*\*epitope\*\*\* .

L5 ANSWER 213 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAW25821 peptide DGENE  
 TI Tandem synthetic HIV peptide(s) useful as immunogens - comprising gag  
     protein T-cell epitope linked to env protein \*\*\*B\*\*\* - \*\*\*cell\*\*\*  
     \*\*\*epitope\*\*\*  
 IN Chong P; Klein M H; Sia C D Y  
 PA (CONN-N) CONNAUGHT LAB LTD.  
 PI \*\*\*US 5639854 A 19970617 41p\*\*\*  
 AI US 1993-73378 19930609  
 PRAI US 1994-257528 19940609  
     US 1993-73378 19930609  
 DT Patent  
 LA English  
 OS 1997-332082 [30]  
 DESC T cell epitope peptide T1.

L5 ANSWER 214 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR99509 peptide DGENE  
 TI Chimeric immunoglobulin with CDR loop subst. for T and/or \*\*\*B\*\*\*  
     \*\*\*cell\*\*\* \*\*\*epitope\*\*\* - useful in vaccine composition to  
     enhance immune response to pathogens  
 IN Bona C; Zaghouani H  
 PA (MOUN) MOUNT SINAI SCHOOL MEDICINE.  
 PI \*\*\*WO 9619584 A1 19960627 131p\*\*\*

PRA1 US 1994-363276 19941222  
 DT Patent  
 LA English  
 OS 1996-309598 [31]  
 DESC T-cell epitope used in construction of chimeric immunoglobulin.

L5 ANSWER 215 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR37210 peptide DGENE  
 TI Synthetic peptide for use in vaccines against Chlamydia trachomatis - contains a conserved T-helper cell stimulating epitope and a neutralising \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\*  
 IN Caldwell H D  
 PA (USSH) US DEPT HEALTH & HUMAN SERVICE.  
 PI \*\*\*US 947671 A0 19930401 30p\*\*\*  
 AI US 1992-947671 19920918  
 PRAI US 1992-947671 19920918  
 DT Patent  
 LA English  
 OS 1993-159481 [19]  
 DESC B-cell neutralising antibody stimulating epitope, VDIV.

L5 ANSWER 216 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAR12563 peptide DGENE  
 TI Vaccine compsn. for immunising against pathogenic agent - comprises cpd. representing \*\*\*B\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* and cpd. representing T cell epitope carrying no information for epitope suppression.  
 IN Etlinger H  
 PA (HOFF) HOFFMANN-LA ROCHE AG.  
 PI \*\*\*EP 429816 A 19910605 16p\*\*\*  
 AI EP 1990-119582 19901012  
 PRAI GB 1989-24438 19891031  
 DT Patent  
 LA English  
 OS 1991-165463 [23]  
 DESC \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* TT73-99 from tetanus toxin.

L5 ANSWER 217 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAP90949 peptide DGENE  
 TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating hormone activity.  
 IN James S; Rowlands D J; Francis M J  
 PA (WELL) WELLCOME FOUND LTD.  
 (PITM) COOPERS ANIMAL HEALTH LT.  
 PI \*\*\*WO 8909228 A 19891005 31p\*\*\*  
 AI WO 1989-GB311 19890323  
 PRAI EP 1988-302656 19880325  
 GB 1988-21076 19880908  
 DT Patent  
 LA English  
 OS 1989-309504 [42]  
 DESC Peptide 359.

L5 ANSWER 218 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAP90947 peptide DGENE  
 TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating hormone activity.  
 IN James S; Rowlands D J; Francis M J  
 PA (WELL) WELLCOME FOUND LTD.  
 (PITM) COOPERS ANIMAL HEALTH LT.  
 PI \*\*\*WO 8909228 A 19891005 31p\*\*\*  
 AI WO 1989-GB311 19890323  
 PRAI EP 1988-302656 19880325  
 GB 1988-21076 19880908  
 DT Patent  
 LA English  
 OS 1989-309504 [42]  
 DESC Peptide 240.

L5 ANSWER 219 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
\*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
hormone activity.

IN James S; Rowlands D J; Francis M J  
PA (WELL) WELLCOME FOUND LTD.  
(PITM) COOPERS ANIMAL HEALTH LT.

PI \*\*\*WO 8909228 A 19891005 31p\*\*\*

AI WO 1989-GB311 19890323  
PRAI EP 1988-302656 19880325  
GB 1988-21076 19880908

DT Patent  
LA English  
OS 1989-309504 [42]  
DESC Peptide 242.

L5 ANSWER 220 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAP90946 peptide DGENE  
TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
\*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
hormone activity.

IN James S; Rowlands D J; Francis M J  
PA (WELL) WELLCOME FOUND LTD.  
(PITM) COOPERS ANIMAL HEALTH LT.

PI \*\*\*WO 8909228 A 19891005 31p\*\*\*

AI WO 1989-GB311 19890323  
PRAI EP 1988-302656 19880325  
GB 1988-21076 19880908

DT Patent  
LA English  
OS 1989-309504 [42]  
DESC Peptide 238.

L5 ANSWER 221 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAP90945 peptide DGENE  
TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
\*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
hormone activity.

IN James S; Rowlands D J; Francis M J  
PA (WELL) WELLCOME FOUND LTD.  
(PITM) COOPERS ANIMAL HEALTH LT.

PI \*\*\*WO 8909228 A 19891005 31p\*\*\*

AI WO 1989-GB311 19890323  
PRAI EP 1988-302656 19880325  
GB 1988-21076 19880908

DT Patent  
LA English  
OS 1989-309504 [42]  
DESC Variant of residues 35-53 of bovine growth hormone.

L5 ANSWER 222 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAP90944 peptide DGENE  
TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
\*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
hormone activity.

IN James S; Rowlands D J; Francis M J  
PA (WELL) WELLCOME FOUND LTD.  
(PITM) COOPERS ANIMAL HEALTH LT.

PI \*\*\*WO 8909228 A 19891005 31p\*\*\*

AI WO 1989-GB311 19890323  
PRAI EP 1988-302656 19880325  
GB 1988-21076 19880908

DT Patent  
LA English  
OS 1989-309504 [42]  
DESC Variant of residues 35-53 of bovine growth hormone.

L5 ANSWER 223 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAP90943 peptide DGENE  
TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
\*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
\*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating

IN James S; Rowlands D J; Francis M J  
 PA (WELL) WELLCOME FOUND LTD.  
 (PITM) COOPERS ANIMAL HEALTH LT.  
 PI \*\*\*WO 8909228 A 19891005 31p\*\*\*  
 AI WO 1989-GB311 19890323  
 PRAI EP 1988-302656 19880325  
 GB 1988-21076 19880908  
 DT Patent  
 LA English  
 OS 1989-309504 [42]  
 DESC Variant of residues 35-53 of bovine growth hormone.  
  
 L5 ANSWER 224 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAP90942 peptide DGENE  
 TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
 \*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
 \*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
 hormone activity.  
 IN James S; Rowlands D J; Francis M J  
 PA (WELL) WELLCOME FOUND LTD.  
 (PITM) COOPERS ANIMAL HEALTH LT.  
 PI \*\*\*WO 8909228 A 19891005 31p\*\*\*  
 AI WO 1989-GB311 19890323  
 PRAI EP 1988-302656 19880325  
 GB 1988-21076 19880908  
 DT Patent  
 LA English  
 OS 1989-309504 [42]  
 DESC Variant of residues 35-53 of bovine growth hormone.  
  
 L5 ANSWER 225 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAP90939 peptide DGENE  
 TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
 \*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
 \*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
 hormone activity.  
 IN James S; Rowlands D J; Francis M J  
 PA (WELL) WELLCOME FOUND LTD.  
 (PITM) COOPERS ANIMAL HEALTH LT.  
 PI \*\*\*WO 8909228 A 19891005 31p\*\*\*  
 AI WO 1989-GB311 19890323  
 PRAI EP 1988-302656 19880325  
 GB 1988-21076 19880908  
 DT Patent  
 LA English  
 OS 1989-309504 [42]  
 DESC Th-epitope of VP3 capsid protein of foot and mouth disease virus O1  
 Kaufbeuren.  
  
 L5 ANSWER 226 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAP90941 peptide DGENE  
 TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
 \*\*\*epitope\*\*\* of foot and mouth virus - and opt. \*\*\*B\*\*\* -  
 \*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
 hormone activity.  
 IN James S; Rowlands D J; Francis M J  
 PA (WELL) WELLCOME FOUND LTD.  
 (PITM) COOPERS ANIMAL HEALTH LT.  
 PI \*\*\*WO 8909228 A 19891005 31p\*\*\*  
 AI WO 1989-GB311 19890323  
 PRAI EP 1988-302656 19880325  
 GB 1988-21076 19880908  
 DT Patent  
 LA English  
 OS 1989-309504 [42]  
 DESC Residues 35-53 of bovine growth hormone.  
  
 L5 ANSWER 227 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
 AN AAV37175 DNA DGENE  
 TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
 \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
 e.g. generation of immune response, and particularly for treating or  
 preventing papilloma virus infection  
 IN Azoury-ziadeh R; Frazer I H; Tindle R  
 PA (CSLC-N) CSL LTD.

PI \*\*\*WO 9823635 AI 19980604 70p\*\*\*  
AI WO 1997-AU820 19971201  
PRAI AU 1996-3903 19961129  
DT Patent  
LA English  
OS 1998-322657 [28]  
DESC Primer 2, used to amplify a modified BPV1L1 gene.

L5 ANSWER 228 OF 268 DGENE COPYRIGHT 2004 The Thomson Corp on STN  
AN AAV37174 DNA DGENE  
TI New peptide(s) comprising promiscuous \*\*\*T\*\*\* \*\*\*helper\*\*\*  
\*\*\*cell\*\*\* \*\*\*epitopes\*\*\* from papilloma virus proteins - used for  
e.g. generation of immune response, and particularly for treating or  
preventing papilloma virus infection  
IN Azoury-ziadeh R; Frazer I H; Tindle R  
PA (CSLC-N) CSL LTD.  
(UYQU) UNIV QUEENSLAND.  
PI \*\*\*WO 9823635 AI 19980604 70p\*\*\*  
AI WO 1997-AU820 19971201  
PRAI AU 1996-3903 19961129  
DT Patent  
LA English  
OS 1998-322657 [28]  
DESC Primer 1, used to amplify a modified BPV1L1 gene.

L5 ANSWER 229 OF 268 DISSABS COPYRIGHT (C) 2004 ProQuest Information and  
Learning Company; All Rights Reserved on STN  
AN 95:41438 DISSABS Order Number: AAINN95210  
TI CHARACTERIZATION OF THE IMMUNOGENIC PROPERTIES OF THE MENGO VIRION  
AU KOBASA, DARWYN LAWRENCE [PH.D.]; SCRABA, DOUGLAS G. [advisor]  
CS UNIVERSITY OF ALBERTA (CANADA) (0351)  
SO Dissertation Abstracts International, ( \*\*\*1994\*\*\* ) Vol. 56, No. 3B, p.  
1336. Order No.: AAINN95210. 163 pages.  
ISBN: 0-315-95210-5.  
DT Dissertation  
FS DAI  
LA English  
ED Entered STN: 19950906  
Last Updated on STN: 19950906

L5 ANSWER 230 OF 268 DISSABS COPYRIGHT (C) 2004 ProQuest Information and  
Learning Company; All Rights Reserved on STN  
AN 94:45912 DISSABS Order Number: AARMM87103  
TI BIOPHYSICAL CHARACTERIZATION OF HIV-RELATED TANDEM PEPTIDES USING CIRCULAR  
DICHROISM AND PROTON NMR TECHNIQUES  
AU PAPALIA, GIUSEPPE ARMANDO [M.SC.]; CARVER, JEREMY [advisor]  
CS UNIVERSITY OF TORONTO (CANADA) (0779)  
SO Masters Abstracts International, ( \*\*\*1993\*\*\* ) Vol. 32, No. 6, p. 1605.  
Order No.: AARMM87103. 158 pages.  
ISBN: 0-315-87103-2.  
DT Dissertation  
FS MAI  
LA English  
ED Entered STN: 19941201  
Last Updated on STN: 19941201

L5 ANSWER 231 OF 268 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN  
AN 1993-52291 DRUGU M  
TI Epitope Selection and Design of Synthetic Vaccines. Molecular Approaches  
to Enhancing Immunogenicity and Cross-Reactivity of Engineered Vaccines.  
AU Berzofsky J A  
LO Bethesda, Maryland, United States  
SO Ann.N.Y.Acad.Sci. (690, 256-64, 1993) 48 Ref.  
CODEN: ANYAA9 ISSN: 0077-8923  
AV Molecular Immunogenetics Branch, National Cancer Institute, NIH Building  
10, Room 6B12, Bethesda, Maryland 20892, U.S.A.  
LA English  
DT Journal  
FA AB; LA; CT  
FS Literature

L5 ANSWER 232 OF 268 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS  
AN RESERVED. on STN  
DN 92246611 EMBASE  
DN 1992246611

AU Bessier W.G.; Jung G.  
 CS Institut fur Immunobiologie, Universitat, D7800 Freiburg, Germany  
 SO Research in Immunology, (1992) 143/5 (548-553).  
 ISSN: 0923-2494 CODEN: RIMME5  
 CY France  
 DT Journal; Conference Article  
 FS 026 Immunology, Serology and Transplantation  
 037 Drug Literature Index  
 LA English  
 SL English

L5 ANSWER 233 OF 268 Elsevier BIOBASE COPYRIGHT 2004 Elsevier Science B.V.  
 On STN  
 AN 1994177524 ESBIOBASE  
 TI Immunization with a multiple antigen peptide containing defined B- and T-cell epitopes: Production of bactericidal antibodies against group B Neisseria meningitidis  
 AU Christodoulides M.; Heckels J.E.  
 CS M. Christodoulides, Molecular Microbiology, University of Southampton, Southampton General Hospital, Tremona Road, Southampton SO18 6YD, United Kingdom.  
 SO Microbiology, ( \*\*\*1994\*\*\* ), 140/11 (2951-2960)  
 CODEN: MROBEO ISSN: 1350-0872  
 DT Journal; Article  
 CY United Kingdom  
 LA English  
 SL English

L5 ANSWER 234 OF 268 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 04012772 IFIPAT; IFIUDB; IFICDB  
 TI \*\*\*T\*\*\* \*\*\*HELPER\*\*\* \*\*\*CELL\*\*\* \*\*\*EPITOPES\*\*\* ; DERIVED  
 FROM CANINE DISTEMPER VIRUS  
 IN Ghosh Souravi (AU); Jackson David Charles (AU); Walker John (AU)  
 PA Commonwealth Scientific and Industrial Research Org AU  
 CSL Ltd AU  
 Hall, Walter & Eliza Institute of Medical Research The AU  
 Melbourne, University of AU  
 Queensland Institute of Medical Research Council of AU  
 (19280, 28601, 35004, 40730, 54000)  
 PI US 6685947 B1 20040203  
 WO 2000046390 20000810  
 AI US 2002-890650 20020322  
 WO 2000-AU70 20000207  
 20020322 PCT 371 date  
 20020322 PCT 102(e) date  
 PRAI AU 1999-8533 19990205  
 AU 1999-2013 19990804  
 FI US 6685947 20040203  
 DT Utility; Granted Patent - Utility, no Pre-Grant Publication  
 FS CHEMICAL  
 GRANTED  
 CLMN 16  
 GI 4 Drawing Sheet(s), 4 Figure(s).  
 FIG. 1. Amino acid sequence of the fusion protein of CDV  
 FIG. 2. Stimulation indices to Th-epitope P25 and its truncated versions from dogs immunised with P25-LHRH. (X-axis concentration of peptides nmoles/well)  
 FIG. 3. Stimulation indices to Th-epitope P27 and its truncated 15-mer from dogs immunised with P27-LHRH. (X-axis concentration of peptides nmoles/well)  
 FIG. 4. Stimulation indices to Th-epitope P35 and its truncated versions from dogs immunised with P35-LHRH. (X-axis concentration of peptides nmoles/well)

L5 ANSWER 235 OF 268 IFIPAT COPYRIGHT 2004 IFI on STN  
 AN 03979492 IFIPAT; IFIUDB; IFICDB  
 TI MULTI OLIGOSACCHARIDE GLYCOCONJUGATE BACTERIAL MENINGITIS VACCINES; FORMING IMMUNOGENIC MOLECULES HAVING MULTIPLE DIFFERENT CARBONHYDRATE FRAGMENTS WITH FUNCTIONAL \*\*\*B\*\*\* - \*\*\*CELL\*\*\* \*\*\*EPITOPES\*\*\* ATTACHED TO CARRIER CONTAINING FUNCTIONAL T-CELL EPITOPES  
 IN Chong Pele (CA); Klein Michel H (CA); Lindberg Alf (FR)  
 PA Aventis Pasteur Ltd CA (57882)  
 PI US 6656472 B1 20031202  
 WO 9942130 19990826  
 AI US 2000-622782 20001222

20001222 PCT 371 date  
20001222 PCT 102(e) date

FI US 6656472  
DT Utility; Granted Patent - Utility, no Pre-Grant Publication  
FS CHEMICAL  
GRANTED  
MRN 011593 MFN: 0637  
CLMN 8  
GI 12 Drawing Sheet(s), 12 Figure(s).

FIG. 1 shows a schematic diagram of several pneumococcal CPs randomly conjugated to a carrier protein, such as TT, and the procedure employed. FIG. 2 shows a schematic diagram of the sequential cross-linking of chemically activated pneumococcal oligosaccharides to a lysine-branched peptide containing several functional T-cell epitopes from pneumococcal proteins. FIG. 3 shows the elution profile obtained during purification of acid-hydrolysed oligosaccharides of *S. pneumoniae* 14 using gel permeation chromatography on a Sephadex registered-G100 column. FIG. 4 shows the elution Profile obtained during purification of the acid-hydrolysed oligosaccharides of *N. meningitidis* Group B using a Sephadex registered-G100 gel permeation chromatography. FIG. 5 shows an elution profile obtained during purification of multivalent *S. pneumoniae* oligosaccharides-TT conjugates. FIG. 6 shows rabbit antibody responses to multivalent *S. pneumoniae* oligosaccharides-TT conjugates formulated in FCA. FIG. 7 shows rabbit antibody responses to multivalent *S. pneumoniae* oligosaccharides-TT conjugates formulated in alum. FIG. 8 shows mouse antibody responses to multivalent *S. pneumoniae* oligosaccharides-TT conjugates formulated in FCA. FIG. 9 shows rabbit antibody responses to multivalent *N. meningitidis* oligosaccharides-TT conjugates formulated in FCA. FIG. 10 shows rabbit antibody responses to multivalent *S. pneumoniae* glycopeptide conjugates formulated in FCA. FIG. 11 shows rabbit antibody responses to multivalent *S. pneumoniae* oligosaccharides-MAP conjugates formulated in FCA.

L5 ANSWER 236 OF 268 MEDLINE on STN  
AN 97344510 MEDLINE  
DN PubMed ID: 9200920  
TI Molecular mimicry and mechanisms of autoantibody production.  
AU Miyazawa M  
CS Department of Immunology, Kinki University School of Medicine.  
SO Nippon rinsho. Japanese journal of clinical medicine, \*\*\* (1997 Jun) \*\*\*  
55 (6) 1370-6. Ref: 18  
CY Journal code: 0420546. ISSN: 0047-1852.  
Japan  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA Japanese  
FS Priority Journals  
EM 199709  
ED Entered STN: 19970922  
Last Updated on STN: 19970922  
Entered Medline: 19970905

L5 ANSWER 237 OF 268 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:313947 PROMT  
TITLE: Pathogenesis (HBV) Mutation Location Findings Have Impact on Vaccines  
SOURCE: Vaccine Weekly, ( \*\*\*2 Jun 1997\*\*\* ) pp. N/A.  
ISSN: 1074-2921.  
LANGUAGE: English  
WORD COUNT: 677  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 238 OF 268 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.  
on STN  
AN 94:210513 SCISEARCH  
GA The Genuine Article (R) Number: MY175  
TI IDENTIFICATION OF A MURINE \*\*\*T\*\*\* - \*\*\*HELPER\*\*\* \*\*\*CELL\*\*\*  
\*\*\*EPITOPE\*\*\* ON THE MAJOR (L1) CAPSID PROTEIN OF HUMAN PAPILLOMAVIRUS  
TYPE-16 AND ITS UTILIZATION TO POTENTIATE SERUM AND SECRETORY  
ANTIBODY-RESPONSES TO A \*\*\*B\*\*\* - \*\*\*CELL\*\*\* \*\*\*EPITOPE\*\*\*

CS UMDS, ST THOMAS HOSP, RAYNE INST, RICHARD DIMBLEBY LAB CANC VIROL, LONDON  
SE1 7EH, ENGLAND  
CYA ENGLAND  
SO JOURNAL OF CELLULAR BIOCHEMISTRY, ( \*\*\*13 FEB 1994\*\*\* ) Supp. 18C, pp.  
229.  
ISSN: 0730-2312.  
DT Conference; Journal  
FS LIFE  
LA ENGLISH  
REC Reference Count: 1

L5 ANSWER 239 OF 268 TOXCENTER COPYRIGHT 2004 ACS on STN  
AN 1993:157600 TOXCENTER  
CP Copyright 2004 ACS  
DN CA11907070352R  
TI HLA antigen-restricted hepatitis B virus cytotoxic T-lymphocyte ( \*\*\*CTL\*\*\* ) \*\*\*epitopes\*\*\*  
AU Vitiello, Maria A.; Chesnut, Robert W.  
CS ASSIGNEE: Cytel Corp.  
PI WO 933764 A1 4 Mar 1993  
SO ( \*\*\*1993\*\*\* ) PCT Int. Appl., 89 pp.  
CODEN: PIXXD2.  
CY UNITED STATES  
DT Patent  
FS CAPLUS  
OS CAPLUS 1993:470352  
LA English  
ED Entered STN: 20011116  
Last Updated on STN: 20020917

L5 ANSWER 240 OF 268 USPATFULL on STN  
AN 2004:276346 USPATFULL  
TI Peptide composition as immunogen for the treatment of allergy  
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States  
Walfield, Alan M., Huntington Station, NY, United States  
PA United Biomedical, Inc., Hauppauge, NY, United States  
PI US 6811782 B1 20041102  
WO 9967293 19991229 20001201 (9) <--  
WO 1999-US13959 19990621  
RLI Continuation-in-part of Ser. No. US 1998-100287, filed on 20 Jun 1998,  
now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 2806  
INCL INCLM: 424/185.100  
INCLS: 424/193.100; 530/324.000  
NCL NCLM: 424/185.100  
NCLS: 424/193.100; 530/324.000  
IC [7]  
ICM: A61K039-385  
ICS: A61K039-00; C07K017-02  
EXF 530/324; 424/185.1; 424/193; 424/194.1

L5 ANSWER 241 OF 268 USPATFULL on STN  
AN 2003:228155 USPATFULL  
TI Methods of inhibiting an autoimmune response in a human suffering from  
an autoimmune disease by administering an antibody that binds to a  
protein to which monoclonal antibody 5C8 binds  
IN Lederman, Seth, New York, NY, United States  
Chess, Leonard, Scarsdale, NY, United States  
Yellin, Michael J., Riverdale, NY, United States  
PA The Trustees of Columbia University in the City of New York, New York,  
NY, United States (U.S. corporation)  
PI US 6610294 B1 20030826  
WO 9309812 19930527  
AI US 1994-244087 19941020 (8)  
WO 1992-US9955 19921116  
RLI Continuation-in-part of Ser. No. US 1991-792728, filed on 15 Nov 1991,  
now patented, Pat. No. US 5474771, issued on 12 Dec 1995  
DT Utility  
FS GRANTED  
LN.CNT 4302  
INCL INCLM: 424/154.100  
INCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/153.100;

NCL NCLM: 530/387.300; 530/388.100; 530/388.220; 530/388.700; 530/388.730;  
 NCL NCLS: 530/388.750; 530/391.300; 530/391.700  
 IC [7]  
 ICM: A61K039-395  
 ICS: C07K016-28  
 EXF 424/1.49; 424/130.1; 424/141.1; 424/152.1; 424/172.1; 424/181.1;  
 435/326; 435/343; 435/346; 435/7.1; 435/7.2; 435/7.21; 435/7.23;  
 530/387.1; 530/388.22; 530/388.75; 530/387.3  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 242 OF 268 USPATFULL on STN  
 AN 2003:221955 USPATFULL  
 TI Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B  
 virus  
 IN Chisari, Francis V., Del Mar, CA, United States  
 Ferrari, Carlo, Parma, ITALY  
 Penna, Amalia, Parma, ITALY  
 Missael, Gabriele, Parma, ITALY  
 PA The Scripps Research Institute, La Jolla, CA, United States (U.S.  
 corporation)  
 PI US 6607727 B1 20030819  
 WO 9503777 19950209  
 AI US 1996-591502 19960520 (8) <--  
 WO 1994-US8685 19940801  
 RLI Continuation-in-part of Ser. No. US 1993-100870, filed on 2 Aug 1993,  
 now abandoned Continuation-in-part of Ser. No. US 1992-935898, filed on  
 26 Aug 1992, now abandoned Continuation-in-part of Ser. No. US  
 1991-749540, filed on 26 Aug 1991, now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 4966  
 INCL INCLM: 424/227.100  
 INCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;  
 530/324.000; 530/326.000; 530/327.000; 530/328.000; 530/350.000  
 NCL NCLM: 424/227.100  
 NCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;  
 530/324.000; 530/326.000; 530/327.000; 530/328.000; 530/350.000  
 IC [7]  
 ICM: A61K039-29  
 EXF 424/227.1; 530/327; 530/328; 530/350; 530/324; 530/326; 514/12-16  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 243 OF 268 USPATFULL on STN  
 AN 2001:17993 USPATFULL  
 TI Subunit papilloma virus vaccine and peptides for use therein  
 IN Tindle, Robert, Kenmore, Australia  
 Fernando, Germain, Jamboree Heights, Australia  
 Frazer, Ian, St. Lucia, Australia  
 PA The University of Queensland, Queensland, Australia (non-U.S.  
 corporation)  
 CSL Limited, Victoria, Australia (non-U.S. corporation)  
 PI US 6183745 B1 20010206  
 WO 9210513 19920625  
 AI US 1993-75541 19930610 (8) <--  
 WO 1993-AU9100575 19930924  
 19930610 PCT 371 date  
 19930610 PCT 102(e) date  
 PRAI AU 1990-3878 19901212  
 WO 1991-AU575 19911212  
 DT Utility  
 FS Granted  
 LN.CNT 1348  
 INCL INCLM: 424/185.100  
 INCLS: 530/350.000; 530/395.000; 530/403.000  
 NCL NCLM: 424/185.100  
 NCLS: 530/350.000; 530/395.000; 530/403.000  
 IC [7]  
 ICM: A61K039-12  
 EXF 530/300; 530/324.33; 530/350; 530/395; 530/806; 424/88; 424/89;  
 424/185.1; 424/184.1; 424/204.1

L5 ANSWER 244 OF 268 USPATFULL on STN  
AN 2000:145889 USPATFULL  
TI Peptide compositions for the treatment of HIV  
IN Rubinstein, Arye, Monsey-Wesley Hills, NY, United States  
Bloom, Barry R., Hastings on Hudson, NY, United States  
Devash, Yair, Princeton Junction, NJ, United States  
PA Cryz, Stanley J., Berne, Switzerland  
Albert Einstein College of Medicine of Yeshiva University, Bronx, NY,  
United States (U.S. corporation)  
PI US 6139843 20001031 <--  
AI US 1997-946525 19971007 (8)  
RLI Continuation-in-part of Ser. No. US 1997-785696, filed on 17 Jan 1997,  
now abandoned which is a continuation of Ser. No. US 1996-655376, filed  
on 30 May 1996, now abandoned which is a continuation of Ser. No. US  
1994-200744, filed on 23 Feb 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-837781, filed on 14 Feb 1992,  
now abandoned which is a continuation-in-part of Ser. No. US  
1991-681624, filed on 2 Apr 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 4544  
INCL INCLM: 424/208.100  
INCLS: 424/188.100; 424/184.100; 424/193.100; 424/194.100; 424/207.100;  
424/196.110; 424/204.100; 530/324.000; 530/325.000  
NCL NCLM: 424/208.100  
NCLS: 424/184.100; 424/188.100; 424/193.100; 424/194.100; 424/196.110;  
424/204.100; 424/207.100; 530/324.000; 530/325.000  
IC [7]  
ICM: A61K039-21  
ICS: A61K039-00; A61K039-38; A61K039-385  
EXF 424/188.1; 424/184.1; 424/193.1; 424/194.1; 424/207.1; 424/208.1;  
424/204.1; 424/196.11; 530/324; 530/325  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 245 OF 268 USPATFULL on STN  
AN 2000:134749 USPATFULL  
TI Recombinant flagellin vaccines  
IN Majarian, William R., Mt. Royal, NJ, United States  
Stocker, Bruce A. D., Palo Alto, CA, United States  
PA Newton, Salete M. C., Mountain View, CA, United States  
American Cyanamid Company, Madison, NJ, United States (U.S. corporation)  
The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 6130082 20001010 <--  
AI US 1992-837668 19920214 (7)  
RLI Continuation of Ser. No. US 1989-348430, filed on 5 May 1989, now  
abandoned which is a continuation-in-part of Ser. No. US 1988-190570,  
filed on 5 May 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2404  
INCL INCLM: 435/252.300  
INCLS: 536/023.400; 536/023.700; 435/320.100; 435/252.330; 424/192.100;  
424/200.100; 424/258.100; 424/093.200  
NCL NCLM: 435/252.300  
NCLS: 424/093.200; 424/192.100; 424/200.100; 424/258.100; 435/252.330;  
435/320.100; 536/023.400; 536/023.700  
IC [7]  
ICM: C12N001-21  
ICS: C12N015-62; C12N015-00; A61K039-116  
EXF 435/172.3; 435/320.1; 435/252.3; 435/69.1; 435/69.3; 435/69.7;  
435/252.33; 435/254.11; 435/257.2; 424/88; 424/92; 424/93A; 424/192.1;  
424/200.1; 424/201.1; 424/93.2; 424/258.1; 935/47; 935/48; 935/65;  
935/72; 536/23.4; 536/23.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 246 OF 268 USPATFULL on STN  
AN 2000:109527 USPATFULL  
TI Synthetic peptide vaccines for foot-and-mouth disease  
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States  
Shen, Ming, Flushing, NY, United States  
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)  
PI US 6107021 20000822 <--  
AI US 1998-100600 19980620 (9)

FS Granted  
LN.CNT 3425  
INCL INCLM: 435/005.000  
INCLS: 530/324.000; 530/300.000; 536/237.200; 930/022.000  
NCL NCLM: 435/005.000  
NCLS: 530/300.000; 530/324.000; 536/023.720; 930/022.000  
IC [7]  
ICM: C12Q001-70  
ICS: A61K038-00  
EXF 435/5; 530/324; 530/300; 536/23.72; 930/220  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 247 OF 268 USPATFULL on STN  
AN 2000:91543 USPATFULL  
TI Peptide composition for prevention and treatment of HIV infection and  
immune disorders  
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States  
PA United Biomedical Inc., Hauppauge, NY, United States (U.S. corporation)  
PI US 6090388 20000718 <--  
AI US 1998-100409 19980620 (9)  
DT Utility  
FS Granted  
LN.CNT 3077  
INCL INCLM: 424/185.100  
INCLS: 424/186.100; 424/189.100; 424/194.100; 424/236.100; 530/300.000;  
NCL NCLM: 424/185.100  
NCLS: 424/186.100; 424/189.100; 424/194.100; 424/236.100; 530/300.000;  
IC [7]  
ICM: A61K039-00  
ICS: A61K039-12; A61K039-385; A61K039-02; A61K038-00  
EXF 530/300; 530/323; 530/326; 530/324; 424/189.1; 424/194.1; 424/185.1;  
424/236.1; 424/186.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 248 OF 268 USPATFULL on STN  
AN 2000:18553 USPATFULL  
TI Artificial \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\*  
as immune stimulators for synthetic peptide immunogens including  
immunogenic LHRH peptides  
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States  
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)  
PI US 6025468 20000215 <--  
AI US 1998-100414 19980620 (9)  
DT Utility  
FS Granted  
LN.CNT 2155  
INCL INCLM: 530/324.000  
INCLS: 530/313.000; 530/326.000; 424/198.100  
NCL NCLM: 530/324.000  
NCLS: 424/198.100; 530/313.000; 530/326.000  
IC [7]  
ICM: A61K038-00  
ICS: A61K038-24; A61K039-00  
EXF 530/313; 530/326; 530/324; 424/198.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 249 OF 268 USPATFULL on STN  
AN 2000:18049 USPATFULL  
TI Recombinant avirulent immunogenic S typhi having rpos positive phenotype  
IN Curtiss, III, Roy, St. Louis, MO, United States  
Nickerson, Cheryl A., Chesterfield, MO, United States  
PA Washington University, St. Louis, MO, United States (U.S. corporation)  
PI US 6024961 20000215 <--  
AI US 1997-970789 19971114 (8)  
DT Utility  
FS Granted  
LN.CNT 2837  
INCL INCLM: 424/200.100  
INCLS: 424/093.200; 435/471.000; 435/252.300; 435/252.800; 435/004.000;  
435/027.000; 435/029.000  
NCL NCLM: 424/200.100  
NCLS: 424/093.200; 435/004.000; 435/027.000; 435/029.000; 435/252.300;  
435/252.800; 435/471.000

1CM: A61K039-02  
EXF ICS: A61K039-112; A61K039-116; A61K039-295; C12N001-21  
424/200.1; 424/258.1; 424/93.2; 435/252.3; 435/252.8; 435/471; 435/274;  
435/29

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 250 OF 268 USPATFULL on STN  
AN 2000:10008 USPATFULL  
TI Synthetic Haemophilus influenzae conjugate vaccine  
IN Chong, Pele, Richmond Hill, Canada  
Kandil, Ali, Willowdale, Canada  
Sia, Charles, Thornhill, Canada  
Klein, Michel, Willowdale, Canada  
PA Connaught Laboratories Limited, Willowdale, Canada (non-U.S.  
corporation)  
PI US 6018019 20000125 <--  
WO 9315205 19930805 <--  
AI US 1994-256839 19941003 (8)  
WO 1993-CA41 19930203  
19941003 PCT 371 date  
19941003 PCT 102(e) date  
PRAI GB 1992-2219 19920203  
DT Utility  
FS Granted  
LN.CNT 2070  
INCL INCLM: 530/324.000  
INCLS: 530/325.000; 530/326.000; 530/327.000; 435/851.000; 424/185.100;  
424/190.100; 424/256.100  
NCL NCLM: 530/324.000  
NCLS: 424/185.100; 424/190.100; 424/256.100; 435/851.000; 530/325.000;  
530/326.000; 530/327.000  
IC [6]  
EXF ICM: A61K038-12  
435/851; 424/185.1; 424/190.1; 424/256.1; 530/326; 530/327; 530/325;  
530/324  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 251 OF 268 USPATFULL on STN  
AN 1999:155510 USPATFULL  
TI Method for in vitro proliferation of dendritic cell precursors and their  
use to produce immunogens  
IN Steinman, Ralph M., Westport, CT, United States  
Inaba, Kayo, Kyoto, Japan  
PA Schuler, Gerold, Innsbruck, Austria  
The Rockefeller University, New York, NY, United States (U.S.  
corporation)  
PI US 5994126 19991130  
AI US 1994-261537 19940617 (8)  
RLI Continuation-in-part of Ser. No. US 1993-40677, filed on 31 Mar 1993,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-981357, filed on 25 Nov 1992, now abandoned which is a  
continuation-in-part of Ser. No. US 1992-861612, filed on 1 Apr 1992  
DT Utility  
FS Granted  
LN.CNT 3717  
INCL INCLM: 435/325.000  
INCLS: 435/326.000; 435/339.000; 435/372.000; 435/373.000; 530/350.000;  
530/351.000; 514/002.000  
NCL NCLM: 435/325.000  
NCLS: 435/326.000; 435/339.000; 435/372.000; 435/373.000; 514/002.000;  
530/350.000; 530/351.000  
IC [6]  
EXF ICM: C12N005-00  
435/240.2; 435/240.21; 435/240.3; 435/240.31; 435/240.23; 435/325;  
435/326; 435/339; 435/373; 435/372; 514/2; 530/350; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 252 OF 268 USPATFULL on STN  
AN 1999:155203 USPATFULL  
TI Synthetic vaccine for protection against human immunodeficiency virus  
infection  
IN Haynes, Barton F., Durham, NC, United States  
Palker, Thomas J., Durham, NC, United States  
PA Duke University, Durham, NC, United States (U.S. corporation)  
PI US 5993819 19991130 <--

RLI Continuation-in-part of Ser. No. US 1994-235305, filed on 29 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-858361, filed on 27 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-832849, filed on 10 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-591109, filed on 1 Oct 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-93854, filed on 8 Sep 1987, now patented, Pat. No. US 5019387

DT Utility  
FS Granted

LN.CNT 2306

INCL INCLM: 424/188.100

INCLS: 424/184.100; 424/208.100; 424/204.100; 530/350.000; 530/325.000; 530/326.000; 530/324.000

NCL NCLM: 424/188.100

NCLS: 424/184.100; 424/204.100; 424/208.100; 530/324.000; 530/325.000; 530/326.000; 530/350.000

IC [6]

ICM: A61K039-21

ICS: A61K039-38; A61K039-12; C07K001-00

EXF 424/188.1; 424/184.1; 424/208.1; 424/204.1; 530/350; 530/325; 530/326; 530/324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 253 OF 268 USPATFULL on STN  
AN 1999:132241 USPATFULL

TI IN Synthesis of polyribosylribitol phosphate oligosaccharides  
Chong, Pele, Richmond Hill, Canada

Kandil, Ali, Willowdale, Canada

Sia, Charles, Thornhill, Canada

Klein, Michel, Willowdale, Canada

PA Connaught Laboratories Limited, North York, Canada (non-U.S. corporation)

PI US 5972349 19991026

AI US 1995-475985 19950607 (8)

<--

RLI Continuation of Ser. No. US 256839

PRAI GB 1992-2219 19920302

DT Utility  
FS Granted

LN.CNT 2097

INCL INCLM: 424/256.100

INCLS: 424/184.100; 424/193.100; 424/194.100; 424/280.000; 514/023.000; 514/025.000; 514/054.000; 514/075.000; 514/099.000; 514/109.000; 514/112.000; 514/120.000; 514/125.000; 514/129.000; 514/139.000; 514/143.000; 514/183.000; 514/506.000; 536/001.110; 536/004.100; 536/018.700; 536/117.000; 536/123.100; 536/126.000; 536/127.000

NCL NCLM: 424/256.100  
NCLS: 424/184.100; 424/193.100; 424/194.100; 514/023.000; 514/025.000; 514/054.000; 514/075.000; 514/099.000; 514/109.000; 514/112.000; 514/120.000; 514/125.000; 514/129.000; 514/139.000; 514/143.000; 514/183.000; 514/506.000; 536/001.110; 536/004.100; 536/018.700; 536/117.000; 536/123.100; 536/126.000; 536/127.000

IC [6]

ICM: A61K039-102

EXF 424/184.1; 424/193.1; 424/194.1; 424/280.1; 424/256.1; 514/23; 514/25; 514/54; 514/75; 514/99; 514/109; 514/112; 514/120; 514/125; 514/129; 514/139; 514/143; 514/183; 514/506; 536/1.11; 536/4.1; 536/18.7; 536/123.1; 536/126; 536/127; 536/117

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 254 OF 268 USPATFULL on STN

AN 1999:88803 USPATFULL

TI IN Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus

PA Chisari, Francis V., Del Mar, CA, United States

PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

PI US 5932224 19990803

AI US 1995-469830 19950606 (8)

<--

RLI Division of Ser. No. US 1995-416950, filed on 4 Apr 1995 which is a continuation of Ser. No. US 1993-100870, filed on 2 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-935898, filed on 26 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-749540, filed on 26 Aug 1991, now abandoned

DT Utility

LN.CNT 1542  
INCL INCLM: 424/227.100  
INCL INCLS: 424/283.100; 424/812.000; 530/327.000; 530/328.000; 530/329.000  
NCL NCLM: 424/227.100  
NCLS: 424/283.100; 424/812.000; 530/327.000; 530/328.000; 530/329.000  
IC [6]  
ICM: A61K039-29  
ICS: A61K047-44; A61K038-08; A61K038-10  
EXF 424/184.1; 424/185.1; 424/189.1; 424/227.1; 424/283.1; 424/812; 514/2;  
514/15; 530/300; 530/328; 530/826; 530/327; 530/329; 930/220; 930/223  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 255 OF 268 USPATFULL on STN  
AN 1999:88797 USPATFULL  
TI Multideterminant peptides eliciting helper T-lymphocyte, cytotoxic  
IN T-lymphocyte, and neutralizing antibody responses against HIV-1  
Berzofsky, Jay A., Bethesda, MD, United States  
Ahlers, Jeffrey D., Kensington, MD, United States  
Pendleton, C. David, Bethesda, MD, United States  
Nara, Peter, Frederick, MD, United States  
Shirai, Mutsunori, Kagawa, Japan  
PA The United States of America as represented by the Department of Health  
& Human Services, Washington, DC, United States (U.S. government)  
PI US 5932218 19990803  
AI US 1995-455625 19950531 (8) <--  
RLI Division of Ser. No. US 1993-60988, filed on 14 May 1993 which is a  
continuation-in-part of Ser. No. US 1992-847311, filed on 6 Mar 1992  
which is a continuation-in-part of Ser. No. US 1988-148692, filed on 26  
Jan 1988, now abandoned, said Ser. No. US 60988 which is a  
continuation-in-part of Ser. No. US 1991-751998, filed on 29 Aug 1991,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 2307  
INCL INCLM: 424/188.100  
INCL INCLS: 424/208.100; 530/324.000  
NCL NCLM: 424/188.100  
NCLS: 424/208.100; 530/324.000  
IC [6]  
ICM: A61K039-21  
ICS: A61K038-00; C07K005-00  
EXF 530/300; 530/324; 424/188.1; 424/208.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 256 OF 268 USPATFULL on STN  
AN 1998:147031 USPATFULL  
TI Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B  
virus  
IN Chisari, Francis V., Del Mar, CA, United States  
Ferrari, Carlo, Parma, Italy  
Penna, Amalia, Parma, Italy  
Missale, Gabriele, Parma, Italy  
PA The Scripps Research Foundation, La Jolla, CA, United States (U.S.  
corporation)  
PI US 5840303 19981124 <--  
AI US 1995-468279 19950606 (8)  
RLI Division of Ser. No. US 1992-935898, filed on 26 Aug 1992, now abandoned  
which is a continuation-in-part of Ser. No. US 1991-749540, filed on 26  
Aug 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1965  
INCL INCLM: 424/189.100  
INCL INCLS: 424/184.100; 424/185.100; 424/186.100; 424/193.100; 424/196.110;  
424/204.100; 424/227.100; 514/002.000; 514/015.000; 530/300.000;  
530/327.000; 530/328.000; 530/403.000  
NCL NCLM: 424/152.100  
NCLS: 424/130.100; 424/133.100; 424/144.100; 424/154.100; 530/388.250  
IC [6]  
ICM: A61K039-29  
ICS: A61K039-12; A61K039-385; C07K007-06  
EXF 424/184.1; 424/185.1; 424/186.1; 424/189.1; 424/193.1; 424/204.1;  
424/225.1; 424/227.1; 424/278.1; 424/283.1; 424/450; 514/2; 514/13;  
530/326; 530/327  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 257 OF 268 USPATFULL on STN  
AN 1998:147025 USPATFULL  
TI Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process  
IN MacDonald, Alex Bruce, Amherst, MA, United States  
An, Ling-Ling, La Jolla, CA, United States  
Sutton-Stuart, Elizabeth, Amherst, MA, United States  
Whittum-Hudson, Judith A., Elkton, MD, United States  
PA Johns Hopkins University, United States (U.S. corporation)  
University of Massachusetts, United States (U.S. corporation)  
PI US 5840297 19981124  
AI US 1993-34572 19930319 (8) <--  
DT Utility  
FS Granted  
LN.CNT 2015  
INCL INCLM: 424/131.100  
INCLS: 424/151.100; 424/134.100; 424/263.100; 424/150.100; 435/327.000;  
NCL NCLM: 424/131.100 435/342.000; 435/340.000; 530/387.200; 530/388.600; 530/388.400  
NCLS: 424/134.100; 424/150.100; 424/151.100; 424/263.100; 435/327.000;  
IC [6] 435/340.000; 435/342.000; 530/387.200; 530/388.400; 530/388.600  
EXF ICM: A61K039-395  
ICS: C12N005-06; C07K016-00  
424/88; 424/131.1; 424/150.1; 424/151.1; 424/134.1; 424/263.1; 435/7.1;  
435/327; 435/342; 435/340; 530/388.4; 530/388.6; 530/387.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 258 OF 268 USPATFULL on STN  
AN 1998:91605 USPATFULL  
TI Peptides for inducing cytotoxic T lymphocyte responses hepatitis B virus  
IN Chisari, Francis V., Del Mar, CA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. Corporation)  
PI US 5788969 19980804 <--  
AI US 1995-464235 19950605 (8)  
RLI Division of Ser. No. US 1995-396283, filed on 27 Feb 1995 which is a  
continuation of Ser. No. US 1993-24120, filed on 26 Feb 1993  
DT Utility  
FS Granted  
LN.CNT 1548  
INCL INCLM: 424/189.100  
INCLS: 424/154.100; 424/155.100; 424/186.100; 424/193.100; 424/196.110;  
424/204.100; 424/227.100; 514/002.000; 514/075.000; 530/300.000;  
NCL NCLM: 424/189.100 530/328.000; 930/220.000; 930/223.000  
NCLS: 424/184.100; 424/185.100; 424/186.100; 424/193.100; 424/196.110;  
424/204.100; 424/227.100; 514/002.000; 514/015.000; 530/300.000;  
IC [6] 530/328.000; 930/220.000; 930/223.000  
EXF ICM: A61K039-29  
ICS: A61K039-12; A61K039-385; C07K007-06  
424/184.1; 424/185.1; 424/186.1; 424/189.1; 424/193.1; 424/196.11;  
424/204.1; 424/227.1; 514/2; 514/15; 530/300; 530/328; 930/220; 930/223  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 259 OF 268 USPATFULL on STN  
AN 1998:82346 USPATFULL  
TI Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus  
IN Chisari, Francis V., Del Mar, CA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. Corporation)  
PI US 5780036 19980714 <--  
AI US 1995-416950 19950404 (8)  
RLI Continuation of Ser. No. US 1993-100870, filed on 2 Aug 1993, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-935898,  
filed on 26 Aug 1992 which is a continuation-in-part of Ser. No. US  
1991-749540, filed on 26 Aug 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1388  
INCL INCLM: 424/189.100  
INCLS: 424/154.100; 424/185.100; 424/186.100; 424/193.100; 424/196.110;  
424/204.100; 424/227.100; 514/002.000; 514/015.000; 530/300.000;  
530/327.000; 530/328.000; 530/403.000

NCL: 424/184.100; 424/185.100; 424/186.100; 424/193.100; 424/196.110;  
424/204.100; 424/227.100; 514/002.000; 514/015.000; 530/300.000;  
530/327.000; 530/328.000; 530/403.000

IC [6]

ICM: A61K039-29

ICS: A61K039-12; A61K039-385; C07K007-06

EXF 514/2; 514/12; 530/300; 530/403; 530/327; 530/328; 536/22.1; 536/23.1;  
536/23.72; 435/69.1; 435/240.2; 435/252.3; 435/320.1; 424/184.1;  
424/185.1; 424/186.1; 424/189.1; 424/193.1; 424/196.11; 424/204.1;  
424/227.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 260 OF 268 USPATFULL on STN  
AN 1998:51478 USPATFULL

TI DNA encoding MAGE-1 C-terminal cytotoxic T lymphocyte immunogenic peptides

IN Fikes, John D., San Diego, CA, United States

Livingston, Brian D., San Diego, CA, United States

Sette, Alessandro D., La Jolla, CA, United States

Sidney, John C., La Jolla, CA, United States

PA Cytel Corporation, San Diego, CA, United States (U.S. corporation)  
PI US 5750395 19980512 <--

AI US 1995-465167 19950605 (8)

RLI DT Division of Ser. No. US 1993-103623, filed on 6 Aug 1993, now abandoned

FS Granted

LN.CNT 1512

INCL INCLM: 435/325.000

INCLS: 435/069.300; 435/252.200; 435/252.300; 435/254.200; 435/320.100;  
536/235.000

NCL NCLM: 435/325.000

NCLS: 435/069.300; 435/252.300; 435/254.200; 435/320.100; 536/023.500

IC [6]

ICM: C12N015-63

ICS: C12N015-12

EXF 435/69.3; 435/252.3; 435/320.1; 435/325; 435/254.2; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 261 OF 268 USPATFULL on STN  
AN 1998:14646 USPATFULL

TI Method for diagnosing a patient for chlamydia

IN MacDonald, Alex Bruce, Amherst, MA, United States

Stuart, Elizabeth S., Amherst, MA, United States

An, Ling Ling, La Jolla, CA, United States

Whipkey, Myron D., Portland, ME, United States

PA Animal House, Inc., Portland, ME, United States (U.S. corporation)  
PI US 5716793 19980210 <--

AI US 1995-406113 19950317 (8)

RLI DT Continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993

FS Granted

LN.CNT 1933

INCL INCLM: 435/007.360

INCLS: 435/007.320; 435/007.900; 435/007.920; 435/007.940; 435/007.950;  
435/965.000; 436/518.000; 436/536.000; 436/548.000; 436/811.000;  
424/150.100; 424/163.100; 424/263.100; 530/388.400; 530/389.500

NCL NCLM: 435/007.360

NCLS: 424/150.100; 424/163.100; 424/263.100; 435/007.320; 435/007.900;  
435/007.920; 435/007.940; 435/007.950; 435/965.000; 436/518.000;  
436/536.000; 436/548.000; 436/811.000; 530/388.400; 530/389.500

IC [6]

ICM: G01N033-53

EXF 435/7.32; 435/7.36; 435/7.92; 435/965; 435/7.9; 435/7.93; 435/7.94;  
435/7.95; 436/518; 436/536; 436/547; 436/548; 436/811; 424/131.1;  
424/150.1; 424/163.1; 424/164.1; 424/263.1; 530/388.4; 530/389.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 262 OF 268 USPATFULL on STN

AN 1998:6917 USPATFULL

TI Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses

IN Chisari, Francis V., Del Mar, CA, United States

Cerny, Andreas, La Jolla, CA, United States

PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

AI US 1994-214650 19940317 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2277  
 INCL INCLM: 435/005.000  
 INCLS: 530/328.000; 424/189.100; 424/228.100  
 NCL NCLM: 435/005.000  
 NCLS: 424/189.100; 424/228.100; 530/328.000  
 IC [6]  
 ICM: C12Q001-70  
 ICS: A61K038-04; A61K039-29  
 EXF 424/189; 424/196.11; 424/228.1; 530/324-8; 435/5; 435/7.2; 435/7.24;  
 436/63  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 263 OF 268 USPATFULL on STN  
 AN 97:96561 USPATFULL  
 TI Synthetic Haemophilus influenzae conjugate vaccine  
 IN Chong, Pele, Richmond Hill, Canada  
 Kandil, Ali, Willowdale, Canada  
 Sia, Charles, Thornhill, Canada  
 Klein, Michel, Willowdale, Canada  
 PA Connaught Laboratories Limited, Willowdale, Canada (non-U.S.  
 corporation)  
 PI US 5679352 19971021 <--  
 AI US 1995-475989 19950607 (8)  
 RLI Continuation of Ser. No. US 1994-256839, filed on 3 Oct 1994  
 PRAI GB 1992-2219 19920302  
 DT Utility  
 FS Granted  
 LN.CNT 1882  
 INCL INCLM: 424/256.100  
 INCLS: 424/185.100; 424/190.100; 424/196.110; 435/034.000; 435/851.000;  
 530/324.000; 530/325.000; 530/326.000; 530/387.100  
 NCL NCLM: 424/256.100  
 NCLS: 424/185.100; 424/190.100; 424/196.110; 435/034.000; 435/851.000;  
 530/324.000; 530/325.000; 530/326.000; 530/387.100  
 IC [6]  
 ICM: A61K039-102  
 ICS: C07K014-285; C07K016-12; C12Q001-04  
 EXF 435/851.4; 435/34; 424/184.1; 424/185.1; 424/170.1; 424/256.1;  
 424/196.11; 530/326; 530/325; 530/324; 530/387.1; 935/15  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L5 ANSWER 264 OF 268 USPATFULL on STN  
 AN 97:70717 USPATFULL  
 TI Oral vaccine comprising anti-idiotypic antibody to chlamydia glycolipid  
 exoantigen and process  
 IN MacDonald, Alex Bruce, Hatfield, MA, United States  
 Whittum-Hudson, Judith A., Elkton, MD, United States  
 Saltzman, William Mark, Baltimore, MD, United States  
 PA The Johns Hopkins University, Baltimore, MD, United States (U.S.  
 corporation)  
 University of Massachusetts, Amherst, MA, United States (U.S.  
 corporation)  
 PI US 5656271 19970812 <--  
 AI US 1995-466752 19950606 (8)  
 RLI Continuation of Ser. No. US 1994-213863, filed on 16 Mar 1994, now  
 abandoned which is a continuation-in-part of Ser. No. US 1993-34572,  
 filed on 19 Mar 1993  
 DT Utility  
 FS Granted  
 LN.CNT 2188  
 INCL INCLM: 424/131.100  
 INCLS: 424/492.000; 424/493.000; 424/497.000; 424/151.100; 424/263.100;  
 424/486.000; 530/387.200; 530/389.500; 530/388.400  
 NCL NCLM: 424/131.100  
 NCLS: 424/151.100; 424/263.100; 424/486.000; 424/492.000; 424/493.000;  
 424/497.000; 530/387.200; 530/388.400; 530/389.500  
 IC [6]  
 ICM: A61K039-118  
 ICS: A61K047-48; C07K016-42; C07K016-12  
 EXF 424/131.1; 424/150.1; 424/151.1; 424/486; 424/497; 424/263.1; 424/492;  
 424/493; 530/387.2; 530/388.4; 530/388.6; 530/389.5; 435/7.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 265 OF 268 USPATFULL on STN  
 AN 95:98944 USPATFULL  
 TI Liposomes that provide thymic dependent help to weak vaccine antigens  
 IN Six, Howard R., East Stroudsburg, PA, United States  
 Garcon, Nathalie B., Rixensart, Belgium  
 PA Research Development Foundation, Carson City, NV, United States (U.S. corporation)  
 PI US 5464630 19951107 <--  
 AI US 1995-380213 19950130 (8)  
 RLI Continuation of Ser. No. US 1993-94398, filed on 19 Jul 1993, now abandoned which is a continuation of Ser. No. US 1992-821242, filed on 10 Jan 1992, now abandoned which is a continuation of Ser. No. US 1990-558960, filed on 27 Jul 1990, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 608  
 INCL INCLM: 424/450.000  
 INCLS: 436/829.000  
 NCL NCLM: 424/450.000  
 NCLS: 436/829.000  
 IC [6]  
 ICM: A61K009-127  
 EXF 424/450; 424/204.1; 424/206.1; 424/210.1; 436/829  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 266 OF 268 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN  
 AN 2000-532904 [48] WPIDS  
 DNC C2000-158795  
 TI Novel \*\*\*T\*\*\* \*\*\*helper\*\*\* \*\*\*cell\*\*\* \*\*\*epitopes\*\*\* derived from canine distemper virus useful for preparation of canine vaccines.  
 DC B04 C06 D16  
 IN JACKSON, D C; SOURAVI, G; WALKER, J; GHOSH, S  
 PA (CSIR) COMMONWEALTH SCI & IND RES ORG; (COUN-N) COUNCIL QUEENSLAND INST MEDICAL RES; (CSLC-N) CSL LTD; (HALL-N) HALL INST MEDICAL RES WALTER & ELIZA; (UYME) UNIV MELBOURNE  
 CYC 91  
 PI WO 2000046390 A1 20000810 (200048)\* EN 54 C12P021-02 <--  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 OA PT SD SE SL SZ TZ UG ZW  
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES  
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS  
 LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL  
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2000027836 A 20000825 (200059) C12P021-02 <--  
 EP 1147212 A1 20011024 (200171) EN C12P021-02  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 KR 2001101796 A 20011114 (200230) C07K014-47  
 JP 2002536384 W 20021029 (200274) 60 C07K014-705  
 ZA 2001006413 A 20021030 (200282) 62 C12P000-00  
 NZ 513482 A 20030829 (200365) C12P021-02  
 AU 765164 B 20030911 (200369) C12P021-02  
 US 6685947 B1 20040203 (200413) A61K039-175  
 ADT WO 2000046390 A1 WO 2000-AU70 20000207; AU 2000027836 A AU 2000-27836 20000207; EP 1147212 A1 EP 2000-906047 20000207, WO 2000-AU70 20000207; KR 2001101796 A KR 2001-709925 20010806; JP 2002536384 W JP 2000-597449 20000207, WO 2000-AU70 20000207; ZA 2001006413 A ZA 2001-6413 20010803; NZ 513482 A NZ 2000-513482 20000207, WO 2000-AU70 20000207; AU 765164 B AU 2000-27836 20000207; US 6685947 B1 WO 2000-AU70 20000207, US 2002-890650 20020322  
 FDT AU 2000027836 A Based on WO 2000046390; EP 1147212 A1 Based on WO 2000046390; JP 2002536384 W Based on WO 2000046390; NZ 513482 A Based on WO 2000046390; AU 765164 B Previous Publ. AU 2000027836, Based on WO 2000046390; US 6685947 B1 Based on WO 2000046390  
 PRAI AU 1999-2013 19990804; AU 1999-8533 19990205  
 IC ICM A61K039-175; C07K014-47; C07K014-705; C12P000-00; C12P021-02  
 ICS A61K038-00; A61K038-09; A61K039-165; A61K039-39; A61P037-04

L5 ANSWER 267 OF 268 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN  
 AN 1993-258681 [32] WPIDS  
 DNN N1993-198976 DNC C1993-114924  
 TI Synthetic Haemophilus influenzae conjugate vaccine - comprising T-helper cell determinants and \*\*\*B\*\*\* - \*\*\*cell\*\*\* \*\*\*epitope\*\*\* (s) linked to synthetic oligo saccharide(s).

IN CHONG, P; KANDIL, A; KLEIN, M H; SIA, C; KLEIN, M; SIA, C D Y  
 PA (CONN-N) CONNAUGHT LAB LTD  
 CYC 27  
 PI WO 9315205 A2 19930805 (199332) \* EN 99 C12N015-31 <--  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
 W: AU BR CA FI JP KR NO RU UA US  
 AU 9334469 A 19930901 (199350) C12N015-31 <--  
 NO 9402867 A 19941003 (199444) A61K000-00 <--  
 EP 625203 A1 19941123 (199445) EN C12N015-31 <--  
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
 FI 9403591 A 19940928 (199445) A61K000-00 <--  
 WO 9315205 A3 19940303 (199515) C12N015-31 <--  
 JP 07505522 W 19950622 (199533) 33 C12N015-09 <--  
 AU 669354 B 19960606 (199630) C07K015-04 <--  
 US 5679352 A 19971021 (199748) 59 A61K039-102 <--  
 US 5972349 A 19991026 (199952) A61K039-102 <--  
 JP 11269188 A 19991005 (199953) 44 C07H015-04 <--  
 US 6018019 A 20000125 (200012) A61K038-12 <--  
 RU 2141527 C1 19991120 (200041) C12N015-31 <--  
 JP 2001064201 A 20010313 (200118) 40 A61K039-00  
 KR 233805 B1 20000315 (200122) C12N015-31 <--  
 KR 246122 B1 20000315 (200122) C12N015-31 <--  
 JP 3421337 B2 20030630 (200343) 54 C12N015-09  
 CA 2129101 C 20040810 (200454) EN C07K014-285  
 ADT WO 9315205 A2 WO 1993-CA41 19930203; AU 9334469 A AU 1993-34469 19930203;  
 NO 9402867 A WO 1993-CA41 19930203, NO 1994-2867 19940802; EP 625203 A1 EP  
 1993-903129 19930203, WO 1993-CA41 19930203; FI 9403591 A WO 1993-CA41  
 19930203, FI 1994-3591 19940802; WO 9315205 A3 WO 1993-CA41 19930203; JP  
 07505522 W JP 1993-512824 19930203, WO 1993-CA41 19930203; AU 669354 B AU  
 1995-34469 19930203; US 5679352 A Cont of US 1994-256839 19941003, US  
 1995-475989 19950607; US 5972349 A Cont of WO 1993-CA41 19930203, Cont of  
 US 1994-256839 19941003, US 1995-475985 19950607; JP 11269188 A Div ex JP  
 1993-512824 19930203, JP 1998-336442 19930203; US 6018019 A WO 1993-CA41  
 19930203, US 1994-256839 19941003; RU 2141527 C1 WO 1993-CA41 19930203, RU  
 1994-40386 19930203; JP 2001064201 A Div ex JP 1993-512824 19930203, JP  
 2000-197292 19930203; KR 233805 B1 WO 1993-CA41 19930203, Div ex KR  
 1994-702655 19940802, KR 1999-700938 19990203; KR 246122 B1 WO 1993-CA41  
 19930203, KR 1994-702655 19940802; JP 3421337 B2 JP 1993-512824 19930203,  
 WO 1993-CA41 19930203; CA 2129101 C CA 1993-2129101 19930203, WO 1993-CA41  
 19930203  
 FDT AU 9334469 A Based on WO 9315205; EP 625203 A1 Based on WO 9315205; JP  
 07505522 W Based on WO 9315205; AU 669354 B Previous Publ. AU 9334469,  
 Based on WO 9315205; US 6018019 A Based on WO 9315205; RU 2141527 C1 Based  
 on WO 9315205; JP 3421337 B2 Previous Publ. JP 07505522, Based on WO  
 9315205; CA 2129101 C Based on WO 9315205  
 PRAI GB 1992-2219 19920203  
 IC ICM A61K000-00; A61K038-12; A61K039-00; C07H015-04; C07K014-285;  
 C07K015-04; C12N015-09; C12N015-31  
 ICS A61K039-21; A61K039-39; A61K039-40; A61K047-48; A61P031-04;  
 A61P037-04; C07H007-00; C07H015-08; C07H015-18; C07H015-203;  
 C07K004-04; C07K007-08; C07K007-10; C07K013-00; C07K014-11;  
 C07K014-16; C07K014-195; C07K015-00; C07K016-12; C07K017-10;  
 C12N015-63; C12Q001-04; G01N033-53; G01N033-569  
 ICA A61K031-00; A61K039-102; A61K039-385; A61K039-395  
 L5 ANSWER 268 OF 268 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN  
 AN 1989-309504 [42] WPIDS  
 CR 1988-272829 [39]  
 DNC C1989-137020  
 TI New peptide contg. \*\*\*T\*\*\* - \*\*\*helper\*\*\* \*\*\*cell\*\*\*  
 \*\*\*epitope\*\*\* of foot-and-mouth virus - and opt. \*\*\*B\*\*\* -  
 \*\*\*cell\*\*\* \*\*\*epitope\*\*\*, useful in vaccines and for potentiating  
 hormone activity.  
 DC B04 C03 D16  
 IN FRANCIS, M J; JAMES, S; ROWLANDS, D J; FRANCIS, M  
 PA (MLCW) MALLINCKRODT VETERINARY INC; (PITM) COOPERS ANIMAL HEALTH LT;  
 (PITM) PITMAN-MOORE LTD; (WELL) WELLCOME FOUND LTD; (FRAN-I) FRANCIS M J;  
 (JAME-I) JAMES S; (ROWL-I) ROWLANDS D J  
 CYC 18  
 PI WO 8909228 A 19891005 (198942) \* EN 31 <--  
 RW: AT BE CH DE FR GB IT LU NL SE  
 W: AU DK HU JP SD SU US  
 AU 8934175 A 19891016 (199008) <--  
 EP 406316 A 19910109 (199102) <--  
 R: BE CH DE DK FR GB IT LI LU NL SE <--

HU 55413 T 19910528 (199127) <--  
JP 03503416 W 19910801 (199137) <--  
EP 406316 B1 19950118 (199507) EN 12 C07K007-00 <--  
R: AT BE CH DE FR GB IT LI LU NL SE  
DE 68920735 E 19950302 (199514) C07K007-00 <--  
EP 406316 A4 19910320 (199515) <--  
HU 210966 B 19950928 (199545) C07K007-00 <--  
US 5864008 A 19990126 (199911) C07K014-09 <--  
ADT WO 8909228 A WO 1989-GB311 19890323; JP 03503416 W JP 1989-504160  
19890323; EP 406316 B1 EP 1989-904596 19890323, WO 1989-GB311 19890323; DE  
68920735 E DE 1989-620735 19890323, EP 1989-904596 19890323, WO 1989-GB311  
19890323; EP 406316 A4 EP 1989-904596 19890323; HU 210966 B HU 1989-2532  
19890323, WO 1989-GB311 19890323; US 5864008 A Cont of US 1990-571615  
19901109, US 1992-921447 19920728  
FDT EP 406316 B1 Based on WO 8909228; DE 68920735 E Based on EP 406316, Based  
on WO 8909228; HU 210966 B Previous Publ. HU 55413, Based on WO 8909228  
PRAI GB 1988-21076 19880908; EP 1988-302656 19880325  
IC A61K039-00; C07K005-00; C07K007-00; C12N015-00  
ICM C07K007-00; C07K014-09  
ICS A61K039-00; A61K039-135; C07K005-00; C12N015-00  
STN INTERNATIONAL LOGOFF AT 14:11:56 ON 19 NOV 2004